



Health
Canada Santé
Canada

April 2003

April 2003

HIV/AIDS

EPI Updates



Canada 



Our mission is to help the people of Canada maintain and improve their health

Health Canada

This report is available:

By mail

Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada, Tunney's Pasture, Address locator: 0900B1, Ottawa, Ontario, Canada, K1A 0L2

Or from

HIV/AIDS Clearinghouse, Canadian Public Health Association, 1565 Carling Avenue, Suite 400, Ottawa, Ontario, Canada, K1Z 8R1, Tel.: (613) 725-3434, Fax: (613) 725-1205

By Internet

HIV/AIDS Epi Updates can be assessed electronically in either official language via Internet at www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/.

Published by authority of the Minister of Health

© Minister of Public Works and Government Services Canada 2003

Cat. H39-1/1-2003E

ISBN 0-662-33911-8

(On-line) Cat. H39-1/1-2003E-IN

ISBN 0-662-33966-5



HIV/AIDS **EPI UPDATES** Centre for Infectious Disease Prevention and Control

Division of HIV/AIDS Epidemiology and Surveillance
Centre for Infectious Disease Prevention and Control
Brooke Claxton Building, Room 0108B
Tunney's Pasture, PL 0900B1
Ottawa, Ontario, K1A 0L2
Tel: (613) 954-5169 Fax: (613) 946-8695

Information to the readers of *HIV/AIDS Epi Updates*

The Division of HIV/AIDS Epidemiology and Surveillance of the Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada, is pleased to provide you with the April 2003 publication of *HIV/AIDS Epi Updates*.

The Centre conducts national surveillance and research on the epidemiology and laboratory science related to HIV/AIDS and other sexually transmitted diseases. As part of this mandate, *Epi Updates* are compiled on an annual basis to summarize recent trends and developments related to the HIV epidemic in Canada.

All *Epi Updates* are available at the address noted above and also at our website: www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/. The *HIV/AIDS Epi Updates* are complementary to other Centre materials which are also available at the website.

Sincerely,

Chris Archibald MDCM, MHSc, FRCPC
Director

Centre for Infectious Disease Prevention and Control

Division of HIV/AIDS Epidemiology and Surveillance

Tel.: (613) 954-5169

Fax: (613) 946-8695

Director

Executive Assistant

Chris Archibald, MDCM, MHSc, FRCPC
Moheene Soondrum

Field Epidemiologist

Co-op Student

Daniel Bolduc, MSc

Tara Smith

HIV and AIDS Surveillance Unit

Head

Acting Head

Statistical Analyst

Surveillance Officer

Jennifer Geduld, MHSc, BSc

Dana Reid, MSc, BSc

Marene Gatali, MHSc, BASc

Bruce Tudin, MA, BES

Injecting Drug Use Unit

Acting Head

Surveillance Officer

Yogesh Choudhri, MD, MPH

Kathleen Lydon-Hassen, DipSc

HIV Research Unit

Head

Surveillance Officer

Vacant

Stephen Cule, BSc

HIV Strain & Drug Resistance Surveillance Unit

Senior Epidemiologist

Gayatri Jayaraman, PhD, MPH

HIV/AIDS

EPI UPDATES

Centre for Infectious Disease Prevention and Control

Table of Contents

1	National HIV Prevalence and Incidence Estimates for 1999: No Evidence of a Decline in Overall Incidence	1
2	Prevalent HIV infections in Canada: Up to One-Third May Not Be Diagnosed	6
3	HIV Infection Reporting in Canada	9
4	HIV and AIDS among Youth in Canada	13
5	HIV and AIDS among Women in Canada	18
6	HIV/AIDS among Older Canadians	21
7	Perinatal Transmission of HIV	25
8	Ethnicity Reporting for AIDS and HIV in Canada	31
9	HIV/AIDS among Aboriginal Persons in Canada: A Continuing Concern	35
10	HIV Infections among MSM in Canada	41
11	HIV/AIDS among Injecting Drug Users in Canada	47
12	Risk Behaviours among Injecting Drug Users in Canada	52
13	Oral Sex and the Risk of HIV Transmission	58
14	HIV-1 Strain Surveillance in Canada	63
15	Primary HIV Anti-retroviral Drug Resistance in Canada	67
16	Nonoxynol-9 and the Risk of HIV Transmission	73



HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- An estimated 4,190 persons in Canada were newly infected with HIV in 1999.
- From 1996 to 1999, there was a 30% rise in incident HIV infections among MSM and 27% drop among IDU.
- An estimated 49,800 people in Canada were living with HIV (including AIDS) at the end of 1999.
- There was a 24% increase in prevalent infections from 1996 to 1999.

National HIV Prevalence and Incidence Estimates for 1999: No Evidence of a Decline in Overall Incidence

Introduction

This report outlines estimates of the total number of Canadians who were living with HIV infection at the end of 1999 (**prevalence**) and the number of individuals who became newly infected in 1999 (**incidence**). Producing national estimates of HIV prevalence and incidence are an integral part of the work of the Centre for Infectious Disease Prevention and Control. They are used as a tool to monitor the HIV epidemic, to help evaluate and guide prevention efforts, and are part of on-going risk assessment and management work conducted by the Centre. It is anticipated that the next set of national estimates will pertain to the year 2002 and will be produced during 2003.

Methods

HIV prevalence and incidence estimates at the national level are estimated by a combination of different methods using data from a wide variety of sources, such as AIDS case reports, provincial HIV testing databases, population-based surveys, targeted epidemiological studies and census data.

Prevalence and incidence estimates are derived separately for the following exposure categories: men who have sex with men (MSM), injecting drug users (IDU), MSM-IDU, heterosexuals (includes sub-categories of heterosexual contact with a person at risk for HIV, origin in a country where HIV is endemic and heterosexual as the only identified risk) and other (includes recipients of clotting factor or blood products, perinatal and occupational transmission).

CIDPC Website:

www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

Two main methods are used to estimate both HIV prevalence and incidence: a direct and an indirect method.

Direct Method:^{1,2}

HIV prevalence:

Prevalence rate: Estimated population size

HIV incidence:

Incidence rate: Estimated population at risk (total population for that group minus those already infected with HIV).

- Prevalence and incidence rates are estimated from targeted epidemiological studies;
- Population sizes are derived using a variety of methods, including projected population estimates, population-based surveys, and capture-recapture analyses (for IDU).

Indirect Method:^{1,2}

Two indirect methods are used together to estimate HIV prevalence. They are both based on the number of HIV diagnoses (obtained from provincial HIV testing databases) and on information about HIV testing behaviour (obtained from population surveys).

- In the first method, the cumulative number of HIV diagnoses (minus cumulative AIDS deaths) is divided by the proportion of the population who have ever been tested for HIV.
- In the second method, the number of HIV diagnoses in 1999 is divided by the proportion of the population who are tested in a one-year period, and the result is then added to the cumulative number of HIV diagnoses to the end of 1998 (minus cumulative AIDS deaths) plus the estimate for 1999 HIV incidence.

HIV incidence is derived using an indirect method by taking the difference between the 1999 and 1996 prevalence estimates and adding 1997-1999 AIDS deaths. The result is an estimate of the number of new infections

occurring during 1997-99 which is divided by three to estimate the number during 1999. See the references for a further description of the methods and results.

These methods are carried out for each of British Columbia (B.C.), Alberta (Alta.), Ontario (Ont.) and Quebec (Que.). These four provinces account for 85% of the population of Canada and for 95% of HIV and AIDS diagnoses in Canada. For each exposure category in these provinces, the mean of the direct and indirect methods is taken as the point estimate for both prevalence and incidence. Ranges of uncertainty are calculated using statistical simulation procedures.

The remainder of the provinces and territories are grouped into Saskatchewan/Manitoba/Northwest Territories/Yukon/Nunavut and the Atlantic provinces (Nova Scotia, New Brunswick, Prince Edward Island, and Newfoundland). The prevalence and incidence estimates for these two regions are extrapolated using estimates from B.C., Alta., Ont. and Que. and regional distribution of reported AIDS cases and positive HIV diagnoses.

Prevalence and Incidence Results

As outlined in Table 1, there were an estimated 49,800 people in Canada living with HIV infection (includes those living with AIDS) at the end of 1999 compared with an estimated 40,100 at the end of 1996. This represents an increase of 24%.

An estimated 4,190 Canadians became newly infected with HIV in 1999 (Table 2). Although the estimated incidence in 1999 was essentially unchanged from 1996, the distribution among exposure categories changed significantly. From 1996 to 1999, there was a 30% increase in the number of new infections per year among MSM (from 1,240 to 1,610) and a 27% decline in the number of new infections among IDU (from 1,970 to 1,430).

Table 1: Point estimates and uncertainty ranges for number of prevalent HIV infections in Canada at the end of 1999 compared with point estimates for 1996, by exposure category

	MSM	MSM-IDU	IDU	Hetero	Other	Total
1999 Range	29,600 (26,000-33,400)	2,100 (1,700-2,600)	9,700 (8,100-11,800)	8,000 (6,300-10,100)	400 (330-470)	49,800 (45,000-54,600)
1996	25,300	1,700	7,100	5,500	500	40,100

Table 2: Point estimates and uncertainty ranges for number of incident HIV infections in Canada in 1999 compared with point estimates in 1996, by exposure category


	MSM	MSM-IDU	IDU	Hetero	Other	Total
1999 Range	1,610 (1,190-2,060)	270 (190-360)	1,430 (1,030-1,860)	880 (610-1,170)	0	4,190 (3,310-5,150)
1996	1,240	290	1,970	700	0	4,200

Tables 1 and 2 reflect a rise in the number of prevalent and incidence infections among heterosexuals. The estimated prevalent number of infections to 1999 is 8,000, 45% higher than the estimate of 5,500 in 1996. The number of new infections among heterosexuals increased 26% over this same time period, from 700 to 880 new infections per year.

An attempt was made to specifically evaluate the heterosexual subcategory 'endemic' to estimate what proportion of the epidemic can be attributed to individuals from a country where HIV is predominantly transmitted through heterosexual contact. Based on the proportions in reported HIV positive test reports and reported AIDS cases, it is estimated that this group represents approximately 20% to 30% of the heterosexual exposure category in the national prevalence and incidence estimates. It is important to note that there is considerable variation in this proportion between provinces, and that this estimate is quite uncertain since a large proportion of HIV test reports do not contain complete exposure category information.

Trends in Exposure Category among New Infections


The distributions of exposure categories among new HIV infections shown in Figure 1 clearly




outline the changes in the HIV epidemic in Canada. Prior to 1999, the proportion of new infections attributed to IDUs had steadily increased from 2% during 1981-1983 to 24% between 1987-1990 to 47% in 1996. However, 1999 incidence estimates indicate that the proportion has now dropped to 34%. Conversely, the proportion of new infections attributed to MSM demonstrated a steady decline from over 80% in 1981-1983 to 30% in 1996. Recently, however, there has been a sharp increase in the proportion of new infections attributed to MSM to 38% in 1999. The proportion of new infections attributed to the heterosexual exposure category has increased steadily in the last two decades reaching 21% of new infections by 1999.

Trends among Women and Aboriginal Populations

An estimated 6,800 women were living with HIV infection (including those living with AIDS) at the end of 1999, a 48% increase from the 1996 prevalence estimate of 4,600. Thus, women accounted for 14% of the prevalent HIV infections in 1999 compared to 11% in 1996. The number of newly infected women remained just below 1,000 cases per year in both 1999 and 1996 (917 and 950 respectively) (Figure 2). In 1999, 54% of all new HIV infections among women were attributed to IDU and 46% were attributed to the heterosexual exposure category.



The estimated number of prevalent HIV infections among Aboriginal populations was 1,430 in 1996 and 2,740 in 1999, an increase of 91% (Figure 3). In 1999, 5.5% of all prevalent HIV infections in Canada were attributed to Aboriginal populations. There were 370 new infections in this group in 1999 (9% of all new HIV infections), 64% of which were attributed to the exposure category IDU, 17% were attributed to heterosexuals, 11% to MSM and 8% to MSM-IDU.



Comment

The methods employed to estimate HIV prevalence and incidence make maximum use of a wide variety of surveillance and research data. The resulting estimates are necessarily imprecise, but the degree of certainty is improved by using several independent methods in a combined approach. The advantages of this approach are its flexibility and its ability to readily incorporate new data and to highlight gaps in existing knowledge. The fact that the methods to estimate national trends of HIV are largely determined by data from large cities is a major limitation. These estimates do not, therefore, necessarily reflect local trends of HIV incidence and prevalence in Canada.

The 1999 estimates clearly illustrate the changing face of the Canadian HIV epidemic. They highlight a potential resurgence of the epidemic among MSM and an increasing urgency of the situation among Aboriginal populations. Although the estimates indicate a reduction in incidence among IDUs, the absolute number of new infections per year is still unacceptably high in this exposure category.

These findings will be critical for the planning and evaluation of prevention and care programs in Canada. The 1999 estimates support the need to strengthen and improve these programs and provide further evidence of the importance of

enhancing existing surveillance and analysis. Furthermore, results underscore the fact that it is not yet time to reduce vigilance with respect to HIV and AIDS in Canada.

References

1. Archibald CP, Remis RS, Farley J, Sutherland D. *Estimating HIV prevalence and incidence at the national level: combining direct and indirect methods with Monte-Carlo simulation*. XI International Conference on AIDS, Geneva, 1998 (Abstract 43475).
2. Geduld J, Archibald C. *National trends of AIDS and HIV in Canada*. *CCDR*. 2000;26:193-201.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
Centre for Infectious Disease Prevention & Control
Health Canada
Tunney's Pasture, Postal Locator 0900B1
Ottawa, ON K1A 0L2
Tel: (613) 954-5169
Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/

*Our mission is to help the people of
Canada maintain and improve their
health*

Health Canada



HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- There were an estimated 49,800 people living with HIV infection in Canada at the end of 1999.
- Of these, approximately 15,000 or 30% are not aware of their infection.
- Given the new treatments for HIV, it is more important than ever that all Canadians are able to access HIV testing.

Prevalent HIV Infections in Canada: Up to One-Third May Not Be Diagnosed

Introduction

This *Epi Update* presents the estimated number of Canadians who were HIV-infected but unaware of their infection at the end of 1999. It also summarizes available data on the characteristics of persons tested for HIV in Canada. It is anticipated that the next set of national estimates will pertain to the year 2002 and will be produced during 2003.

HIV Testing in Canada

Knowledge of one's HIV status can be useful for several reasons. Counselling received at the time of HIV testing can provide critical information about how to reduce the risk of HIV infection. If an individual is found to be HIV infected, consideration can be given to starting antiretroviral therapy. In the case of pregnant women, treatment can reduce the chances that the infant will be infected from about 25% to 8% or less.¹

Canadians have had the opportunity to be tested for HIV infection in Canada since the test became available in 1985. Individuals have accessed HIV testing services through either coded or confidential testing at a doctor's office or clinic, or through anonymous testing sites.

Positive HIV test report data are provided by all provinces and territories in Canada to the Centre for Infectious Disease Prevention and Control (CIDPC) and are presented in the most recent semi-annual report: *HIV and AIDS in Canada: Surveillance Report to December 31, 2001*.² They are based on non-nominal, confidential HIV testing information with duplicate tests for the same individual removed to the extent

CIDPC Website:

www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

possible. The removal of duplicates is necessary to accurately reflect the annual number of new HIV diagnoses. Duplicate removal rates vary by year, province and type of data (nominal, non-nominal or anonymous). It is important to note that in most provinces, the ability to remove duplicates has improved significantly since 1995.

HIV-Infected but Unaware

There have been approximately 46,000 positive HIV tests reported to CIDPC to December 31, 1999.³ After adjusting for under and delayed reporting, it is estimated that about 51,000 Canadians have tested positive for HIV from 1985 (when testing became available) to the end of 1999. Of this total, an estimated 15,000-17,000 individuals had died by the end of 1999 (also adjusted for under and delayed reporting). Therefore, of this 51,000 approximately 34,000-36,000 individuals were aware of their HIV infection and were still alive at the end of 1999.

It is important to note that data on positive HIV tests only represent those who have tested positive for HIV infection and do not represent all persons who have been infected with HIV as some individuals who have been infected with HIV have not yet come forward for testing.

In November 2000, CIDPC published estimates of HIV prevalence in Canada to the end of 1999.⁴ It was estimated that approximately 49,800 Canadians were living with HIV infection (including those living with AIDS) at the end of 1999. This number includes those who are aware of their infection (had a positive HIV test) and those who are unaware of their infection.

The difference between the total number who were HIV-infected and alive at the end of 1999 (49,800) and the number who were aware of their HIV infection and alive (34,000-36,000) at the end of 1999 represents an estimate of the number of persons unaware of their infection (not yet tested positive for HIV) and alive. This difference is approximately 15,000 or about 30% of the estimated 49,800 Canadians living with HIV infection at the end of 1999.

Characteristics of Persons Tested for HIV

A Canada-wide survey conducted in January 1997 found that 18.6% of men aged 15 years and older and 16.2% of women aged 15 years and older had been tested for HIV (excluding tests for blood donation and insurance purposes).⁵ Of those tested, 39% had been tested in the year prior to the survey, 57% in the prior 2 years, and 43% had their most recent test more than 2 years prior to the survey. A 1996 survey found that, taking into account ancillary testing such as donating blood or being tested for life-insurance purposes, 41% of men and 31% of women in Canada had ever been tested for HIV.⁶

National surveys of the general population suggest that those who report risk factors are more likely to be tested:

- Among heterosexuals, those with two or more partners in the last year were more likely to be tested than those with one partner (50.5% vs 17.4%). Of those who reported having had a sexually transmitted disease (STD) in the past 5 years, 58% had been tested compared to 17.4% of those who did not report an STD.⁵
- For men, testing was higher among those who had sexual intercourse with another man (71%), used injecting drugs (62%), received blood or clotting factor between 1978 and 1985 (27%), or had a partner with a risk factor (IDU, having received blood or clotting factor between 1978 and 1985, origin in from country endemic for HIV) (30%).⁵ For women, testing was higher among those who had received blood or clotting factor between 1978 and 1985 (32%), had a high-risk partner (38%), or had sexual intercourse with a man since 1978 (17%).⁶
- Testing is highest among individuals aged 25 to 34 years. Even after taking into account all other risk factors, those aged ≥ 45 years are still less likely to be tested than are those < 45 years.^{5,6}

- Although those reporting risk factors such as IDU, multiple partners, or MSM are more likely to be tested, a substantial proportion of those reporting risk factors have not been tested recently, or have not been tested at all. For example, among those who report more than one partner in the last year and not using condoms consistently, 53% of men and 38% of women have never been tested.⁵

Comment

Canadians with risk factors for HIV infection are more likely to have been tested for HIV than those without such risk factors. However, there is still a significant proportion of persons with risk factors who have never been tested for HIV. It has been estimated that there are approximately 15,000 people or 30% of the HIV-infected population who are unaware that they are infected. More information is needed about individuals who are at risk for HIV, but who have not been tested. Given these data, and the fact that new treatments are available for HIV infection, it is more important than ever that all Canadians be able to access HIV testing, particularly those at highest risk for HIV infection.

References

1. Mofenson LM, McIntyre JA. *Advances and research directions in the prevention of mother-to-child HIV-1 transmission*. Lancet 2000;355:2237-44.
2. Health Canada. *HIV and AIDS in Canada: Surveillance Report to December 31, 2000*. Division of HIV/AIDS Epidemiology and Surveillance, CIDPC, PPHB, Health Canada, April 2001.
3. Health Canada. *HIV and AIDS in Canada: Surveillance Report to December 31, 1999*. Division of HIV/AIDS Epidemiology and Surveillance, CIDPC, PPHB, Health Canada, April 2000.
4. Geduld J and Archibald C. *National trends of AIDS and HIV in Canada*. CDR 2000;26:193-201.
5. Houston SM, Archibald CP, Sutherland D. *Sexual risk behaviours are associated with HIV testing in the Canadian general population*. Can J Inf Dis 1998, 9 (Suppl A): 39A, #239P. And unpublished data from: Canada Health Monitor survey, January 1997, Division of HIV Epidemiology, LCDC, Health Canada.
6. Houston SM, Archibald CP, Strike C, Sutherland D. *Factors associated with HIV testing among Canadians: Results of a population-based survey*. International Journal of STD and AIDS 1998; 9:341-346.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
 Centre for Infectious Disease Prevention & Control
 Health Canada
 Tunney's Pasture, Postal Locator 0900B1
 Ottawa, ON K1A 0L2
 Tel: (613) 954-5169
 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

Our mission is to help the people of Canada maintain and improve their health

Health Canada



HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- **Nominal, non-nominal and anonymous HIV testing is available in Canada.**
- **Although anonymous testing may encourage testing, it is not available in all provinces and territories.**
- **HIV infection is expected to become notifiable in all provinces and territories by May 1, 2003.**

HIV Infection Reporting in Canada

Introduction

The most recent Canadian HIV and AIDS surveillance report indicates that the total number of AIDS cases and positive HIV tests reported in Canada to June 30, 2002 are 18,336 and 51,470 respectively.¹ The positive HIV test results reported to the Centre for Infectious Disease Prevention and Control (CIDPC) are from only those who test positive for HIV through nominal, non-nominal or anonymous testing in the provinces and territories, and whose results are reported to CIDPC by their respective health authority or HIV testing laboratory.

This *Epi Update* provides the most up to date information available on HIV infection reporting in Canada. It describes the types of HIV testing available in each province and territory as well as the jurisdictions in Canada where HIV infection is notifiable.

A notifiable disease is one that is considered to be of such importance to public health that its occurrence is required to be reported to public health authorities. When HIV infection is notifiable it is required by law that it must be reported to the public health authority in the area in which the diagnosis was made. As a notifiable disease must be reported, the two terms, notifiable and reportable, are used interchangeably in discussing HIV/AIDS reporting in Canada.

HIV Infection Becomes Notifiable Across Canada

- As of January 2003, HIV infection was legally notifiable in all provinces and territories except British Columbia; however, it is expected to become notifiable in British Columbia on May 1, 2003. Eight provinces and territories had HIV reporting legislation in place by the mid- to late-1980s. The remaining five will have instituted legislation between 1995 and 2003.

CIDPC Website:

www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

- In most testing situations, laboratories and physicians are responsible for reporting HIV infection, but this varies by province or territory.
 - When HIV infection is notifiable, 'nominal/name-based' or 'non-nominal/non-identifying' information about an individual who tests positive for HIV is forwarded to provincial or territorial public health officials. This includes demographic data, such as the person's age and gender; risks associated with the transmission of HIV; and laboratory data, such as the date of the person's first positive HIV test.
 - HIV infection is not legally notifiable at the national level yet notification to CIDPC is voluntarily undertaken. All positive HIV test reports are provided non-nominally to CIDPC.
 - HIV testing patterns within the general population, along with the profile of people being tested, are important for designing and targeting intervention programs², and for developing a context for HIV/AIDS surveillance data.
- There is collection of patient information (such as age and gender, as well as city of residence, name of diagnosing health care provider, country of birth); information detailing the HIV-related risk factors of the person being tested; and laboratory data. The amount of information collected is dependent upon the province/territory.
 - If the HIV test result is positive, the person ordering the test is legally obligated to notify public health officials of the person's positive test in those jurisdictions where HIV is notifiable.
 - The test result is recorded in the health care record of the person being tested.

2. Non-nominal/non-identifying HIV testing

Similar to Nominal/name-based testing on all points except:

- The HIV test is ordered using a code or the initials of a person being tested (not the full or partial name).

3. Anonymous testing:

- Usually available at specialized clinics, organized and supported by public health departments and by some health care providers.
- The person ordering the HIV test does not know the identity of the person being tested for HIV.
- The HIV test is carried out using a code. The person ordering the HIV test and laboratory carrying out the testing on the blood sample do not know to whom the code belongs. Only the person being tested for HIV knows the unique, non-identifying code.
- Age, gender, HIV-related risk factors and ethnicity of the person being tested for HIV may be collected during anonymous testing depending on the province or territory in which the test is ordered or on the test site.

Three Types of HIV Testing Available in Canada

Canadians choosing to be tested for the presence of HIV infection may have three different testing options depending on the province or territory in which testing takes place:

1. Nominal/name-based HIV testing

- May be carried out at numerous locations, including clinics and the office of a health care provider.
- The person ordering the test knows the identity of the person being tested for HIV.
- The HIV test is ordered using the name of the person being tested.

- Test results are not recorded on the health care record of the person being tested. It is only the person being tested who may subsequently decide to give their name and include the HIV test result in his or her record.

Information regarding where HIV infection is notifiable as well as the types of HIV testing services offered throughout Canada is summarized in Table 1.

Table 1: HIV Testing and Legislation of HIV Reporting by Province/Territory

Prov/ Terr	Type of HIV Testing Available	HIV Infection Reportable Since ¹	HIV Infection Reportable By:	Level of Reporting to the Prov/Terr
B.C.	N, NN, A	2003 ²	L, P	N, NN ³
Yukon	N, NN	1995	P,	N
NWT	N, NN	1988	L, P, RN	N
Nunavut	N, NN	1999	L, P, RN	N
Alta.	N, NN, A	1998	L, P	NN
Sask.	N, NN, A	1988	L, P	NN
Man.	NN	1987	L, P	NN
Ont.	N, NN, A	1985	L, P	N, NN ³
Que.	N, NN, A	2002	L, P	NN
N.B.	N, NN, A	1985	L, P, RN	NN
N.S.	N, NN, A	1985	L, P	N, NN
P.E.I.	N, NN	1988	L, P, RN	N, NN
Nfld.	N, NN, A	1987	L, P	N

N= Nominal/Name-Based, NN = Non-Nominal/Non-Identifying, A= Anonymous, L = Lab, P = Physician, RN = Nurse

- 1 Refers to legislation governing the type of HIV infection reporting to provincial/territorial health officials and the year it came into effect.
- 2 HIV infection is expected to become notifiable in British Columbia on May 1, 2003.
- 3 In Ontario and British Columbia, HIV positive data from Anonymous HIV Testing (AHT) are reported non-nominally at the provincial level.

The Availability of Anonymous HIV Testing (AHT) May Increase Testing

- As anonymous testing offers the highest degree of confidentiality, it may encourage more people to come forward for HIV testing and counselling.³

- An evaluation study of AHT in Ontario suggested that AHT provides testing to a populations that are not otherwise accessing testing.⁴
- Several studies in the United States have shown that AHT programs encourage people to be tested for HIV, especially those at high-risk or who would not volunteer for testing under nominal/name-based or non-nominal/non-identifying circumstances.^{5,6,7}
- In its first year of operation, AHT sites in Ontario tested approximately 5% of the total tested population, and most often served individuals at high risk of HIV infection, especially men who have sex with men.⁸

Information regarding the availability and reporting of anonymous HIV infection in Canada is summarized in Table 2.

Table 2: Status of Anonymous HIV Testing (AHT) by Province/Territory

Prov/ Terr	AHT Since ¹	AHT Sites	AHT Data Reported ²	Counselling Services Available
B.C.	1985	Any Physician's Office	Yes	Yes
Yukon	—	—	—	—
NWT	—	—	—	—
Nunavut	—	—	—	—
Alta.	1992	3	Yes	Yes
Sask.	1993	3	No	Yes
Man.	—	—	—	—
Ont.	1992	33	Yes	Yes
Que	1987	60+	No	Yes
N.B.	1998	7	—	Yes
N.S.	1994	1	No	Yes
P.E.I.	—	—	—	—
Nfld.	**	6	Yes ³	Yes ³

** AHT is available upon request, but are not the official guidelines for the province/territory.

- 1 Refers to the availability of AHT in the respective province/territory, and the year in which AHT was implemented.
- 2 Refers to whether or not positive HIV test data from AHT is reported to the Centre for Infectious Disease Prevention and Control, Health Canada.
- 3 If someone tests positive for HIV through AHT, that individual then becomes part of the nominal/name-based system, where counselling, follow-up care and HIV data reporting are all done nominally.

Comment

As of May 1, 2003 HIV infection is expected to be legally notifiable in all provinces and territories, however, each of these has a different practice for reporting HIV infection. Legislation of HIV infection reporting in all Canadian provinces and territories may increase the number of tests received at CIDPC. A change to mandatory reporting of HIV infection in Alberta in 1998 resulted in a significant increase in HIV tests among both men and women.⁹ As a result, making HIV notifiable across Canada should allow for the collection of more complete epidemiological data as well as enable more accurate and timely monitoring of the HIV epidemic.

All provinces and territories in Canada offer at least one form of HIV testing: 1) nominal/name-based; 2) non-nominal/non-identifying; and/or 3) anonymous testing. At present, nominal/name-based and non-nominal/non-identifying HIV testing is widely available in Canada; however, anonymous HIV testing is available in only eight provinces. Increased availability and accessibility to different types of HIV testing may allow individuals to choose the testing and counselling environment in which they feel most comfortable, thereby encouraging more people to be tested and facilitating the targeting of intervention and treatment programs.¹⁰

For more information on HIV testing, please contact your provincial or territorial public health department.

References

1. Health Canada. *HIV and AIDS in Canada: surveillance report to June 30, 2002*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada, November 2002.
2. Houston S, Archibald CP, Strike C, Sutherland D. *Factors associated with HIV testing among Canadians: results of a population-based survey*. International Journal of STD and AIDS 1998; 9:341-346.
3. Jürgens R, Palles M. *HIV testing and confidentiality: a discussion paper*. Pp. 52-69. Canadian HIV/AIDS Legal Network and the Canadian AIDS Society, 1997.
4. *Anonymous HIV testing Evaluation: January 1992 to June 1993*. AIDS Bureau, Ontario Ministry of Health, November 1994.
5. Keagles SM, Catania JA, Coates TJ et al. *Many people who seek anonymous HIV-antibody testing would avoid it under other circumstances*. AIDS 1990;4(6):585-588.
6. Hoxworth T, Hoffman R, Cohn D et al. *Anonymous HIV testing: does it attract clients who would not seek confidential testing?* AIDS and Public Policy Journal 1994;9(4):182-188.
7. Hertz-Picciotto I, Lee LW, Hoyo C. *HIV test-seeking before and after the restriction of anonymous testing in North Carolina*. American Journal of Public Health 1996;86(10):1446-1450.
8. Browne J, Major C, Galli R, et al. *HIV anonymous testing-does it make a difference?* (Abstract no. PO-C28-3249). IXth International Conference on AIDS. Berlin, 6-11 June, 1993;9(2):758.
9. Jayaraman GC, Preiksaitis JK, Larke B. *Mandatory reporting of HIV infection to public health authorities and opt-out prenatal screening for HIV in Alberta: Effect on testing rates*. CMAJ (in press).
10. Hong BA, Berger SG. *Characteristics of individuals using different HIV/AIDS counseling and testing programs*. AIDS 1994;8:259-262.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
 Centre for Infectious Disease Prevention & Control
 Health Canada
 Tunney's Pasture, Postal Locator 0900B1
 Ottawa, ON K1A 0L2
 Tel: (613) 954-5169 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/

Our mission is to help the people of Canada maintain and improve their health

Health Canada



HIV/AIDS **EPI UPDATE** Centre for Infectious Disease Prevention and Control

- AT A GLANCE**
- Risk behaviour data on young Canadians show the potential for HIV transmission.
 - Street-involved youth, youth who inject drugs are particularly vulnerable to HIV.
 - A wide range of prevention activities needs to be implemented to help minimize the risk of HIV transmission among youth.

HIV and AIDS Among Youth in Canada

Introduction

Although youth (defined here as those aged 10 to 24 years) currently constitute a small proportion of the total number of reported HIV and AIDS cases in Canada, they are a group that has been greatly affected by the HIV/AIDS epidemic at a global level. According to the most recent UNAIDS report, an estimated 11.8 million people aged 15-24 years are living with HIV/AIDS, and half of all new infections worldwide are occurring among young people.¹ Youth, in general, are vulnerable to HIV infection as a result of many factors, including risky sexual behaviour, substance use (including injecting drug use), and perceptions that HIV is not a threat to them. Young Canadians require the necessary information and skills to help them to adopt and maintain behaviours that are protective against HIV. This *Epi Update* provides the most current information on the status of HIV and AIDS among Canadian youth. HIV-related risk behaviours in this population are also highlighted.

AIDS Data²

- As of June 30, 2002, 18,332 AIDS cases with age information had been reported to the Centre for Infectious Disease Prevention and Control (CIDPC). Of these, 627 (3.4%) were among youth aged 10 to 24 years.
- As seen in Table 1, of the cumulative reported AIDS cases in youth, 10 to 19 years of age, almost two thirds of cases were attributed to recipients of blood and blood products. Among youth aged 20 to 24 years of age with AIDS, almost half were attributed to men who have sex with men (MSM), and 20% to heterosexual contact.

CIDPC Website:
www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/

Table 1: Number of reported AIDS Cases with Associated Exposure Categories (%) for Individuals 10 to 24 Years of Age in Canada, Diagnosed up to June 30, 2002.

Category	10 -19 years of age	20-24 years of age
Number of Cases	87	540
Percentage of all reported AIDS cases	0.5%	2.9%
Associated Exposure Categories ¹	62% Blood & Blood Products 10% MSM 7% Heterosexual 6% IDU 6% MSM/IDU 1% Other*	48% MSM 20% Heterosexual Contact/Endemic 11% MSM/IDU 10% IDU 5% Blood & Blood Products 0% Other*

IDU = Injecting Drug Users, MSM = Men who have sex with men

¹ Percentages based on the total number of cases minus those reports for which exposure category was unknown or "not identified."

* Mode of transmission is known but cannot be classified into any of the major exposure categories.

HIV Testing Data²

Data received from provincial and territorial HIV testing programs do not allow separation of the 10 to 14 and 20 to 24 year age groups before 1998, thus restricting the analysis of HIV test reports for youth.

- As of June 30, 2002, 46,801 positive HIV tests with age information have been reported to CIDPC. Of these, 684 (1.5%) were among youth aged 15 to 19 years, and 12,595 (26.9%) were among individuals aged 20 to 29 years.
- The proportion of females among positive HIV test varies considerably by age and is highest among adolescents and young adults. In 2001, females accounted for 44.5% of positive HIV test reports among those aged 15 to 29 years, an increase from 41% in 2000.
- For the first half of 2002, heterosexual contact, MSM and injecting drug use accounted for 40%, 40%, and 15%

respectively of reported positive HIV tests with known exposure category among those aged 20 to 29 years. Heterosexual contact and injecting drug use accounted for 55% and 36% of reported HIV tests with known exposure category among those aged 15 to 19 years (n=19).

- A cumulative total of 708 positive HIV test reports had been received for individuals less than 15 years of age by June 2002. Among the 354 cases in this group with known exposure category information, perinatal transmission and exposure to infected blood or blood products accounted for over 90% of cases.

HIV Incidence and Prevalence among Youth

HIV prevalence and incidence information, in conjunction with HIV/AIDS surveillance data, are more useful than surveillance data alone for depicting the current magnitude of the HIV epidemic in various population sub-groups. To date, a small number of Canadian studies have examined HIV prevalence or incidence among youth, although most research has involved higher risk populations:

- In the Vancouver Injection Drug User Study (VIDUS), the prevalence of HIV among injecting drug users aged 24 years and younger during the period 1996-2001 was 17%. HIV incidence among participants in this age category was reported as 2.96 for males and 5.69 for females per 100 person years.³
- In the Montreal Street Youth Cohort study (MSYC), participants between 14 and 25 years old have been observed since January 1995. HIV prevalence at study entry in the cohort was 1.4% (14 of 1013 subjects). HIV incidence up to September 2000 was 0.69 per 100 person years.⁴ Among male participants in the Montreal Street Youth study in 2000 who reported having sex with men, the prevalence of HIV was 4.9% and incidence was 1.2 per 100 person years.^{4,5}

- An HIV prevalence of 0.25% was observed in the mid-1990s among young offenders aged 12 to 19 years in British Columbia, many of whom reported a history of injecting drug use.⁶
- Sentinel hospital surveillance of HIV infection in Quebec (early 1990s)⁷, a study of women seeking prenatal care in British Columbia (early 1990s)⁸, and a survey of youth from across Canada involved in an international exchange program (early to mid 1990s)⁹ reported prevalence rates of 0.04% to 0.08% among young people aged 14 to 25 years. In a study in the late 1990s of women seeking abortions in Montreal, the prevalence of HIV among those aged 20 to 24 years was 0.0015%, and there were no infections detected among women under 20 years of age.¹⁰ It should be noted that these latter studies involved relatively small, non-representative samples of youth, and, thus, a zero to very low HIV prevalence rate is not necessarily reassuring.

Risk Behaviour Data Among Youth

Research shows that Canadian youth begin to have sexual intercourse at a relatively early age:

- In the 1996 National Population Health Survey (NPHS), 25.6% of female participants in the 15 to 19 year age group reported that they had had intercourse by the age of 15 years. Almost 20% of young men in this age group also reported that they had begun having intercourse by this age.¹¹

A substantial proportion of young people report having multiple sexual partners in the past year:

- Among sexually experienced, single respondents (those never-married, divorced and widowed) in the 1996 NPHS, 29.4% of males aged 15 to 19 years had had more than one sex partner in the past 12 months, and 27.5% of males aged 20 to 24 years had had more than one sex partner in this same time period. In comparison, 21.8% of

females aged 15 to 19 years had had more than one intercourse partner in the past 12 months, and the same percentage of females (21.9%) aged 20 to 24 years had had more than one intercourse partner in this time frame.¹¹

- In a study of young gay and bisexual men aged 15 to 30 in Vancouver, 16% of the study subjects reported selling sex for money or drugs. HIV prevalence among those subjects that had engaged in prostitution was significantly higher than those that did not (7.3% vs. 1.1%), and incidence was higher as well (4.7 per 100 person years vs. 0.9 per 100 person years).¹²

Research suggests that many Canadian youth are having unprotected sexual intercourse. Not using condoms appears to be more common among young women than it is among young men:



- Among sexually active youth aged 15 to 19 years in the 1994 NPHS (excluding subjects who had a single sex partner and who were married, common-law, divorced, or widowed), 51% of females and 29% of males reported never or only sometimes using a condom in the past year.¹³ The corresponding percentages among those aged 20 to 24 years were 53% and 44%.¹³
- In an ongoing study of Montreal street youth, only 13.2% of participants reported always using condoms during vaginal intercourse, and only 32.4% reported always using condoms during anal intercourse.¹⁴

The extent of unprotected intercourse among youth is further captured in rates of chlamydia and gonorrhoea among those aged 15 to 24 years:

- Figure 1 shows that in 2000, the reported incidence of chlamydia in Canada was highest among females aged 15 to 19 years (1236.1/100,000 women). The reported incidence of gonorrhoea in Canada was also highest among this group of young women (96.4/100,000).^{15,16} (Figure 2)

Research reveals that levels of injecting drug use and injecting risk behaviours among youth, particularly those who are street-involved, require ongoing assessment:

- In a study of IDUs in Calgary in 1998, 46% of participants who were under age 25 years reported that they had borrowed injection equipment in the previous six months compared to 24% of participants who were aged 25 years or older.¹⁷
- Recent results from the ongoing Montreal Street Youth Cohort Study showed that 47.2% of participants had a history of injecting drug use.⁴ Also alarming was the incidence of the initiation of injecting drug use in street youth, estimated to be 7.9 per 100 person-years.¹⁸



Comment

HIV/AIDS is affecting many subgroups of the Canadian population, including youth. Although the limited data that are available suggest that HIV prevalence is currently low among youth, sexual risk behaviour and STD data clearly indicate that the potential for HIV spread exists among young Canadians. More incidence and prevalence information as well as trend data on HIV-related risk behaviours are needed in order to guide and evaluate prevention programs for young Canadians. Epidemiologic and behavioural data for high-risk youth, such as street youth, are also needed to assess fully the risk of HIV transmission among Canada's youth population.

References

1. UNAIDS. *Report on the global HIV/AIDS epidemic*. July 2002, Geneva.
2. Health Canada. *HIV and AIDS in Canada, surveillance report to June 30, 2002*. Division of HIV/AIDS Surveillance, CIDPC, Health Canada, November 2002.
3. Miller CL, Tyndall M, Li K, Laliberte N, Spittal P, Schechter MT. *High Rates of HIV Positivity Among Young Injection Users*. *Can J Infect Dis* 2001; 12(Suppl B):65B {Abstract 340P}.
4. Roy E, Haley N, Leclerc P, Cédras L, Boivin JF. *HIV incidence in the Montreal Street Youth Cohort (MSYC)*. *Can J Infect Dis* 2002; 12(Suppl A):49A {Abstract 317}.
5. Roy E, Hayley N, Boivin JF, Frappier JY, Claessens C, Lemire N. *Étude de cohorte sur l'infection au VIH chez les jeunes de la rue de Montréal*. Final report to LCDC, March 1998 and Roy E (personal communication to M. Nguyen, Division of HIV Epidemiology, Bureau of HIV/AIDS, STD and TB, LCDC, HPB, Health Canada March 2000).
6. Rethon D, Strathdee SA, Cook D, Cornelisse PGA. *Determinants of HIV-related high risk behaviours among young offenders: a window of opportunity*. *Can J Public Health* 1997; 88(1):14-17.
7. Alary M, Joly JR, Parent R, Fauvel M, Dionne M. *Sentinel hospital surveillance of HIV infection in Quebec*. *CMAJ* 1994; 151(7):975-80.
8. Pi D, Ballem PJ, Schechter MT. *The B.C. prenatal study: 1989-94*. Final Report to LCDC, January 1995.
9. Morrisset R, Czyziw E, Lambert J. *HIV infection in young Canadian adults before and after an international exchange program: 1986-96*. 6th Conference of the International Society of Travel Medicine, Montreal, Canada, June 1999.

10. Remis RS, Leclerc P, Palmer RW, Eason EL, Lebel F, Fauvel M. *HIV prevalence and incidence and reported risk factors among women undergoing abortion in Montreal*. *Can J Infect Dis* 1997; 8(Suppl A):33A {Abstract 242} and Leclerc P (personal communication to M. Nguyen Division of HIV Epidemiology, Bureau of HIV/AIDS, STD and TB, LDCD, HPB, Health Canada).
11. Maticka-Tyndale E, Barrett M, McKay A. *Adolescent sexual and reproductive health in Canada: a review of national data sources and their limitations*. *Can J Hum Sex*, 2000; 9(1):41-65.
12. Weber AE, Craib KJP, Chan K, Martindale SL, Miller ML, Schechter MT, Hogg RS. *Sex trade involvement and rates of human immunodeficiency virus positivity among young gay and bisexual men*. *Int J Epidemiol*, 2001; 30(6):1449-54.
13. Galambos NL, Tilton-Weaver LC. *Multiple-risk behaviour in adolescents and young adults*. *Health Rep* 1998; 10(2):9-20.
14. Roy E, Haley N, Leclerc P, Lemire N, Boivin J-F, Frappier J-Y, Claessens C. *Prevalence of HIV infection and risk behaviours among Montreal street youth*. *Int J STD AIDS* 2000; 11(4):241-247.
15. Health Canada. *STD Data Tables Appendix 1.1*. Division of Sexual Health Promotion and STD Prevention and Control, CIDPC, Health Canada. <http://www.hc-sc.gc.ca/pphb-dgsp/STD-mts/>
16. Health Canada. *STD Data Tables Appendix 2.2*. Division of Sexual Health Promotion and STD Prevention and Control, CIDPC, Health Canada. <http://www.hc-sc.gc.ca/pphb-dgsp/STD-mts/>
17. Guenter CD, Fonesca K, Nielsen DM, Wheeler VJ, Pim CP. *HIV Prevalence Remains Low Among Calgary's Needle Exchange Program Participants*. *Can J Public Health* 2000; 91(2):129-132.
18. Roy E, Haley N, Leclerc P, Boivin JF, Cédras L. *Drug use behaviours of new injectors in the Montreal street youth cohort*. *Can J Infect Dis* 2000; 11(Suppl B):54B {Abstract 301}.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
 Centre for Infectious Disease Prevention & Control
 Health Canada
 Tunney's Pasture, Postal Locator 0900B1
 Ottawa, ON K1A 0L2
 Tel: (613) 954-5169 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/

*Our mission is to help the people of
 Canada maintain and improve their
 health*

Health Canada



HIV/AIDS **EPI UPDATE** Centre for Infectious Disease Prevention and Control

5

- AT A GLANCE**
- **In Canada, a total of 1,437 AIDS cases and 6,250 HIV cases have been reported in adult women up to June 30, 2002.**
 - **Women represent an increasing proportion of reported HIV cases in Canada, and accounted for 26% of positive HIV test reports in the first half of 2002.**
 - **Heterosexual contact and injecting drug use are the two major risk factors for HIV infection in women.**

CIDPC Website:
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

HIV and AIDS Among Women in Canada

Introduction

The HIV/AIDS epidemic in Canada has changed from the early epidemic that affected primarily men who have sex with men (MSM) to the current epidemic, which increasingly affects other groups such as injecting drug users (IDU) and heterosexuals. As a result of this shift, HIV/AIDS affects a growing number of women. The HIV/AIDS epidemic among women is of particular concern because of the potential for transmission to their infants. This report updates the status of HIV and AIDS among adult and adolescent women (15 years and older) in Canada.

AIDS

In Canada, of the 18,124 cumulative AIDS cases in adults reported up to June 30, 2002 to the Centre for Infectious Disease Prevention and Control (CIDPC), 1,437 (7.9%) were among women. The proportion of AIDS cases among women (relative to all reported AIDS cases in adults for which gender and age are known) has increased over time, from 5.6% before 1992 to 8.3% in 1995 and peaking at 16.4% in 1999. In 2001, the proportion of AIDS cases among women has remained at 16%.¹


Of all cumulative reported AIDS cases in women, 67.4% are attributed to heterosexual contact, 22.9% to injecting drug use and 9.5% to recipients of blood and blood products. There has been a steady increase in the proportion of adult female AIDS cases attributed to IDU, from 17.8% prior to 1996 to 26.6% in 1996 and 34.9% in 2000.

HIV

AIDS data can contribute to an understanding of trends in HIV infections, but only on those acquired approximately 10 years in the past. In contrast, positive HIV test reports provide a picture of more recent infections. Data from provincial and territorial HIV testing

programs indicate that a total of 6,250 positive HIV tests with known age and gender have been reported in adult women up to June 30, 2002.¹

Women account for a growing proportion of positive HIV tests reports with known age and gender among adults in Canada. The proportion of females each year has risen, from 9.7% in the years between 1985 and 1995 to nearly 25% of adult positive HIV test reports between January 1999 and December 31, 2001. In the first half of 2002, this proportion increased slightly to 25.8%. The proportion of women among positive HIV tests vary considerably by age and is highest among adolescents and young adults (Figure 1). In 2001, women accounted for 44.5% of positive HIV test reports among those aged 15 to 29 years, an increase from 41% in 2000. In the first half of 2002, this proportion decreased slightly to 42%.¹



Among women, the primary exposure categories associated with newly diagnosed HIV infection are heterosexual contact and IDU (Table 1). The proportion of HIV tests in females attributed to heterosexual contact has increased over time from 46% for the period 1985-1996 to 62% in 2001. The proportion attributed to IDU has however remained fairly constant at around 36% (Table 1). Heterosexual contact still remains the main risk factor for HIV infection in women. However, injecting drug use continues to be a significant risk for HIV among Canadian women and in some studies this risk is greater for female IDUs than for male IDUs.²

Table 1: Proportion of Positive HIV Tests among Adult Females by Exposure Category and Year of Test, Canada (1985- June 30, 2002)¹

Year	Exposure Category		
	Heterosexual Contact	IDU	Blood & Blood Products
1985-96	46.0	38.8	9.0
1997	45.5	45.2	1.4
1998	52.9	38.7	3.6
1999	48.0	47.9	1.2
2000	54.8	39.7	1.7
2001	62.2	32.6	1.4
2002*	62.1	35.5	1.6
TOTAL	49.2	39.5	5.8

* Data to June 30, 2002.

HIV Incidence Estimates Suggest Rising Number of New Infections Among Women in Canada

Data from positive HIV test reports do not provide the complete picture of the annual number of new HIV infections since only a proportion of those newly infected are tested in the same year. Furthermore, not all HIV tests reported in a given year were infected in that year. The CIDPC has estimated the annual number of new HIV infections using information from AIDS case reports, provincial HIV testing databases, population-based surveys, targeted epidemiologic studies, and census data. In 1999, approximately 4,190 persons in Canada became newly infected with HIV, with an estimated 920 (21.9%) among women.³ The estimated proportion of women among new HIV infections has increased since the 1980s. In 1996 and 1999, it was estimated that women accounted for more than one of every five new infections³ (Figure 2).

These recent estimates also indicate that the number of women in Canada living with HIV, including those with AIDS, continues to grow. By the end of 1999, an estimated 6,800 women were living with HIV, an increase of 48.0 % from the 1996 estimate of 4,600.³

HIV among Pregnant Women and Women of Childbearing Age


HIV testing during pregnancy is an option available to women across Canada. However, physician guidelines and/or recommendations encouraging informed decisions regarding HIV testing during pregnancy vary by province and territory. These are discussed in detail in the *Epi Update* entitled "Perinatal Transmission of HIV," April 2003.

HIV prevalence studies among pregnant women can provide an important source of information on the prevalence rate of HIV in the general heterosexual population. Prenatal seroprevalence studies in Canada report an estimated national rate of HIV infection among pregnant women of 3-4/10,000 population.

Large metropolitan areas report higher rates of HIV infection among pregnant women (4.7 for Vancouver versus 3.4 for the rest of B.C. in 1994.⁴ 15.3 for Montreal versus 5.2 for the province of Quebec in 1990⁵). Even provinces without large metropolitan areas have indicated significant rates (for example, 4.1/10,000 in New Brunswick for 1994-96⁶). Data from Manitoba suggest an increasing trend of HIV infection among women of childbearing age, from 0.7/10,000 in 1991 to 3.2/10,000 in 1994-95.⁷ A study is ongoing in B.C. to update the prevalence estimates of HIV among pregnant aboriginal women.

An ongoing HIV seroprevalence study among pregnant women in Ontario reported a rate of 3.7/1000.⁸ This rate is based on pregnant women who voluntarily tested (approximately 70%) whereas the rates in the other provinces are based on complete samples from unlinked anonymous studies.

Figure 2: Estimated Proportion of Women Among New HIV Infections



Comment

Women in Canada are increasingly becoming infected with HIV, especially injecting drug users and women with high-risk sexual partners. Efforts to reduce transmission of HIV will need to focus on promoting safer sexual behaviours and reducing substance abuse.

All women, and especially women of childbearing age, should have access to HIV testing, counselling and care. Better data on the trends, risk factors and geographic shifts of HIV among Canadian women are needed to help target prevention and care programs.

References

1. Health Canada. HIV and AIDS in Canada. *Surveillance report to June 30, 2002*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada, November 2002.
2. Spittal PM, Craib KJP, Wood E, Laliberté N, Li K, Tyndall MW, O'Shaughnessy MV, Schechter MT. *Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver*. *CMAJ* 2002; 166(7): 894-899.
3. Geduld J, Archibald C. *National trends of AIDS and HIV in Canada*. *CDCR*. 2000; 26:193-201.
4. Pi D, Ballem PJ, Schechter MT. *The B.C. Prenatal Study: 1989-94*. Final report to LCDC; January 1995.
5. Hankins C, Hum L, Tran T et al. *HIV seroprevalence in women giving birth to live infants in Northern Quebec (1989-93)*. *Can J Infect Dis* 1995; 6 Suppl B:39 {Abstract 314} 1995.
6. Getty G, Leighton P, Mureika R et al. *NB antenatal seroprevalence study*. *Can J Infect Dis* 1997; 8:24A {Abstract 205} 1997.
7. Blanchard J, Hammond G, Fast M et al. *HIV seroalence among antenatal women in Manitoba: August, 1994 through August, 1995*. Final report to LCDC 1996.
8. Remis RS. Unpublished data to be presented at CAHR 2003 conference. April 2003, Halifax.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
 Centre for Infectious Disease Prevention & Control
 Health Canada
 Tunney's Pasture, Postal Locator 0900B1
 Ottawa, ON K1A 0L2
 Tel: (613) 954-5169 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

*Our mission is to help the people of
 Canada maintain and improve their health*

Health Canada



HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- As of June 30, 2002, **11.6% (2,123) of all reported AIDS cases have been among persons age 50 years or older.**
- **Approximately 10% of the positive HIV test reports in Canada each year since the beginning of the epidemic have been among those age 50 years or older.**
- **Sexual contact is the major risk factor for HIV infection in older Canadians.**

CIDPC Website:
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

HIV/AIDS among Older Canadians

Introduction

HIV/AIDS is generally believed to be a younger person's disease and therefore, little focus has been given to the issue of HIV/AIDS among older Canadians. It should be noted that the age range for "older" is subjective, and the lower age limit in the literature varies between 40 years to 55 years of age. For the purpose of this report, older individuals will be defined as those age 50 years or older.

AIDS Case Report Data¹

- As of June 30, 2002, 18,332 AIDS cases with age information have been reported to the Centre for Infectious Disease Prevention and Control (CIDPC). Of these reports, 2,123 (11.6%) have been among persons 50 years of age or older.
- Figure 1 shows that the number of annual AIDS cases reported among older adults has decreased since the first half of the 1990s. This is similar to the decrease in the number of overall AIDS cases, which is due in part to the introduction of new, effective anti-HIV drugs in the mid-1990s. However, with respect to all reported AIDS cases, the proportion among those aged 50 years or older has increased over time to 21.3% in 2001. This increase may be influenced by the use of the new anti-HIV drugs, since it has likely delayed the onset of AIDS among those for whom AIDS has been prevented.




Table 1 shows the distribution of exposure categories for all reported AIDS cases among older Canadians up to June 30, 2002. Men who have sex with men (MSM) made up the majority of reported cases among those age 50-59 and those age 60 years and older. Other common exposure categories were exposure to blood and blood products (before 1985) and heterosexual contact.

Table 1. Distribution of exposure categories among reported AIDS cases for individuals 50 years of age and older in Canada, diagnosed up to June 30, 2002.

Exposure Category	% in each Exposure Category ¹	
	50-59 years (n=1453)	≥ 60 years (n=517)
MSM	70.5	51.3
MSM/IDU	2.3	1.0
IDU	3.5	1.5
Blood/Blood Products	5.6	17.4
Heterosexual Contact	17.7	27.7
Other *	0.3	1.0


IDU = Injecting Drug Users, MSM = Men who have sex with men
 1 Percentages based on the total number of cases minus those reports for which exposure category was unknown or "not identified."

* Mode of transmission is known but cannot be classified into any of the major exposure categories.

HIV Testing Data¹

While AIDS data provide information on HIV infection that occurred about ten years in the past, HIV data provide a picture of more recent infections.

Data from provincial and territorial HIV testing programs indicate that 3,858 positive HIV tests with known age information have been reported among persons 50 years and older up to June 30, 2002. As seen in Figure 2, the proportion of annual positive HIV test reports among those age 50 years or older has been roughly 10% since the early to mid 1990s. Men have accounted for 88.2% of the cumulative 3,586 positive HIV test reports with known gender information among those age 50 years or older (data not shown).



In 2001, 46% of HIV positive test reports among those age 50 years and older with known exposure category information were attributable to MSM. Heterosexual contact accounted for 34.4% of positive HIV test reports among those age 50 years or older (Table 2).

Table 2. Distribution of exposure categories among Positive HIV Test Reports for Individuals 50 years of age and older in Canada, reported between January 1, 2001 and December 31, 2001

Exposure Category	% 50 years and older ¹ (n=119)
MSM	46.3
MSM/IDU	0.8
IDU	10.9
Blood/Blood Products	3.4
Heterosexual Contact	34.4
Other*	4.2

IDU = Injecting Drug Users, MSM = Men who have sex with men
 1 Percentages based on the total number of cases minus those reports for which exposure category was unknown or "not identified."
 * Mode of transmission is known but cannot be classified into any of the major exposure categories.

More Information Needed: Older Adults and Risk Behaviours, HIV Testing Patterns, and Knowledge of HIV/AIDS

Healthy sexual relationships continue to be an important part of life for the majority of older adults. The availability of sexual partners and one's state of health may be greater factors in determining sexual activity than is age.²

- In one international study of adults age 45 years and older (n=1,384), 51.7% of men and 55.1% of women who reported having a sexual partner (n=949) reported having sexual intercourse once a week or more during the past six months.²

Although surveillance data for Canada suggest that sexual contact is the major risk factor for HIV infection among older adults, very little research has been conducted on risky sexual behaviour among older Canadians. However, some information has been captured by national population surveys:

- Table 3 compares selected sexual risk behaviours among respondents age 50-59 in the 1996 National Population Health Survey to all respondents.³ While sexual risk behaviours were reportedly lower among older participants, they were not insubstantial.

Table 3: High-Risk Sexual Behaviours among Canadians Age 15-59 Compared to Those age 50 to 59 years, 1996 National Population Health Survey³

Age Category	Never used condoms ^{*,a,b}	Did not use condom at last sex ^{*,a,b}	3+ sexual partners in last year ^b
15-59 yrs	8%	16%	3%
50-59 yrs	7%	8%	1%

* Use of a condom with a sexual partner of less than 12 months duration.
 a As a percentage of those in a relationship with a partner of less than 12 months duration.
 b As a percentage of those who had sexual intercourse in the previous year.

- Table 4 suggests that older Canadians are less likely to have had an HIV test during their lifetime than the general adult population. Additionally, the percentage of older adults who have been tested for HIV declines with age.

Table 4: Lifetime Testing for HIV/AIDS, 1996 National Population Health Survey³

Age Category	% Lifetime HIV Testing
All ages 18 +	15%
45-54 yrs	11%
55-64 yrs	7%
65-74 yrs	4%
75+ yrs	2%

International studies suggest that some older adults may not be aware of HIV prevention methods or behaviours that put them at risk of HIV:

- In a 1996 US-based study, 14.7% of the respondents age 50-64 did not know if condoms were effective in preventing HIV infection compared to 6.3% of the respondents age 18-49.⁴

Comment

Older adults constitute a substantial minority of reported HIV and AIDS cases in Canada. More epidemiological and behavioural data are needed to better understand the HIV/AIDS situation among older adults and to inform prevention and care programs. Population-based surveys should include questions regarding condom use and number of sexual partners, as well as HIV testing behaviours, for all age groups. Attitudes and knowledge about HIV/AIDS should be studied among those age 50 years and older in order to assess the potential misconceptions or knowledge gaps that older adults may have in regard to HIV transmission and prevention. Given that one of the main exposure categories among reported positive HIV tests among older adults is MSM, research into the risk behaviours of older MSM needs to be supported, and qualitative studies examining the reasons why some older MSM engage in higher risk practices need to be undertaken.

As our society ages and persons with HIV/AIDS live longer due to improved medical treatment, it is likely that HIV/AIDS among older adults will become a greater issue. While older adults have historically been excluded from many aspects of HIV/AIDS policy and programming, the available data show that this should not be the case. The data presented here should help to overcome the ageist assumption that persons age 50 years and older are not at risk of HIV infection.

References

1. Health Canada. *HIV and AIDS in Canada, surveillance report to June 30, 2002*. Division of HIV/AIDS Surveillance, CIDPC, Health Canada, November 2002.
2. *AARP/Modern Maturity Sexuality Survey*. August 1999. http://research.aarp.org/health/mmsurvey_1.html
3. *Statistical Report on the Health of Canadians*. Prepared by the Federal, Provincial and Territorial Advisory Committee on Population Health for the Meeting of Ministers of Health Charlottetown, P.E.I. September 16-17, 1999.
4. Mack KA, Bland SD. *HIV Testing Behaviours and Attitudes Regarding HIV/AIDS of Adults Aged 50-64*. *Gerontologist* 1999; 39(6):687-694.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
Centre for Infectious Disease Prevention & Control
Health Canada
Tunney's Pasture, Postal Locator 0900B1
Ottawa, ON K1A 0L2
Tel: (613) 954-5169 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/

*Our mission is to help the people of
Canada maintain and improve their
health*

Health Canada

HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- **HIV testing and antiretroviral treatment can dramatically reduce mother-to-child HIV transmission.**
- **Provincial HIV prevalence rate among pregnant women is 3-4/10,000 in Canada.**
- **The use of antiretroviral therapy in HIV-positive pregnant women is increasing.**
- **All pregnant women, and women considering pregnancy, should have access to prenatal care that includes the offer of HIV testing as well as appropriate counselling and care.**

CIDPC Website:

www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

Perinatal Transmission of HIV

Introduction

Perinatal (or vertical) transmission of HIV is the transmission of HIV from an infected pregnant woman to her newborn child. Transmission can occur during gestation (in utero), during delivery (when the fetus makes contact with maternal blood and mucosa in the birth canal) or after delivery, through breastmilk. Therefore, women of childbearing age (15-44 years) are of particular concern since they may transmit HIV infection to their newborn children. In this report, the status of perinatal HIV transmission in Canada and HIV testing recommendations for pregnant women are discussed.

AIDS Case Reports

As of June 30, 2002, 18,124 AIDS cases among adults have been reported to the Centre for Infectious Disease Prevention and Control (CIDPC) in Canada, including 1,437 (7.9%) among women (aged 15 and older). Of these, 1,152 (80%) were among women of childbearing age (15-44 years).¹ For pediatric AIDS cases (children 0-14 years), 208 cases have been reported, and 165 of these (79%) were attributed to perinatal transmission.²

HIV among Pregnant Women and Women of Childbearing Age


HIV prevalence studies among pregnant women indicate a provincial rate for Canada of about 3-4/10,000, although data for some provinces have not been updated for 5 or more years. The provincial range is from 1.9/10,000 (Ontario 1991-1992³) to 8.7/10,000 (Newfoundland 1991-1993⁴) and large metropolitan areas have higher rates (4.7 for Vancouver versus 3.4 for the rest of B.C. in 1994⁵, and 15.3 for Montreal versus 5.2 for the province of Quebec in 1990⁶). However, even provinces without large metropolitan areas have significant

rates (for example, 4.1/10,000 in New Brunswick for 1994-1996) and data from Manitoba suggest an increasing trend of HIV infection among women of childbearing age (from 0.7/10,000 in 1991 to 3.2/10,000 in 1994-1995⁸). A study is currently underway in Ontario to update the HIV prevalence in pregnant women. Preliminary results indicate a prevalence of 3.7/10,000 among the approximately 72% of pregnant women who agreed to voluntary testing in the third quarter of 2002.⁹

Transmission of HIV from Mother to Child

In Ontario, 34 HIV-infected infants were born to HIV-positive mothers during 1984-1989, and 59 such infants were born during 1990-1997. During 1984-1997, just over 58% of the HIV positive mothers reported their risk factor for HIV as being from an endemic country, where heterosexual transmission of HIV is the most likely mode of transmission.¹⁰

At the national level, over the past decade, the number of infants born to HIV-infected mothers (HIV-exposed infants) has increased from 56 in 1991 to 138 in 2001, as seen in Figure 1.² The figure also depicts the reported number of infants born to HIV positive mothers and the number of infants who, to date, have confirmed HIV infection (data from the Canadian Pediatric AIDS Research Group).²



Of the reported 1,384 infants who were exposed to HIV from their mothers between 1984 and 2001, 375 have been confirmed HIV positive and an additional 56 have indeterminate serostatus and are currently being monitored. Of the exposed infants over the past decade, an increasing proportion had received some treatment during the course of their gestation and/or after birth. This is in part reflected in the decreasing number of HIV positive infants born since 1996.

Provincial Prenatal HIV Screening Recommendations

In all Canadian provinces, HIV testing of pregnant women remains the choice of the woman. There are two different prenatal HIV testing approaches in Canada. Under the opt-in approach, women typically are provided pre-HIV test counselling and must consent specifically to an HIV test. Under the opt-out approach, women are notified that an HIV test will be included in the routine prenatal tests and procedures and that they may refuse testing. Guidelines and/or recommendations have been developed in each province to encourage informed decisions in terms of HIV testing during pregnancy.

Newfoundland and Labrador: In 1997, the Newfoundland and Labrador Advisory Committee on Infectious Diseases recommended that HIV testing be added to the existing prenatal screening program. HIV testing is done as part of the routine prenatal screen, unless the woman declines. The Newfoundland and Labrador Medical Association and the provincial Public Health Laboratory and Department of Health and Community Services have supported this recommendation and have worked to actively notify physicians and patients of this recommendation.¹¹

Prince Edward Island: In June 1999, the PEI Department of Health and Social Services formally adopted a policy of supporting HIV testing for all pregnant women and recommends that physicians offer HIV testing at the first prenatal visit.¹²

Nova Scotia: The Reproductive Care Program recommends that HIV testing should be offered to all pregnant women, together with other prenatal tests in the first trimester. Women who decline testing in the first trimester or who are known to engage in high risk activities should be offered testing again during the latter stages of their pregnancy.¹²

New Brunswick: The New Brunswick Medical Society's Subcommittee on Perinatal Health Care recommended, in July 1999, that physicians should routinely encourage all pregnant women to be tested for HIV with appropriate pre- and post-test counselling and informed consent. In addition, nominal and non-nominal HIV testing and counselling are available through physicians at Public Health sexual health centres and provincial correctional institutions, and anonymous testing is available at Public Health sexual health centres and correctional institutions in the province.¹³

Quebec: Since 1997, as part of an intervention program on HIV infection and pregnancy, the Ministry of Health and Social Services, in accordance with the College of Physicians, initiated a program recommending that all pregnant women and women contemplating pregnancy be offered an HIV test. This program is currently under revision in view of the evaluation data available. A new policy for HIV testing among pregnant women will be implemented in 2003.¹⁴

Ontario: On December 1, 1998, the Minister of Health announced that the prenatal screening program would be expanded to include HIV testing. Through this expanded program, all pregnant women are offered an HIV test as part of their prenatal care. The HIV test is performed only after counselling is provided and informed consent is given.¹⁵

Manitoba: On April 24, 2002, Dr. Greg Hammond, Director, Public Health Branch, Manitoba Health sent out a province-wide letter announcing the revised prenatal HIV testing policy. The current policy strongly recommends that all health care providers provide appropriate information and offer HIV testing to all pregnant women as part of

routine prenatal care. The decision not to be tested should be voluntary and based on informed choice.¹⁶

Saskatchewan: The College of Physicians issued guidelines for physicians to assess a woman's risk and inform her that testing is available.¹⁷

Alberta: On September 1, 1998, HIV screening was added to the routine prenatal blood tests for all women in Alberta. HIV screening is done unless the woman declines to be tested (opt-out policy). As of August 2002, initial screening and confirmatory testing for HIV and hepatitis B on prenatal blood samples is conducted at the Provincial Laboratory for Public Health (Microbiology). The Canadian Blood Services laboratories in Calgary and Edmonton continue to do blood grouping, Rh determination, anti-erythrocyte antibodies.¹⁸

British Columbia: In June 1994, the B.C. Ministry of Health recommended that HIV testing be offered as a routine prenatal component, with informed consent and pre- and post-test counselling.¹⁹

Northwest Territories (NWT): In 1993, the Northwest Territories Maternal and Perinatal Committee, which has representation from the Department of Health and Social Services and the Northwest Territories Medical Association, recommended that all pregnant women be routinely tested for HIV. Prenatal HIV testing was initially introduced as an opt-in program, but in 1998 it became fully integrated with routine prenatal care, although women are still provided the opportunity to opt out.²⁰

Nunavut (new territory separated from the NWT in 1999): same policy as in NWT.²¹

Yukon: In 1994, the Chief Medical Officer of Health, in conjunction with Yukon Communicable Disease Control, "strongly recommended" testing of all pregnant women. Women who present for testing are also encouraged to recommend their partner be tested as well.²²

Canadian Women Can Access Prenatal HIV Screening Programs

Data from prenatal HIV screening programs can provide important information on the effectiveness of prenatal HIV screening recommendations. Below are data from several provinces:

Alberta: During the first year of their program, 4% of a total of 51,500 eligible pregnancies declined testing. These data have found 15 HIV positive women, for a rate of 2.91/10,000. In the following year, 2.4% of pregnant women declined testing and the HIV prevalence rate was 3.47/10,000.¹⁸

Quebec: A recent study examined changes in medical practice regarding prenatal HIV testing in Ste-Justine hospital, the referral centre for the province of Quebec, after the 1997 implementation of the HIV-screening strategy during pregnancy. The program consists of universal counselling and offering HIV testing to all pregnant women. The study found that the percentage of HIV tests offered to pregnant women was 61.8% in 2001. The percentage of tests offered in the previous years was fairly constant at 60.6% in 1998 and 57.4% in 1999 and 2000.²³

British Columbia: About 55% of pregnant women were tested for HIV in 1995; this proportion was estimated to be up to 80% in 1999 (60% through routine prenatal testing and 20% through groups identified as high risk).²⁴

Newfoundland and Labrador: Almost all pregnancies in 2000 (estimated to be 9,000) were tested for HIV and no HIV-positive results were found.²⁵

Ontario: HIV-testing uptake has gradually increased from 40% in 1999 to 79% in the third quarter of 2002, 72% during the pregnancy and 6% previously. The highest HIV test uptake was in Windsor-Essex (94%) and the lowest in Kent-Chatham (61%). In only three health units, test uptake was less than 70%. Among the 318,386 pregnancies for which the woman was tested for HIV, 119 were HIV-positive giving a rate of 3.7 per 10,000.⁹

Antiretroviral Treatment Can Reduce the Likelihood of Transmission of HIV from Mother to Infant During Pregnancy

HIV testing during pregnancy can provide the opportunity to offer antiretroviral treatment to the mother and infant. For example, a full AZT protocol, which includes administering AZT to the mother during the second or third trimester, during labor and delivery, and after delivery to the infant for 6 weeks can reduce the likelihood of transmission of HIV from mother to newborn by about 2/3.²⁶ Clinical trials in developing countries have recently shown that short course AZT regimes (given to pregnant women starting at 36 weeks gestation and during labor) can reduce vertical transmission rates by about 50%.²⁷ Recent studies indicate that even greater reductions can be achieved using single-dose nevirapine.²⁸

In Quebec, at Sainte-Justine Pediatric Hospital, the use of antiretroviral therapy (AZT) reduced the likelihood of mother-to-infant HIV transmission from 28.3% transmission among mother-infant pairs who had not received any AZT, to 3.75% for mother-infant pairs who had received partial or full AZT therapy.²⁹

Similarly, a more recent study (1993-1999) on AZT use in B.C. found a reduction in the HIV vertical transmission rate from 28% in untreated women-infant pairs to 13% in partially-treated pairs and 0% in completely-treated pairs.³⁰

In Alberta, a study examining the prevention of perinatal HIV transmission from 1998 –1999 found that when HIV-positive mothers were treated with antiretrovirals during pregnancy and intrapartum, 31 of 36 babies (86%) were not HIV infected.³¹

Data from the national surveillance program of Pediatric Centres and HIV clinics in Canada (where 95% of the diagnosed HIV-exposed infants are followed) indicate that the proportion of pregnant women receiving antiretroviral therapy has increased steadily in the last 5 years,

from 37% in 1994 to 53-58% in 1995-1996, 72% in 1997 and 84% in 1998. The resulting perinatal HIV transmission rate was reduced to 4.8% with AZT monotherapy and to 2.5% with combined therapy.³² Recent data from this group indicate that from 1995 - 1999, of the 93 HIV infected infants born during this period, 83 were born to women who did not receive antiretroviral therapy. Most of these women were not offered antiretroviral therapy because their HIV status was not identified before or during their pregnancy.³³

Canadian Prenatal HIV Screening Programs Are Valuable

Screening pregnant women for HIV clearly represents an important opportunity to prevent the transmission of HIV to infants. From the perspective of a cost-benefit analysis (which includes the costs of screening tests, counselling and treatment), the benefit of screening is obviously greater in areas with higher HIV prevalence among childbearing women. For areas of lower HIV prevalence, the benefit per unit cost is more dependent on variables such as whether or not physicians bill separately for the counselling time associated with prenatal HIV testing.³⁴ It is estimated that if such programs screened 90% of pregnant women across Canada, there would be a 65% reduction in the number of HIV-infected newborns (compared to no prenatal testing and assuming 24% of untreated pregnancies and 6% of treated pregnancies result in HIV-infected infants).³⁵ Assuming HIV prevalence rates of 6/10,000 among pregnant women in B.C. Ontario and Quebec and 3/10,000 elsewhere, this reduction in absolute number terms would be from 56 to 20 infected newborns, or 36 infections prevented annually.

Comment

There is still a risk for the perinatal transmission of HIV in Canada and as more women are becoming infected, this risk is increasing. Elsewhere, we have estimated that about 15,000 Canadians (including women) are HIV-infected, but unaware of their infection (see *Epi Update*

entitled "Prevalent HIV Infections in Canada: Up to One-Third May Not Be Diagnosed", April 2003). Given this, and the fact that perinatal infections are preventable, it is important that all pregnant women, and women considering pregnancy, should have access to prenatal care that includes the offer of HIV testing as well as appropriate counselling and care.

References

1. Health Canada. *HIV and AIDS in Canada: Surveillance Report to June 30, 2002*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, population and Public Health Branch, November 2002.
2. Health Canada. *HIV and AIDS in Canada: Surveillance Report to December 31, 2001*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, population and Public Health Branch, April 2002.
3. Coates RA, Frank JW, Jackson L et al. *The Ontario HIV seroprevalence study of childbearing women*. *Can J Infect Dis* 1992;3:16A-17A.
4. Ratnam S, Hogan K, Hankins C. *Prevalence of HIV infection among pregnant women in Newfoundland*. *Can Med Assoc J* 1996;154(7):1027-31.
5. Pi D, Ballem PJ, Schechter MT. *Final Report: the BC prenatal study: 1989-94*. Report submitted to Laboratory Centre for Disease Control, Jan 1995, and Rekart M. HIV in pregnancy. *BC AIDS Update Quarterly Report: 4th Quarter 1995*.
6. *Seroprevalence of HIV-1 antibodies in women giving birth to live infants: a five-year trend analysis for selected regions outside Montreal, 1989-93*. Report submitted to Laboratory Centre for Disease Control, Nov 1994 and Hankins D, Laberge C, Lapointe N et al. HIV infection among Quebec women giving birth to live infants. *Can Med Assoc* 1991;144 (3):277-80.
7. Getty G, Leighton P, Mureika R et al. *Seroprevalence of HIV infection in pregnant women in New Brunswick*. *Can J Infect Dis* 1997;8:24A.
8. Blanchard J, Hammond G, Fast M et al. *Manitoba antenatal study*. Report submitted to Laboratory Centre for Disease Control, June 1996.
9. Remis RS. Unpublished data to be presented at CAHR 2003 conference. April 2003, Halifax.
10. *Using HIV Perinatal Surveillance Data for the Evaluation of Prevention Intervention: Provincial example, Ontario*. Presentation by Remis R. in the Proceedings of a Scientific Meeting to review the Vertical Transmission of HIV in Canada. Ottawa, Ontario June 11, 1998.
11. Communication with Dr. F. Stratton, Provincial Medical Officer of Health, Department of Health and Community Services, Newfoundland, January 2003.

12. Communication with T. MacDonald, Field Surveillance Officer, Atlantic Region, Health Canada, January 2003.
13. Communication with M. Collette, Epidemiology Program Officer Provincial Epidemiology Service, New Brunswick Department of Health and Wellness, N.B. January 2003.
14. Communication with Dr. D. Auger, Direction de la protection de la santé publique, Ministère de la Santé et des Services sociaux, Quebec. January 2003.
15. Communication with L. Scheidel, Nurse Epidemiologist, Disease Control and Epidemiology Service, Ontario Ministry of Health, March 2002.
16. Communication with M. M. Wood, Field Surveillance Officer, Cadham Provincial Laboratory, Manitoba Health, January 2003.
17. Communication with S. Harmen, Field Surveillance Officer, Saskatchewan Communicable Disease Control, January 2003.
18. Communication with Dr. G. Jayaraman, Field Surveillance Officer, Alberta Provincial Laboratory for Public Health, January 2003.
19. Communication with E. Wong, Field Surveillance Officer, B.C. Centre for Disease Control, January 2003.
20. Communication with Dr. A. Corriveau, Chief Medical Health Officer, Department of Health & Social Services, GNWT, January 2003.
21. Communication with C. Palacios. Communicable Disease Consultant, Department of Health and Social Services, Government of Nunavut, January 2003.
22. Communication with C. Hemsley, Communicable Disease Officer, Yukon Territory, January 2003.
23. M Boucher, J Samson, N Lapointe. *HIV Screening among pregnant women in the province of Quebec : Success and Failure.* Can J Infect Dis 2002;13 (Suppl A): 30A (Abstract 223)
24. Communication with M. Rekart, B.C. Centre for Disease Control, March 2002.
25. Communication with C. O'Keefe, Disease Control and Epidemiology and M. Pond, Program and Policy Development, Department of Health and Community Services, Newfoundland, April 2001.
26. Connor EM, Sperling RS, Gelber R et al. *Reduction of maternal/infant transmission of human immunodeficiency virus type 1 with zidovudine treatment.* Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
27. Shaffer N, Chuachoowong R, Mock P et al. *Short course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized clinical trial.* Lancet 1998;353(9155):773.
28. Marseille E, Kahn JG, Mmiro F et al. *Cost effectiveness of singledose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.* Lancet 1999;354(9181): 803-9.
29. *Antiretroviral Therapy in Pregnant Women (CPARG): Access and Outcome (1995-1997) and the Experience of Transmission of HIV in Treated Pregnant Women at Ste. Justine's Clinic, Quebec.* Presentation by Lapointe N. in the Proceedings of a Scientific Meeting to Review the Vertical transmission of HIV in Canada June 1998.
30. Forbes JC, Money DM, Remple VP et al. *Effect of antiretroviral use on HIV vertical transmission rate and injection drug use on adherence in British Columbia, Canada.* Can J Infect Dis 2000;11:46B {Abstract 246P}.
31. Robinson JL, Bonita EL. *Prevention of perinatal transmission of HIV infection.* CMAJ 2000;163(7):831-832.
32. King SM, Singer J, Forbes J et al. *Trends in antiretroviral therapy (ART) in pregnant women in Canada, 1994-98.* Can J Infect Dis 2000;11:57B {Abstract 312}.
33. King SM, Forbes J, Lapointe N, Samson L, Embree J, Vaudry W, Read SE, Singer J and The Canadian pediatric AIDS Research Group (CPARG). *Perinatal HIV prevention in Canada.* Can J Infect Dis 2001;12(Suppl B):73B (Abstract 365P)
34. Nagarajan KV, Sahai V, Pong RW. *Screening pregnant women for HIV infection in Ontario: economic and human resources implications.* Final report submitted to Bureau of HIV/AIDS, STD, and TB, Health Canada, March 1998.
35. Archibald CP, Farley J, Yan P, Sutherland J, Sutherland D. *Estimating the impact of antenatal HIV testing in Canada: a lesson on the difference between efficacy and effectiveness.* Can J Infect Dis 1999;10:43B {Abstract C304}.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
 Centre for Infectious Disease Prevention & Control
 Health Canada
 Tunney's Pasture, Postal Locator 0900B1
 Ottawa, ON K1A 0L2
 Tel: (613) 954-5169 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

*Our mission is to help the people of
Canada maintain and improve their
health*

Health Canada



HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

- AT A GLANCE**
- **Aboriginal and Black persons are over-represented among reported AIDS cases in Canada.**
 - **Approximately half of all positive HIV test reports among Aboriginal and Black persons are female, yet females account for only 16.8% of reports among Whites.**
 - **Among positive HIV test reports that contain ethnic information, over 60% were IDU among Aboriginal persons, and over 80% were from heterosexual exposure categories among Blacks. Among Whites, 34.7% and 21.6% of reports were attributed to each respective category.**

CIDPC Website:
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

Ethnicity Reporting for AIDS and HIV in Canada

Introduction

Documentation of ethnicity among reported AIDS cases and positive HIV test reports has become an important component of AIDS and HIV surveillance due to the unique perspective it offers on the epidemic. As with other demographic identifiers, ethnic information can contribute to the creation and evaluation of targeted prevention and treatment programs as well as to the development of health policy.

This *Epi Update* presents a summary of ethnic information from the national AIDS and HIV surveillance system. Additional information is available in "HIV and AIDS in Canada: Surveillance Report to June 30, 2002".¹

AIDS

Improved Ethnicity Reporting Among AIDS Cases

Since 1982, when the first AIDS case was reported in Canada, a total of 85.7% (15,713/18,336) of AIDS case reports have included ethnic information. During this time, the proportion of cases with this information has increased. Between 1982 and 1991, 80.7% of reported AIDS cases indicated ethnicity. This figure increased to 89.4% in the period between 1992-2001. In the first six months of 2002, reporting of ethnicity was 85.3%.

Reported AIDS Cases and Ethnicity: A Balance of Changing Proportions

The total annual number of reported AIDS cases has declined over the last 10 years from 1,723 cases in 1992 to 297 in 2001. From January to June, 2002; 75 AIDS cases were reported. The number of cases in some ethnic groups, however, has not declined at the same rate as others. In order to better


understand trends by ethnic status, it is helpful to examine the proportion of all reported AIDS cases attributed to a particular ethnic group.

Whites have historically represented the largest proportion of reported AIDS cases, yet this proportion has declined over the last 10 years. The proportion of reported AIDS cases with known ethnicity attributed to Whites was highest in 1988 at 91.0%, but declined steadily to 67.7% in 1999. Since that time, the proportion increased to 74.8% in 2000 and dropped to 68.4% in 2001. In the first six months of 2002, 64.1% of reported AIDS cases with known ethnicity were among Whites.

With a decrease among Whites, there has been a corresponding increase in the proportion of reported AIDS cases among other ethnic groups. The increase in the proportion has been most notable among Aboriginal persons and the Black population since 1994 (Figure 1).

In 2001, Aboriginal persons and Blacks comprised 3.3% and 2.2% of Canada's population, respectively.² In the same year, they respectively accounted for 5.3 % and 13.9% of reported AIDS cases with known ethnicity. Between January and June 30, 2002 these proportions were 14.1% and 15.6% respectively. This indicates that both Aboriginal persons and Blacks are over represented in reported AIDS cases.

Figure 1: Proportion of Reported AIDS Cases for Selected Ethnic Groups, by year



HIV

Missing Pieces: Positive HIV Tests Often Reported Without Ethnicity Information

Ethnicity reporting for positive HIV test reports is not as complete as that of reported AIDS cases because ethnicity data are available only for some provinces and territories. Reporting of HIV is more recent than AIDS and there is still some concern regarding documentation of confidential information. As a result, the analysis of ethnicity information for HIV test reports presents a challenge.

Ethnicity data for positive HIV test reports have only been available since 1998, and therefore comparisons are possible only for this limited period of time. Between January 1998 and June 30, 2002, a total of 29.5% of positive HIV test reports have included ethnic information (2975/10075). The proportion of positive HIV test reports with ethnicity information was 26.5% in 1998, and peaked at 32.2% in 2000 before dropping to 31.3% in 2001. In the first six months of 2002, ethnicity reporting for positive HIV tests reports was its lowest at 25.6%.


When examining HIV data, it must also be considered that the source of the HIV reports which include ethnicity are some areas where the Aboriginal population is high in comparison with other parts of Canada. Provinces and territories that report ethnic information include British Columbia, Yukon Territory, Alberta, Saskatchewan, Manitoba, Prince Edward Island, and Newfoundland and Labrador. HIV ethnicity data are not available for the remaining provinces and territories. As a result, the ethnicity data for HIV test reports should not be viewed as representative of all of Canada.

Aboriginal Persons Constitute A Notable Proportion of Positive HIV Tests With Known Ethnicity

The majority of positive HIV test reports with ethnicity information are among Whites, similar to the situation seen in reported AIDS cases. Whites represented 67.3% of positive HIV test reports with known ethnicity in 1998. This figure dropped to near 60.0% between 1999-2001, and was 58.5% in the first half of 2002.

In 1998, 19.2% of positive HIV tests with known ethnicity were among Aboriginal persons as compared to a high of 25.5% in 2001 (Figure 2). The proportion of positive HIV test reports attributed to Aboriginal persons between January and June 30, 2002 is 26.5%. These proportions are higher than the proportions attributed to Aboriginal persons for reported AIDS cases. For example, in 2001, Aboriginal persons comprised 5.3% of reported AIDS cases with known ethnicity. This difference is likely due in part to HIV ethnicity information being primarily from western provinces where the Aboriginal population is greater. For additional information on HIV/AIDS among Aboriginal people, refer to the *Epi Update* entitled "HIV/AIDS Among Aboriginal Persons in Canada: A Continuing Concern", April 2003.³

Compared to other non-White ethnic groups, Aboriginal persons account for a higher proportion of positive HIV test reports where ethnicity has been recorded (Figure 2). However, one must remember that the two largest provinces, Ontario and Quebec are not represented in the HIV ethnicity data.



Positive HIV Tests Reflect Differences Among Ethnic Groups

Of the 2975 positive HIV test reports with ethnic information reported between January 1998 and June 30, 2002; 692 were among Aboriginal people, 211 among the Black population and 1836 among Whites. The remaining 236 reports were attributed to other ethnic categories. Table 1 shows the distribution of gender, age and exposure category among positive HIV test reports for the three named ethnic groups. Such information may be of assistance in the design and targeting of prevention and care programs.

Table 1: Comparison of Positive HIV Test Reports Between Selected Ethnic Groups, 1998 June 30, 2002

	White	Aboriginal	Black
Gender	n = 1823	n = 688	n = 209
Female	16.8%	45.3%	49.3%
Age (Years)	n = 1836	n = 691	n = 211
20-29	16.9%	27.9%	33.6%
30-39	39.7%	39.5%	40.3%
40-49	28.4%	22.3%	15.2%
Exposure Category	n = 1750	n = 677	n = 206
MSM	38.8%	7.7%	8.7%
IDU	34.7%	60.6%	7.8%
HET	21.6%	26.4%	80.1%

MSM = Men who have sex with men; IDU = Injecting Drug Users; HET = Heterosexual Risk (Originate from a Pattern II country, Sexual contact with a person at risk, No Identified Risk Heterosexual). Subtotals differ due to unknown gender, age and exposure in some reports. Provinces with ethnicity reported include BC, YK, AB, SK, MB, PEI, NFLD and Labrador).

As shown in Table 1, available evidence suggests that among Aboriginal persons and the Black population, in contrast to Whites, positive HIV test reports with known ethnicity are equally distributed between males and females and there is a higher proportion at a younger age. Injecting drug use has been a key mode of transmission among Aboriginal persons. As shown in Table 1, injecting drug users comprised 60.6% of positive HIV test reports among Aboriginal persons between 1998-June 30, 2002.

Among Whites, the highest proportion of positive HIV test reports was attributed to men who have sex with men (38.8%) and injecting drug users (34.7%). People whose HIV infection was attributed to heterosexual exposure represented the largest proportion of positive HIV test reports among the Black population (80.1%). The majority of these (113/165) are categorized to the subgroup indicating origin in Pattern II country (a country where heterosexual transmission of HIV predominates).

Limitations of Ethnicity Data from Reported HIV and AIDS Cases

There are several significant limitations regarding the accuracy of ethnicity data obtained from AIDS and HIV surveillance information. The following should be kept in mind when examining such data:

- Misclassifications of ethnic status may occur at the time of HIV or AIDS diagnosis.
- People in certain communities may not wish to identify their ethnicity, resulting in under representation.
- For AIDS reporting, patients and health care providers are constrained by the list of ethnic categories available on the AIDS Case Report Form that may compromise the accuracy of ethnicity reporting.
- Not all provinces and territories routinely collect and/or report ethnicity.
- Variations in the completeness of ethnicity reporting between and within provinces may result in a systematic over-or under representation of specific communities.
- Reporting delay may vary by ethnicity, and may therefore affect the representativeness of ethnicity data for recently reported HIV and AIDS cases.

Given these limitations, caution should be exercised in interpreting the AIDS and HIV ethnicity data presented. This is particularly true of positive HIV test reports for which there is less complete ethnicity information.

Comment

Community health groups and public health officials may use ethnicity data on HIV/AIDS to more effectively plan prevention and care programs for the different ethnic communities. When combined with other epidemiologic descriptors of the HIV/AIDS epidemic, such as gender, age group, and exposure category, such information becomes a powerful tool for directing programs to where they will have the most impact. To increase our ability to do this, it is essential that the completeness and accuracy of ethnicity reporting in surveillance data be improved.

References

1. Health Canada. *HIV and AIDS in Canada: Surveillance Report to June 30, 2002*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada, April 2002.
2. StatisticsCanada.
<http://www12.statcan.ca/english/census01/products/highlight/Ethnicity/Page.cfm?Lang=E&Geo=PR&View=1&Table=1&StartRec=1&Sort=2&B1=Counts>, January 30, 2003.
3. Health Canada. *HIV/AIDS among Aboriginal Persons in Canada: A Continuing Concern*, HIV/AIDS Epi Update, Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada, April 2003.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
Centre for Infectious Disease Prevention & Control
Health Canada
Tunney's Pasture, Postal Locator 0900B1
Ottawa, ON K1A 0L2
Tel: (613) 954-5169 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

Our mission is to help the people of Canada maintain and improve their health

Health Canada



HIV/AIDS **EPI UPDATE** Centre for Infectious Disease Prevention and Control

AT A GLANCE

- **Aboriginal persons are disproportionately affected by HIV infection.**
- **Injecting drug use is the main exposure category among Aboriginal HIV/AIDS cases reported to CIDPC and account for an estimated two-thirds of new HIV infections in this population.**
- **A high proportion of HIV-infected pregnant women are Aboriginal.**
- **Compared to non-Aboriginal persons, Aboriginal persons with a positive HIV test report are more likely to be female, to be younger than 30 years of age and are more likely to become infected by injecting drug use.**

HIV/AIDS Among Aboriginal Persons in Canada: A Continuing Concern

Introduction

In Canada, the Aboriginal populations are very diverse with many sub-groups (First Nations, Inuit and Metis) that reflect variations in historical backgrounds, language and cultural traditions. These groups represent 3.3% of the Canadian population.¹ However, they are disproportionately affected by many social, economic and behavioral factors (such as high rates of poverty, substance abuse, sexually transmitted diseases, limited access to or use of health care services) which increase their vulnerability to HIV infection. Hence, in recent years, an increase in the HIV/AIDS epidemic has been observed in some Aboriginal communities, particularly those in inner-cities. This report updates current information on the status of the HIV/AIDS epidemic among Aboriginal persons in Canada.

Increasing Proportion of Reported AIDS Cases Attributed to Aboriginal Persons

- As of June 30, 2002, there have been 18,336 AIDS cases reported to the Centre for Infectious Disease Prevention and Control (CIDPC) in Canada of which 15,713 contained ethnic information.² Of that total, 459 were reported as Aboriginal persons. In 1993, the proportion of reported AIDS cases with known ethnicity attributed to Aboriginal persons was 2.0%. This proportion steadily increased until reaching a high of 10.0% in 1999. In 2000 and 2001, the proportion of reported AIDS cases among Aboriginal persons decreased to 7.9% and 5.3% respectively; however an increase was seen in the first six months of 2002, where Aboriginal persons accounted for

CIDPC Website:
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

14.1% of the total reported AIDS cases where ethnicity was known. This trend will be monitored closely to see if it is confirmed when data for the full year are available.

Injecting Drug Use - A Major Risk Factor

- There have been 352 Aboriginal males with a reported AIDS diagnosis up to June 30, 2002. Of those with known exposure, 46.2% were men who have sex with men (MSM), 27.6% were injecting drug users (IDU), 12.2% were MSM/IDU, 11.3% were at risk through heterosexual contact, 0.9% had received blood/clotting factors and 1.5% were infected through perinatal transmission.
- There were 106 Aboriginal women with a reported AIDS diagnosis up to June 30, 2002. Among those with known exposure, 64.4% were IDU, 31.7% at risk through heterosexual contact, 2.0% had received blood/clotting factors, 2.0% were infected through perinatal transmission.
- Of reported AIDS cases with known exposure, the proportion of Aboriginal cases attributed to injecting drug use has dramatically increased over time, from 10.3% prior to 1992 to 30.0% during 1992-1996 and 53.1% during 1997-2001. In the first six months of 2002, 55.6% of reported AIDS cases among Aboriginal persons were attributed to injecting drug use.² The proportion of females and the proportion less than 30 years old among reported Aboriginal AIDS cases are higher than among non-Aboriginal AIDS cases. (Table 1) Also, there is a higher proportion of Aboriginal AIDS cases that are IDU as an exposure category compared to non-Aboriginal cases (35.9% vs 6.3%).²

Table 1: Gender, Age and Injecting Drug Use among Aboriginal and Non-Aboriginal Reported AIDS Cases up to June 30, 2002

	Aboriginal	Non-Aboriginal
Gender	n=458	n=15,237
Female	23.1%	8.2%
Age (years)	n=459	n=15,253
<30 years old	24.6%	16.5%
Exposure category	n=446	n=14,874
IDU	35.9%	6.3%

Reported AIDS Cases among Canada's Aboriginal Communities

- Of the 459 AIDS cases among Aboriginal persons reported to June 30, 2002, 18 were identified as Inuit, 35 as Metis, and 372 as Native Indians (i.e. First Nations), and 34 as Aboriginal unspecified.
- Reported AIDS cases among First Nations and Inuit communities are most often male, however as shown in Table 2, females make up a notable proportion of cases at 24.8% and 38.9% respectively. Females however, make up 8.6% of reported AIDS cases among Metis persons.
- When examined by age group, reported AIDS cases among the Inuit and Metis population tend to be younger than those reported for First Nations communities. Those under 30 years accounted for nearly 40% of cases among Inuit persons, whereas they accounted for just over 20% of reported AIDS cases attributed to people from the First Nations.
- The exposure category MSM is attributed to over one-third of reported AIDS cases in each of the three identified Aboriginal populations where risk factors are known. However, the proportion of reported AIDS cases attributed to injecting drug use in First Nations communities is 39.1%, compared to 22.2% and 28.6% for Inuit and Metis

communities respectively. Although 33.3% of reported AIDS cases among Inuit persons are attributed to heterosexual HIV transmission, 16.1% and 17.1% of First Nations and Metis cases can be attributed to the same exposure category.

- When examining national surveillance data for persons identified from an Aboriginal population, it is important to consider that over 7% (34/459) were not identified as being of one specific Aboriginal group. In addition, the number of reported cases is small. As a result, these data should be interpreted with caution.

Table 2: Gender, Age and Exposure Categories of Reported AIDS Cases among Aboriginal groups in Canada up to June 30, 2002

	First Nations	Inuit	Metis	Aboriginal Unspecified
Gender	n=371	n=18	n=35	n=34
Female	24.8%	38.9%	8.6%	11.8%
Age (years)	n=372	n=18	n=35	n=34
20-29	21.2%	38.9%	31.4%	23.5%
30-39	47.6%	44.4%	34.3%	50.0%
40-49	22.6%	11.1%	28.6%	20.6%
Exposure Category	n=361	n=18	n=35	n=32
MSM	33.0%	33.3%	40.0%	65.6%
IDU	39.1%	22.2%	28.6%	15.6%
MSM/IDU	8.9%	5.6%	11.4%	15.6%
Heterosexual	16.1%	33.3%	17.1%	3.1%

A Notable Proportion of Positive HIV Test Reports is Among Females

- Positive HIV reports from provinces with ethnicity reporting (British Columbia, Yukon Territory, Alberta, Saskatchewan,

Manitoba, Prince Edward Island, and Newfoundland and Labrador) indicate that Aboriginal persons were over-represented among new HIV diagnoses, i.e. 19.2% in 1998, averaging 24.0% in 1999-2001, and peaking at 26.5% in the first six months of 2002.

- Table 3 shows the distribution of gender, age, and exposure category among positive HIV test reports from 1998-June 2002 for Aboriginal and non-Aboriginal persons. Females represent nearly half (45.3%) of all positive HIV test reports among Aboriginal persons, however females represent 19.9% of reports for non-Aboriginal persons. In addition, compared to non-Aboriginal persons, a higher proportion of Aboriginal persons test positive for HIV infection at a younger age. Although proportions are comparable for HIV infection through heterosexual transmission, Aboriginal persons have a higher proportion of reports attributed to IDU and a smaller proportion to MSM.²

Table 3: Gender, Age and Exposure Categories among Reported HIV Tests, Aboriginal vs Non-Aboriginal Persons in Provinces with Reported Ethnicity, 1998-June 30, 2002**

	Aboriginal	Non-Aboriginal
Gender	n = 688	n = 2,267
Female	45.3%	19.9%
Age (years)	n = 691	n = 2,283
20-29	27.9%	19.6%
30-39	39.5%	39.7%
40-49	22.3%	26.1%
Exposure Category	n = 677	n = 2,166
MSM	7.7%	35.7%
IDU	60.6%	30.8%
Heterosexual	26.4%	28.8%

** BC, YK, AB, MB, SK, PEI, NFLD and Labrador
Subtotals differ due to unknown gender, age and exposure in some reports.

Aboriginal Persons over-represented Among IDU

IDU continue to be an important risk group in the Canadian HIV epidemic. Recent evidence supports the trends seen in surveillance data suggesting that injecting drug use is a particularly important risk factor for HIV among Aboriginal persons.

The Vancouver Injection Drug Users Study (VIDUS) is an open cohort of IDU. Of the 1,400 recruited between May 1996 and May 2000, 25% of participants were Aboriginal persons, more than half of whom were female (54% female, 46% male). In contrast, females accounted for 29% of Non-Aboriginal participants.³

- In a further analysis of the VIDUS study, investigators found that Aboriginal status was significantly associated with new HIV infection, separately in both men and women⁴ and also among study participants 24 years of age or younger.⁵
- VIDUS has reported that as of December 2001, 19.1% of Aboriginal participants had seroconverted compared to 9.6% of persons who identified as non-Aboriginal.⁶ In a 2003 publication, investigators conclude that in Vancouver, Aboriginal IDUs are becoming HIV positive at twice the rate of non-Aboriginal IDUs.⁷
- In a study of Calgary's Needle Exchange Program, most participants were Caucasian (75%), however Aboriginal persons were the second highest ethnic group, representing 20% of total participants.⁸
- A 2000 study of IDU's in Regina, Saskatchewan indicated that of the 255 participants, 90% self-identified as an Aboriginal person.⁹

Aboriginal Women and Children

- Infected pregnant women are at risk for transmitting HIV to their unborn child. Recent data from some sites in western Canada have shown that a high proportion of HIV-infected pregnant women who deliver are Aboriginal. Among all pediatric centers across Canada where children and HIV infected mothers were followed between 1995-1997, 19% (n=259) were Aboriginal women.¹⁰ Of 32 HIV-infected women who delivered in Northern Alberta or the NWT in 1996-98, 29 (91%) were Aboriginal.¹¹
- Despite high numbers of Aboriginal women seen at HIV clinic and pediatric centres, there was encouraging news that during the period 1995-1997, pregnant Aboriginal women (62%) were as likely to be on antiretroviral therapy as pregnant Caucasian women (66%) and pregnant Black women(63%).¹²
- In a recent study of antiretroviral therapy in a cohort of HIV-positive pregnant women recruited in 7 sites in Ontario, Manitoba and Saskatchewan, results show that 20% of women were Aboriginal. Late use of antiretroviral therapy (in third trimester or intrapartum) was unequally distributed by ethnic status occurring in 38% of Aboriginal, 27% of Black and 9% of White women.¹³

Of the infants known to have contracted HIV via maternal fetal transmission in British Columbia between 1994-1999, 50% were Aboriginal.¹⁴

Aboriginal Men Who Have Sex with Men

- A study done among MSM in Winnipeg in 1995 found that 17% were Aboriginal persons.¹⁵
- The proportion of Aboriginal participants was 41% in a recent cross-Canada study (1999-2000) among male street youth who reported having sex only with men.¹⁶

- In a study of young MSM in Vancouver, 8% of participants were Aboriginal men. These Aboriginal MSM were more likely than non-Aboriginal MSM to be unemployed, to live in unstable housing, to have higher depression scores, to report non-consensual sex or sexual abuse during their childhood, and to be involved in the sex trade.¹⁷

Aboriginal Inmates

- Across Canada, 14% of federal inmates are Aboriginal persons, with rates up to 40% in provincial or federal jails in some provinces.¹⁸⁻²⁰

Increasing Proportion of Aboriginal Persons among Estimated HIV Prevalent and Incident Infections at the National Level

According to the latest estimates of HIV prevalence and incidence produced by CIDPC, the number of Aboriginal persons living with HIV has increased from 1,430 in 1996 to 2,740 in 1999 (91% increase during the 3 year period).²¹ The estimated number of incident infections among Aboriginal persons increased from 310 in 1996 to 370 in 1999. Although Aboriginal persons comprised only 2.8% of the general Canadian population in 1996, they accounted for 5.5% (2,740/49,800) of all prevalent infections and 8.8% (370/4,190) of all new infections in Canada in 1999. In 2001, 3.3% of Canada's populations identified themselves as Aboriginal. The estimated exposure category distribution of prevalent and incident infections among Aboriginal persons in 1999 is shown in Table 4. Injecting drug use is the predominant risk factor for HIV infections among Aboriginal populations representing an estimated 54% of prevalent infections and 64% of incident infections in 1999. When the exposure category MSM/IDU is included, these proportions increase to 60% and 72%, respectively. New estimates of prevalence and incidence for 2002 are expected to be released later in 2003.

Table 4: Estimated Exposure Category Distribution among prevalent and incident HIV infections among Aboriginals in Canada, 1999

Exposure Category	Prevalent Infections (n=2,740)	Incident Infections (n=370)
IDU	54%	64%
Heterosexual contact	15%	17%
MSM	23%	11%
MSM/IDU	6%	8%

Comment

Aboriginal HIV and AIDS data are incomplete for several reasons. The major reason is the incomplete ethnic information in current surveillance data. Since 1982, 14% of reported AIDS cases have had no ethnic information. Ethnicity data for positive HIV test reports have only been available since 1998. Furthermore, 71% of positive HIV test reports between 1998 and June 30, 2002 lack ethnic information. Other reasons include inter-provincial variations in reporting ethnicity, misclassification of ethnic status, and delays in reporting. With respect to positive HIV test reports among Aboriginal persons, they only represent those infected individuals who came forward for testing and are subsequently reported. Therefore, the numbers do not represent the total number of Aboriginal persons infected with HIV. Despite these limitations, available evidence suggests that Aboriginal persons are infected at a younger age than non-Aboriginal persons, that injecting drug use is the most important mode of transmission, and that the HIV epidemic among the Aboriginal community shows no sign of abating. Furthermore, the mobility of Aboriginal persons between inner cities and rural areas may bring the risk of HIV to even the most remote Aboriginal community. Better data on HIV/AIDS epidemiology and HIV testing among Aboriginal persons in Canada are needed to guide prevention and control strategies.

References

1. Statistics Canada. The Daily. "Aboriginal Peoples of Canada: A demographic profile". 21 January, 2003. <http://www12.statcan.ca/english/census01/products/analytic/companion/abor/canada.cfm>.
2. Health Canada. *HIV and AIDS in Canada. Surveillance report to June 30, 2002* and unpublished data from the Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada, November 2002.
3. Tyndall MW, Craib KJP, Currie S, Li K, O'Shaughnessy MV, and Schechter MT. *Impact of HIV infection on mortality in a cohort of injection drug users.* JAIDS 2001; (28) 4:351-357
4. Spittal PM, Craib KJP, Wood E, Laliberté N, Li K, Tyndall MW, O'Shaughnessy MV, and Schechter MT. *Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver.* CMAJ 2002; (7) 166:894-899
5. Miller CL, Tyndall M, Spittal P, Li K, LaLiberte N and Schechter MT. *HIV incidence and associated risk factors among young injection drug users.* AIDS 2002, (16) 3: 491-493.
6. Craib KIP, Spittal PM, Li K, Heath K, Laliberte N, Tyndall M, O'Shaughnessy M and Schechter M. *Comparison of HIV incidence rates among aboriginal and non-aboriginal participants in a cohort of injection drug users in Vancouver.* Can J Inf Dis 2002, (13) Supp A;48A {Abstract 315}.
7. Craib KJP, Spittal PM, Wood E, Laliberte N, Hogg R, Li K, Heath K, Tyndall MW, O'shaughnessy MV and Schechter MT. *Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver.* CMAJ; (168) 1: 19-24.
8. Guenter CD, Fonseca K, Nielsen DM, Wheeler VJ, Pim Cp. *HIV prevalence remains low among Calgary's Needle Exchange Program Participants* Can J Public Health 2000; (91) 2: 129-132
9. Findlater R, Young, Bangura H, Sidaway F, Hay K, Archibald C, Siushansian J, Williamson N. *The Regina Seroprevalence study: A profile of injection drug use in a prairie city, 2000.* Unpublished report. Available through the Division of HIV/AIDS Epidemiology and Surveillance, Health Canada.
10. Forbes JC, Burdge DR, Money D. *Pregnancy outcome in HIV infected women in British Columbia; the impact of antiretroviral therapy on maternal-infant HIV transmission.* Can J Inf Dis 1997;(8):31A {Abstract 235} and personal communication (Forbes J).
11. Birse E, Shokoples S, Houston S. *Demographic and clinical features of Aboriginal and non-Aboriginal patients with HIV infection in Northern Alberta.* Can J Infect Dis 1999;(10) Suppl B:66B {Abstract C387P}.
12. Lapointe N, Forbes J, Singer J, et al. *Antiretroviral therapy in pregnant women in Canada: Access and outcome 1995-97.* Can J Inf Dis 1998;(9) Suppl A:70A {Abstract 449P}.
13. King SM and the Motherisk-HIV Network Members. *Antiretroviral therapy (ART) in a cohort of HIV-positive pregnant women in Canada.* Can J Infect Dis 2001;(12) Suppl B: 26B {Abstract 203}.
14. Ogilvie G, Money D, Forbes J, Remple V, Alimenti A and Burdge D. *Perinatal infection in Aboriginal maternal infant pairs (MIP) in British Columbia.* Can J Inf Dis 2002; (13) Suppl A:50A {Abstract 321}.
15. Myers T, Calzavara L, Morrison K. *A report on a National Research Needs Assessment for HIV prevention among gay and bisexual men and a socio-behavioural and epidemiological pilot study in a non-clinical sample of self-identified gay and bisexual men.* Final report to the Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada, August 1995.
16. Presentation by Wong T. in Proceedings of the MSM/IDU Consultative Meeting (March 8-9, 2001, Ottawa, Canada). Centre for Infectious Disease Prevention and Control, Health Canada.
17. Heath KV, Cornelisse PGA, Strathdee S. *HIV-associated risk factors among young Canadian Aboriginal and non-Aboriginal men who have sex with men.* Int J STD and AIDS 1999;(10):582-7.
18. Correctional Services Canada (personal communication, Portman J, October 1996).
19. Alberta Justice (personal communication, Harrison S, March 1997).
20. Rethon DA, Strathdee SA, Cook D, Cornelisse PGA. *Determinants of high risk behaviours for HIV infection among young offenders in British Columbia detention centres.* Can J Infect Dis 1995;(6) Suppl:32B.
21. Geduld J, Archibald CP. *National Trends of AIDS and HIV in Canada.* CCDCR 2000;26(23):193-201.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
Centre for Infectious Disease Prevention & Control
Health Canada
Tunney's Pasture, Postal Locator 0900B1
Ottawa, ON K1A 0L2
Tel: (613) 954-5169 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

*Our mission is to help the people of
Canada maintain and improve their
health*

Health Canada

HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- In Canada, MSM account for 77.6% of cumulative AIDS cases among adult males.
- MSM account for 70.9% of positive HIV test reports among adult males since testing began in 1985.
- Increased rates of new HIV infection were observed in MSM in some cities of the country in 1999-2000 and levels of risk behaviour continue to be high.

CIDPC Website:

www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/



HIV Infections Among MSM In Canada

Introduction

In Canada, the HIV/AIDS epidemic has had a tremendous impact on men who have sex with men (MSM). Even though the toll of the epidemic no longer affects MSM to the same extent that it did in the early-to-mid 1980s, this group still accounts for the largest number of HIV and AIDS case reports. Recent data on HIV incidence and risk behaviours suggest that MSM continue to be at risk for HIV infection and other sexually transmitted diseases (STDs). This report updates the current information on the status of HIV and AIDS among MSM in Canada.

AIDS Surveillance Data

- As of June 30, 2002, the Centre for Infectious Disease Prevention and Control (CIDPC) reported a cumulative total of 18,336 AIDS cases. Of the 16,669 adult male AIDS cases, 77.6% were attributed to MSM and an additional 5.0% were attributed to the combined group MSM and injecting drug users (MSM/IDU).¹
- Figure 1 shows a steady decrease in the proportion of adult AIDS cases attributed to MSM reported to CIDPC from 1986-1999. In 2000, this proportion increased to 50.4% and has decreased to 46.4% in 2001 and to 40.3% in the first half of 2002. The annual number of AIDS cases attributed to MSM (unadjusted for reporting delay) peaked in 1992-1994, decreased sharply during 1995-97, began to level off in 1999-2000, and decreased again in 2001.¹



- The proportion of adult AIDS cases attributed to MSM who are also injecting drug users (MSM/IDU) has remained relatively steady, varying between 3.7 and 5.3% during the last 5 years.¹

HIV Surveillance Data

While AIDS data provide information on HIV infection that occurred about 10 years in the past, HIV data provide a picture of more recent infections.

- Data from provincial HIV testing programs, collated and synthesized at the national level by CIDPC, shows that prior to 1996, 77.1% of positive HIV test reports among adult males were attributed to MSM. (Figure 2) This proportion decreased steadily to level off at around 48.5% during 1997-1999. It increased to 53.6% in 2000 and then decreased to 48.3% in 2001. In the first half of 2002, this percentage was 51.4%.¹
- A similar trend is observed in the absolute number of positive HIV test reports among adult males attributed to MSM: a steady decline to 421 reports in 1999, an increase to 467 in 2000, and a decrease to 402 cases reported in 2001. The year 2000 was the first time an increase has been seen among MSM test reports in the HIV surveillance data since the 1980s.¹

High rates of new HIV infections in some parts of Canada

- Data from Ontario show a recent increase in the rate of new HIV infections among MSM who are repeat testers for HIV, from 0.79 infections per 100 person-years in 1996 to 1.39 in 1999. Incidence was significantly higher in Toronto and Ottawa compared to the rest of Ontario.² In both centers, incidence rates increased in 1996-1999 (Toronto: relative risk = 1.11 per year; $p=0.006$, Ottawa: relative risk = 1.49 per year; $p=0.02$).² In 2000, incidence appears to have stabilized in Ontario.² Using a new laboratory technique to identify recent infections among those newly diagnosed for HIV (STARHS assay) during 1999-2001, HIV incidence appeared to decrease among MSM in Toronto over the 22-month study period, from 4.3 in 1999 to 2.8 in 2001. In contrast, HIV incidence among MSM in Ottawa appeared to increase, from less than 0.1 in 1999 to 0.86 in first half of 2001.³
- In Quebec, the Omega Cohort provides information on the incidence and psychosocial determinants of HIV infection among MSM living in Montreal. From October 1996 to August 2001, overall HIV incidence remained relatively stable, varying from 0.44 to 0.71 per 100 PY

without any clear increasing or decreasing trend. However, trends in HIV incidence varied by age. The relative rates in 2001 over 2000 were 2.7 for younger MSM and 1.3 for older MSM.⁴ From October 1996 to August 2001, the incidence was 0.57 per 100 PY.⁵

- In British Columbia, results from the Vanguard study, a prospective cohort of young gay and bisexual men in Vancouver, show that the annual rate of new HIV infections among these men who had never injected drugs increased from a range of 0.2-1.0 per 100 PY during the years 1996-99 to 2.0 per 100 PY in 2000 and to 2.5 per 100 PY in the first nine months of 2001.⁶
- With respect to HIV prevalence, data (self-reported or tested) from surveys done directly among MSM showed a very high rate before 1990: 23-32% in Vancouver;⁷⁻⁸ 27-57% in Toronto;^{7,9} 20-25% in Montreal;^{7,10} and between 10-20% in other regions of Canada.⁷ By 1998/2000, it appeared that there was some decline in HIV prevalence rate among MSM surveyed by similar methods (e.g. 16% in Vancouver,¹¹⁻¹² 10-16% in Montreal).¹³⁻¹⁵ However, a high prevalence rate is still seen among MSM who are also injection drug users, for example, 23-28% among MSM/IDU attending needle exchange programs in Ontario (1991-94)¹⁶ and 14-22% among those in Quebec (1995-2000).¹⁷⁻¹⁸
- In the Omega Cohort, results found that HIV prevalence increased with age from a rate of 0.0% in MSM under 20 years, to 3.1% in those aged 40-44 years, and then decreased to 0.4% among those 45 years of age or over. However, this trend was not statistically different.⁴

Continuing Risk Behavior Among MSM

Recent data on risk behaviours suggest that MSM continue to be at considerable risk for HIV infection and other STDs by engaging in receptive or insertive unprotected anal intercourse (UAI) with casual or regular partners, or practicing unsafe sex (oral or anal) with a known HIV positive partner:

- It is estimated that around 15% of Montreal's MSM are currently HIV infected. Results from the Montreal Omega Cohort Study indicate that 12% of MSM practice UAI with casual partners. This could result in a significant increase in the risk of new HIV infections.¹⁹ From 1997 to 2001, an increasing trend in UAI is seen among casual partners (8.2-12.8%, $p=0.007$).²⁰
- In another survey in Montreal, the prevalence of reported UAI was 12% among MSM recruited in bars or saunas, but was up to 21-24% among MSM who were HIV-positive.¹³⁻¹⁴ About 4% of the 500 surveyed men reported having consensual unprotected anal sex with a HIV-positive male partner.¹⁴
- With respect to relapse to risky behaviors, available data indicate that 10% of the Montreal cohort and 26-30% of the Vancouver cohort who reported safe sex at baseline, disclosed relapse to unprotected anal sex at follow-up six to twelve months later.²¹⁻²²
- Between May 1995 and September 2001, men aged 15 to 35 years enrolled in a cohort study of MSM in the Greater Vancouver region reported increasing unprotected insertive (relative risk:3.5) and receptive (relative risk:5.1) anal sex with an HIV positive partner in association with seroconversion.²³

- Data from the Vancouver cohort and the Montreal cohort were combined and analyzed, comparing the sexual behaviours for HIV-positive and HIV-negative gay and bisexual men, aged 16-30 years. Results show that 56% of HIV-positive men and 40% of HIV-negative men reported having engaged in receptive UAI during the previous 6 months or year.²⁴ More recently, high-risk behaviour among MSM in both cities was associated with nitrite inhalant use and sex in public and commercial sex venues. Independent determinants of risk-taking for men in both cities were the use of poppers (Vancouver: odds ratio:2.1, Montreal: OR:2.9) and having sex in a bathhouse (Vancouver: OR:1.9, Montreal OR: 1.8). In Vancouver, having sex in a bar (OR:1.8) and having at least 20 casual partners in the previous year (OR:1.7) were associated with high-risk sex. For men in Montreal, having a casual partner (OR:3.0) and having at least two regular partners in the previous year (OR:3.0) were independently associated with high-risk sexual behaviour.²⁵
- STD data may be used as a marker for unsafe sexual behavior. Preliminary data for 1999-2000 show increased reports of rectal gonorrhoea among adult males in Toronto and Ottawa compared to earlier years, and a potential outbreak of syphilis among MSM in Calgary.²⁶ These data suggest increases in unprotected sexual encounters among MSM.

Comment

A number of biases must be taken into account when interpreting the results noted above. HIV diagnostic data are limited to persons who present themselves for testing and so trends in these numbers may be influenced by testing patterns or improved ability to remove duplicate tests. In addition, identifying information that accompanies HIV testing data is sometimes incomplete or inaccurate, and this may limit the

usefulness of HIV incidence estimates derived from repeat-tester data. Results of cohort studies are limited by selection biases, loss to follow-up, and problems with generalizability.

Despite these limitations, available data suggest that there was an increase in HIV infections among MSM in some centres in 1999-2000 compared to immediately preceding years. Meanwhile, high-risk behaviours are still present nationally among MSM.

Similar data indicating increasing of high-risk taking among MSM, and a potential for an increase of HIV incidence, have been noted elsewhere. For example, increases have been seen for HIV-associated risk behaviours and/or STDs among MSM in the USA,²⁷⁻²⁹ Amsterdam,³⁰ and Sydney, Australia.³¹

Several hypotheses might explain these increases in HIV associated risk behaviours, including: feelings of complacency or optimism related to the success of antiretroviral therapy,²⁶ false reassurance upon learning an HIV-negative result, a lack of direct experience of the AIDS epidemic among the younger generation of gay men, a desire to escape the rigorous norms and standards required for a lifetime of safe sex^{2,32-33} alcohol/drug use^{25,34-36} and the impact of internet chat rooms as a risk environment.³⁷

Taken together, the recent findings indicate that HIV infections increased among MSM in some parts of Canada during 1999-2000. There is a clear need for innovative prevention programs to reduce the spread of HIV and also STD among the gay community. National risk behaviour measures over time would be useful to better characterize the epidemic among MSM and to support effective prevention programs. If antiretroviral therapy becomes less effective because of the viral resistance, the actual level of risk behaviour could significantly increase the incidence of HIV.

References

1. Health Canada. *HIV and AIDS in Canada: Surveillance Report to June 30, 2002*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada, November 2002.
2. Calzavara L, Burchell A, Major C, Remis R, Corey P, Myers T, Millson P, Wallace E, and the Polaris Study Team. *Increases HIV incidence among men who have sex with men undergoing repeat diagnostic HIV testing in Ontario, Canada*. *AIDS* 2002, 16:1655-1661.
3. Remis RS; Major C; Swantee C; Fearon M; Wallace E; Whittingham E *Trends in HIV incidence in Ontario based on the STARHS assay: Update to July 2001*. *Can J Infect Dis*, 2002; Vol 13 (Suppl A): 66A, 372.
4. Remis RS, Alary M, Otis J, Demers E, Masse B, Vincelette J, Turmel B, Lavoie R, LeClerc R, Parent R, and the OMEGA Study Group. *Trends in HIV infection in the omega cohort of men who have sex with men (MSM) in Montreal, 1996-2001*. *Canadian Journal of Infectious Diseases* 2002, 13 [Supplement A], 50A (Abstract 320).
5. Alary M, Remis RS, Otis J, Masse B, Turmel B, LeClerc R, Lavoie R, Vincelette J, Parent R, and the OMEGA Study Group. *Risk factors for HIV seroconversion among men having sex with men (MSM) in Montreal*. *Canadian Journal of Infectious Diseases* 2002, 13 [Supplement A], 50A, 307.
6. Martindale SL, Cook D, Weber AE, Miller ML, Chan K, Craib KJP, Hogg RS. *The impact of STARHS "Detuned Assay" results on HIV incidence calculations in an ongoing cohort of men who have sex with men (MSM) in Vancouver*. *Can J Infect Dis* 2002; 13(Supplement A): 65A (Abstract 369P).
7. Myers T, Godin G, Calzavara L, Lambert J, Locker D and the Canadian AIDS Society Team. *The Canadian Survey of Gay and Bisexual Men and HIV Infection: Men's Survey*. The National AIDS Clearing House, Ottawa, Ontario (Catalogue ISBN 0-921906-14-5).
8. Craib KJP, Strathdee SA, Hogg RS, Cornelisse PGA, Willoughby BC, Schechter MT et al. *Incidence Rates of HIV-1 Infection, AIDS Progression and Mortality in the Vancouver Lymphadenopathy-AIDS Study: Results at 14 years* {Abstract 213}. *Can J Inf Dis* 1998;9:31A.
9. Coates R, Calzavara LM, Read SE, Fanning MM, Shepherd F, Mac Fadden DK et al. *A Prospective Study of Male Sexual Contacts of Individuals With ARC or AIDS*. Final report to National Health Research and Development Program, 1992.
10. Remis RS, Najjar M, Pass C, Paradis G. *Seroepidemiological Study of HIV Infection And Sexual Behaviour Among Men Attending a Medical Clinic in Montreal* {Abstract W.A.P.42}. Vth Int Conf on AIDS, Montreal, Canada, June 1989.
11. Low-Beer S, Bartholomew K, Weber AE, Chan K, Landolt M, Oram D, Schilder A, Hogg R. *A demographic and health profile of gay and bisexual men in a large Canadian urban setting*. *AIDS Care* 2002; 14 (1):111-115.
12. Lou-Beer S, Weber AE, Bartholomew K, Landolt M, Oram D, Schilder A, O'Shaughnessy MV, Hogg RS. *A Demographic And Health Profile of HIV-Positive Gay and Bisexual Men in The West End of Vancouver*. *Can J Infect Dis* 1999;10:62B.
13. Dumas J, Lavoie R, Desjardins Y. *Project national Three Cities, Volet Montréalais: Etudes de besoins en matière de santé des hommes gais de Montréal. Action Séro Zéro*. Report to the HIV/AIDS Policy, Coordination and Program Division, Health Canada, July 2000; presentation by Lavoie R. in Proceedings of the MSM/IDU Consultation Meeting (March 8-9, 2001, Ottawa, Canada). Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada.
14. Lavoie R, Desjardins Y, Otis J. *Sex et Réalités: Les nouvelles thérapies pour le VIH/sida et les comportements sexuels sécuritaires des hommes ayant des relations sexuelles avec d'autres hommes. Action Séro Zéro*. Report to the HIV/AIDS Policy, Coordination and Program Division, Health Canada, July 2000.
15. Low-Beer S, Bartholomew K, Weber AE, Chan K, Landolt M, Oram D, Schilder AJ, and Hogg RS. *A demographic and health profile of gay and bisexual men in a large Canadian urban setting*. *AIDS Care* 2002, 14{1}, 111-115.
16. Millson PE, Myers T, Rankin J, Major C, Fearon M, Rugby J. *Double Jeopardy: HIV infection risk in male drug injectors who also have sex with men* {Abstract 324}. *Can J Infect Dis* 1995;6:41B.
17. Poulin C, Alary M, Noel L, Classens C, Lachance C. *Prevalence and Incidence of HIV Among Injecting Drug Users (IDU) Attending a Needle Exchange Program NEP in Quebec City* {Abstract 218}. *Can J Inf Dis* 1997; 8 Suppl A:27.
18. Hankins C, Alary M, Parent R, Blanchette C, Claessens and the SurvUDI Working Group. *Knowledge of HIV status among MSM and heterosexual men who inject drugs*. Paper presented at the 10th Annual Canadian Conference on HIV/AIDS Research (May 2001, Toronto) and personal communication (Hankins C, April 2001).
19. Dufour A, Alary M, Otis J, Remis RS, Masse B, Turmel B, Vincelette J, Parent R, Lavoie R, LeClerc R and the Omega Study Group. *Risk behaviours and HIV infection among men having sexual relations with men: Baseline characteristics of participants in the Omega Cohort Study, Quebec, Canada*. *Can J Public Health* 2000; (91) 5:345-349.
20. George C, Alary M, Otis J, Demers E, Remis RS, Turmel B, LeClerc R, Lavoie R, Vincelette J, Parent R, Masse B, and the OMEGA Study Group. *Increase in unprotected anal intercourse (UAI) among men having sexual relations with other men (MSM) participating in the Omega Cohort Study. Has this North American wave finally reached Montreal?* *Canadian Journal of Infectious Diseases* 2002, 13[Suppl.A], 45A, 306.
21. Remis RS, Alary M, Otis J. *HIV infection and risk behaviours in young gay and bisexual men* [Letter to Editor]. *CMAJ* 2000;163(1):14-15; and Response to this Letter by Hogg RS, Strathdee SA, Chan K, Martindale SL, Craib KJP.

22. Strathdee SA, Martindale SL, Cornelisse PGA, Miller ML, Craib KJP, Schechter MT, O'Shaughnessy M, Hogg RS. *HIV infection and risk behaviours among young gay and bisexual men in Vancouver*. CMAJ 2000;162(1):21-25 and personal communication (Hogg B, April 2001).
23. Weber AE, Craib KJP, Chan K, Marindale SL, Miller ML, Cook K, Schechter MT, and Hogg RS. *Predictors of HIV sero conversion among young men who have sex with men*. Can J Infect Dis, 2002; Vol 13 (Suppl A): 49A, 319.
24. Weber, AE *Risk Factors associated with HIV Infection among young gay and bisexual men in Canada*. JAIDS 2001; (28)1:81-88.
25. Weber AE, Otis J, Chan K, Lavoie R, Martindale SL, LeClerc R, Miller ML, Turmel B, Craib KJP, Alary M, Schechter MT, And Hogg RS. *Factors associated with high-risk sexual behaviour among men who have sex with men (MSM) in two Canadian cohorts*. Canadian Journal of Infectious Diseases 2002, 13[Suppl.A], 45A, 355.
26. Presentation by A. Singh in *Proceedings of the MSM/IDU Consultation Meeting (March 8-9, 2001, Ottawa, Canada)*. Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada.
27. Denning P, Nakashima AK, Wortley P. *Increasing rates of unprotected anal intercourse among HIV-infected men who have sex with men in the United States*. 13th International AIDS Conference, July 9-14, 2000, Durban, South Africa (Abstract no. ThOrC714).
28. Page-Shafer KA, McFarland W, Kohn R, Klausner J, et al. *Increases in unsafe sex and rectal gonorrhea among men who have sex with men - San Francisco, California, 1994-97*. MMWR 1999;48:45-8.
29. Handsfield HH, Whittington WLH, Desmon S, Celum C, Krekeler B. *Resurgent bacterial sexually transmitted disease among men who have sex with men - King County, Washington, 1997-99*. MMWR 1999;48:773-7.
30. Dukers N, de Wit J, Goudsmit J, Coutinho R. *Recent increase in sexual risk behaviour and sexually transmitted diseases in a cohort of homosexual men: the price of highly active antiretroviral therapy?* 13th International AIDS Conference on AIDS, Durban, South Africa, July 9-14, 2000 {Abstract ThOrC715}.
31. Van De Ven P, Prestage G, French J, Knox S, Kippax S. *Increase in unprotected anal intercourse with casual partners among Sydney gay men in 1996-98*. Aust N Z Public Health 1998;22:814-8.
32. Ostrow DG, Fox K, Chmiel JS. *Attitudes toward highly active antiretroviral therapy predict sexual risk-taking among HIV infected and uninfected gay men in the Multicenter AIDS Cohort Study (MACS)*. 13th International AIDS Conference on AIDS, Durban, South Africa, July 9-14, 2000 {Abstract ThOrC719}.
33. Katz MH. *AIDS epidemic in San Francisco among men who report sex with men: successes and challenges of HIV prevention*. J Acquir Immune Defic Syndr 1997;14(Suppl 2):838-46.
34. Dufour A, Alary M, Otis J, Noel R, Remis RS, Masse B, Parent R, Turmel B, Lavoie R, LeClerc R, Vincelette and the Omega Study Group. *Correlates of Risky Behaviours Among Young and Older Men Having Sexual Relations With Men in Montréal, Québec, Canada*. JAIDS 2000;23:272-8.
35. Mansergh G, Colfax GN, Marks G, Rader M, Guzman R, Buchbinder S. *The Circuit Party Men's Health Survey: Findings and Implications for Gay and Bisexual Men*. American Journal of Public Health 2001; 91:953-8.
36. Dolezal C, Meyer-Bahlburg HF, Remien RH and Petkova E. *Substance Use During Sex and Sensation Seeking as Predictors of Sexual Risk Behaviour Among HIV+ and HIV- Gay Men*. AIDS and Behavior 1997; 1:19-28.
37. McFarlane M, Bull S, Reitmeijer S. *The Internet as a newly emerging risk environment for sexually transmitted disease*. JAMA 2000;284(4):443-6.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
 Centre for Infectious Disease Prevention & Control
 Health Canada
 Tunney's Pasture, Postal Locator 0900B1
 Ottawa, ON K1A 0L2
 Tel: (613) 954-5169
 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

*Our mission is to help the people of
 Canada maintain and improve their
 health*

Health Canada

HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- **Injecting drug use accounts for 6.9% of cumulative adult AIDS cases and 16.4% of cumulative positive adult HIV test reports up to June 30, 2002.**
- **From 1996 to 1999, the estimated number of annual HIV infections among IDU in Canada decreased from 1,970 to 1,430.**
- **Despite a slight drop in national HIV infections among IDU, the absolute number of infections in this group remains unacceptably high.**

CIDPC Website:

www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

HIV/AIDS Among Injecting Drug Users in Canada


In the early 1980s, the Canadian HIV epidemic was concentrated among men who have sex with men (MSM). By the early-to-mid 1990s, there was a change toward increasing transmission among injecting drug users (IDU) such that in 1996, approximately 47% or 1,970 of the estimated 4,200 new HIV infections that occurred in Canada that year were among IDU.¹ The national HIV estimates for 1999 show a slight drop in the number of new infections among IDU (1,430 of a total of 4,190 or 34%).² A similar trend occurred in the number of positive HIV test reports among adults reported to the Centre for Infectious Disease Prevention and Control (CIDPC). In 1996, 33.7% of positive HIV test reports were attributed to IDU and 28.7% in 1999.³ This *Epi Update* presents information on the status of HIV/AIDS among IDU in Canada.

AIDS Surveillance Data

Injecting Drug Use Remains a Significant Exposure Category among AIDS Cases

As of June 30, 2002, 18,336 cumulative AIDS cases had been reported to the Centre for Infectious Disease Prevention and Control (CIDPC).³ Of the 17,471 cumulative adult AIDS cases with known exposure category information, 6.9% (1,214) were attributed to injecting drug use and 4.6% (812) to men who have sex with men who are also IDU (MSM/IDU).

After steadily increasing to a peak of just over 21% in 1998-2000, the proportion of adult AIDS cases attributed to injecting drug use decreased to 14.1% in 2001. (Figure 1) In the first half of 2002, this proportion has risen to 23.9%, a level similar to those reported pre-2001. We will be monitoring this trend to see if it is sustained when data for the full year are available.



Of the 1,214 adult AIDS cases attributed to injecting drug use as of June 30, 2002, 74% were males and 26% were females. The proportion of adult male AIDS cases attributed to IDU steadily increased from 3.4% in 1991 to a peak of 19.3% in 2000. This proportion decreased to 15.7% in 2001 and in the first half of 2002 has increased to 18.2%.

The proportion of adult female AIDS cases attributed to injecting drug use increased steadily from 19.4% in 1991 to a peak of 46.1% in 1998. While in 2001, this proportion dropped to 7%, in the first half of 2002, it has increased to reach 45.5%. It should be noted that these proportions are based on a relatively small number of cases.

HIV Surveillance Data

Proportion of HIV Positive Test Reports among IDU continues gradual decline

While AIDS data provide information on HIV infections that occurred about ten years in the past, HIV data provide a picture of more recent infections.

As of June 30, 2002, of the 25,530 cumulative positive HIV tests reported among adults to CIDPC since 1985 with exposure category information, 16.4% were attributable to injecting drug use. An additional 2.3% were attributed to the combined category of MSM who also inject drugs.³




Figure 2 shows the proportion of adult positive HIV tests attributed to injecting drug use to the end of 2001. Prior to 1996, the proportion was 10.7%. This proportion increased substantially to 29.5% in 1995 and peaked at just over 33% in 1996 and 1997. Since 1997, this proportion has gradually declined to 25.1% in 2001 and this trend has continued in the first half of 2002 when it decreased to 23.3%.³

The proportion of IDU among adult female positive HIV test reports peaked at 47.9% in 1999, declined to 32.6% in 2001 and rose slightly to 35.5% in the first half of 2002. The corresponding figures among adult male test reports remained stable at just over 22% in 2000/2001 and decreased slightly to 19.8% in the first half of 2002.³

Among positive HIV test reports attributed to IDU up to June 30, 2002 with age information, the highest proportion remained among those aged 30-39 years (42.3%).³

HIV Incidence and Prevalence Remain unacceptably High among IDU

The SurvUDI study has been ongoing since 1995 and consists of centres providing needle exchange services to IDU in the province of Quebec, and Ottawa, Ontario. Results indicate that HIV incidence among repeat service attendees in the network were 4.3 per 100

person-years in 1997, 4.0 in 1998, 3.4 in 1999, 3.9 in 2000 and 3.3 in 2001.⁴ Overall incidence from 1995 to August 31, 2002 was 3.0 per 100 person-years in Quebec City, 4.7 in Montreal, 5.1 in Ottawa/Hull and 3.9 for the overall SurvUDI network.⁵

The POLARIS study investigates HIV incidence according to risk category among repeat testers in Ontario's diagnostic HIV-testing database during the period 1992-2000. HIV incidence among IDU decreased from 0.64 per 100 person-years in 1992 to 0.14 per 100 person-years in 2000.⁶

Results from the Vancouver Injection Drug Use Study (VIDUS) showed that HIV incidence was 1.5 per 100 person-years in 2000, down from 10.3 in 1997 and 3.2 in 1999.⁷

Results from the Winnipeg Injection Drug Epidemiology (WIDE) study suggest that the prevalence of HIV infection among IDU in that city increased from 2.3% in 1986-90 to 12.6% in 1998.⁸

A 1999 seroprevalence survey among 159 IDU using the needle exchange program (NEP) in Victoria, B.C., showed that 21% were HIV-positive. This was significantly higher than the prevalence of about 6% found in a small study of NEP attendees in the same city in the early 1990s.⁹

Research conducted by Calgary's Needle Exchange Program, Safeworks, showed that the prevalence of HIV among IDU attending that city's NEP increased from 2.2% in 1992 to 3.3% in 1998.¹⁰

The Regina Seroprevalence Study conducted in 2000, estimated that HIV seroprevalence was 2.0% among self-identified IDU participants.¹¹ Results from the Prince Albert Seroprevalence and Risk Behaviour Survey (PASS) in 1998 suggested that HIV seroprevalence among self-identified IDU was 1.1%.¹²

Results from the SurvUDI study showed that overall HIV prevalence among study participants from 1995 to August 31, 2002 was

14.7%.⁵ In 2001, HIV prevalence was highest among urban IDU (19.7% in Ottawa/Hull, 19.1% in Montreal and 14.5% in Quebec City).⁴

Women, Youth and Aboriginal IDU Are Particularly at Risk for HIV Infection

Women

Since 1996, approximately one third to one half of new HIV test reports among women have been attributed to injecting drug use. The latest national HIV estimates published by CIDPC for 1999 indicate that an estimated 54% of all new HIV infections among women were attributed to IDU.²

Findings from the VIDUS study in Vancouver show that during the period May 1996 and December 2000, HIV incidence rates among female IDU in Vancouver were about 40% higher than those of male IDU.¹³

Youth

High HIV incidence rates were found among young IDU when the VIDUS study in Vancouver examined rates of HIV positivity among IDU participants who were 24 years of age and younger. HIV incidence rates in this age group were 2.96 for males and 5.69 for females per 100 person years,¹⁴ compared to an overall incidence rate of 1.5 per 100 person years in 2000.⁷

The HIV incidence among street youth in the Montreal Street Youth Cohort Study was 0.69 per 100 person years as of September 2000. Injecting drug use was the strongest predictor of seroconversion (becoming HIV positive).¹⁵

Results from Phase II of the Enhanced Surveillance of Canadian Street Youth Study conducted in 1999, showed that overall, 20% of participants (n=1,733) had ever injected drugs. There was considerable regional variation with 10% of participants in Halifax, to 30% of participants in Saskatoon, to 36% of participants in Vancouver reporting a history of injecting drug use.¹⁶

Aboriginal


Aboriginal persons are over-represented among IDU populations, and a larger proportion of Aboriginal HIV and AIDS cases are attributed to IDU than non-Aboriginal cases.¹⁷ The 1999 national HIV estimates indicate that 64% of all new HIV infections among Aboriginal people in 1999 were attributable to injecting drug use.²

An analysis comparing the seroconversion rates of Aboriginal IDU with non-Aboriginal IDU participating in VIDUS study in Vancouver found that Aboriginal IDU are seroconverting at twice the rate of non-Aboriginal IDU.¹⁸

International trends

A report published by UNAIDS and the WHO in December 2002, indicates that an estimated 42 million people in the world are living with HIV/AIDS, of whom 19.2 million are women and 3.2 million are children under 15 years of age. IDU is cited as one of the main modes of transmission for those living with HIV/AIDS in 7 of the 10 regions of the world and include North America, North Africa and Middle East, Western Europe and East Asia and Pacific. In Eastern Europe and Central Asia, where the epidemic began relatively later than in other regions (early 1990's), IDU is listed as the single main mode of transmission in that region.¹⁹ Figure 3 shows the proportion of AIDS cases attributed to IDU in selected countries since 1995. While caution should be taken when comparing and interpreting data where surveillance systems may differ, it is interesting to note that while Canada is in the lower half of the graph, countries like Australia, Netherlands and UK have even lower proportions of reported AIDS cases attributed to IDU. While such ecological comparisons have their limitations, it may be related to the availability and acceptability of programs and services which advocate harm reduction within the IDU population in these countries. More research is needed to study the effectiveness of these programs and whether similar approaches could be applicable in the Canadian setting.

Figure 3: Proportion of Reported AIDS cases attributed to IDU in selected countries by Year*



*Sources

Australia: National Center in HIV Epidemiology and Clinical Research. HIV/AIDS viral hepatitis and sexually transmissible infection in Australia Annual Surveillance Report 2002. National Center in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW. 2002. www.med.unsw.edu.au/ncheer

Italy, Netherlands, Poland, Switzerland, Ukraine, UK: (1995-96) European Center for the Epidemiological Monitoring of AIDS. HIV/AIDS surveillance in Europe: Report no. 61, 30 June 1999. www.eurohiv.org/AidsSurv/pdf/rap61.pdf

Italy, Netherlands, Poland, Switzerland, Ukraine, UK (1997-2001)

Iran, Thailand, US: UNAIDS/WHO. Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections. July 2002.

www.unaids.org/hiv/aidsinfo/statistics/fact_sheets/index_en.htm

Canada: Health Canada. HIV and AIDS in Canada: Surveillance Report to June 30, 2002. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada, November 2002.

Comment

A number of biases must be taken into account when interpreting the results noted above. HIV diagnostic data are limited to persons who present themselves for testing, and so trends in these numbers may be influenced by testing patterns or improved ability to remove duplicate tests. In addition, identifying information that accompanies HIV testing data is sometimes incomplete or inaccurate, and this may limit the usefulness of HIV data. Results of cohort studies are limited by selection biases, loss to follow-up, and problems with generalizability. Studies that have a cross-sectional design have their own respective limitations.

Despite these issues, available data show that the HIV epidemic among IDU in Canada continues to be a serious problem. HIV infection continues to

spread in vulnerable populations and across geographic boundaries. Although the problem is best documented in larger cities, increasingly, it is now being seen outside major urban areas. Additional epidemiologic data are needed to better define the extent of the problem and to guide the development and refinement of effective prevention policies and programs. These data are especially needed for areas outside major urban areas and for Aboriginal populations, women and youth. Given the geographic mobility of IDU and their social and sexual interaction with non-users, the dual problem of injecting drug use and HIV infection is one that ultimately affects all of Canadian society.

References

1. Archibald CP, Remis RS, Farley J, Sutherland D. *Estimating HIV prevalence and incidence at the national level: combining direct and indirect methods with Monte-Carlo simulation*. XII International Conference on AIDS, Geneva, June-July 1998 (Abst. 43475).
2. Geduld J, Archibald CP. *National trends of AIDS and HIV in Canada*. *CDCR* 2000;26:193-201.
3. Health Canada. *HIV and AIDS in Canada: surveillance report to June 30, 2002*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control (CIDPC), Health Canada, November 2002.
4. Communication with R. Parent, Institut national de santé publique du Québec, Direction des risques biologiques, environnementaux et occupationnels, Infections transmissibles sexuellement ou par le sang (groupe ITSS), January 2003
5. Alary M, Hankins C. et Le Réseau SurvUDI. *Surveillance épidémiologique de l'infection par le virus de l'immunodéficience humaine chez les utilisateurs de drogues par injection*. Le Réseau SurvUDI. Rapport Intérimaire, Novembre 2002
6. Burchell A, Calzavara LM, Major C, Remis RS, Corey P, Myers T, Millson PE, Wallace E, and the Polaris Study Team. *HIV Incidence among persons undergoing repeat diagnostic HIV testing in Ontario, 1992-2000*. *Can J Infect Dis* 2002 13(Suppl A), 48A (Abstract 315)
7. Tyndall M, Johnston C, Craib K, Li K, Spittal P, O'Shaughnessy M, Schechter M. *HIV Incidence and mortality among injection drug users in Vancouver - 1996-2000*. *Can J Infect* 2001; 11 (Suppl B):69B 354P
8. Elliot LJ, Blanchard JF, Dinner KI, Dawood MR, Beaudoin C. *The Winnipeg Injection Drug Epidemiology (WIDE) Study*. Eighth Annual Canadian Conference on AIDS, Vancouver BC May 1-4 1999. *Can J Infect Dis* 1999;10 (suppl B):C314
9. Poffenroth L. *RARE Project in Victoria*. Proceedings of the Division of HIV/AIDS Epidemiology and Surveillance Annual Meeting, Halifax, November 16-18, 2000. Centre for Infectious Disease Prevention and Control, PPHB, Health Canada.
10. Guenter DC, Fonseca K, Nielsen DM, Wheeler VJ, Pim CP. *HIV Prevalence remains low among Calgary's Needle Exchange Program Participants*. *Can. J Pub Hlth*. 2000;91(2):129-132
11. Regina Health District, Saskatchewan Health, Division of HIV/AIDS Epidemiology and Surveillance, CIDPC, Health Canada. *The Regina Seroprevalence Study: A Profile of Injection Drug Use in a Prairie City*. 2000
12. Siushansian J, Hay K, Findlater R, Bangura H, Archibald C, Young E.. *The Prince Albert seroprevalence study (PASS): prevalence of HIV, hepatitis B, and hepatitis C and high risk behaviours among injection drug users and their sexual partners*. Report prepared for the Prince Albert Health District and Saskatchewan Health, Division of HIV/AIDS Epidemiology and Surveillance, CIDPC, 2001
13. Spittal PM, Craib KJP, Wood E, Laliberte N, Li K, Tyndall MW, O'Shaughnessy MV, Schechter MT. *Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver*. *CMAJ* 2002, 166(7):894-899
14. Miller C, Tyndall M, Li K, Laliberte N, Spittal P, Schechter MT. *High rates of HIV positivity among young injection users*. *Can J Infect Dis* 2001 Vol 12 Suppl B: 340P
15. Roy E, Haley N, Leclerc P, Cédras L, Boivin JF. *HIV Incidence in the Montreal Street Youth Cohort (MSYC)*. *Can J Infect Dis* 2002; 13(Suppl A):49A (Abstract 317)
16. Wong T. *Enhanced surveillance of Canadian street youth*. Proceedings of the MSM/IDU Data Consultation Meeting, Ottawa, March 8-9, 2001. Centre for Infectious Disease Prevention and Control, CIDPC, Health Canada.
17. Health Canada. "HIV/AIDS among Aboriginal Persons in Canada : a Continuing Concern", HIV/AIDS Epi Update, Division of HIV/AIDS Epidemiology and Surveillance, CIDPC, Health Canada, April 2003.
18. Craib KJP, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, Heath K, Tyndall MW, O'Shaughnessy MV, Schechter MT. *Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver*. *CMAJ* 2003;168(1):19-24
19. *AIDS epidemic update, December 2002*. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2002

For more information please contact:

<p>Division of HIV/AIDS Epidemiology & Surveillance Centre for Infectious Disease Prevention & Control Health Canada Tunney's Pasture, Postal Locator 0900B1 Ottawa, ON K1A 0L2 Tel: (613) 954-5169 Fax: (613) 946-8695 www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/</p>

Our mission is to help the people of Canada maintain and improve their health

Health Canada



HIV/AIDS **EPI UPDATE** Centre for Infectious Disease Prevention and Control

AT A GLANCE

- Available data indicate that the sharing of drug injecting equipment remains high among IDU.
- Research suggests that IDU engage in high levels of unprotected sexual intercourse.
- Behavioural trend data are needed to reliably interpret changes in HIV incidence and prevalence among IDU, and to help evaluate prevention programs targeting this population.

Risk Behaviours Among Injecting Drug Users in Canada

Introduction

In 1999, 34.1% of the estimated 4,190 new HIV infections that occurred in Canada were among injecting drug users (IDU).¹ In contrast, 46.7% of the estimated 4,200 incident HIV infections that occurred in 1996 were among IDU.¹ Despite a slight drop in the estimated new infections among IDU in this time period, HIV among injecting drug users remains a major problem. A similar trend has been observed in the number of HIV positive cases attributed to injecting drug use, and reported to Centre for Infectious Disease Prevention and Control (CIDPC). The percentage of reported HIV positive cases attributed to injecting drug use has declined from 33.5% in 1997 to 28.7% in 1999 and 25.3% at the end of 2001.² In the absence of a vaccine for HIV, behaviour change remains the main tool for preventing HIV infection among drug injectors. Behaviour change concerns both IDU who are HIV-infected and those who are uninfected, and relates mainly to their injecting-related and sexual behaviour. This *Epi Update* briefly describes the drug injecting and sexual risk behaviours that have been reported for IDU in Canada.

Neither a Borrower Nor a Lender Be: The Sharing of Drug Injecting Equipment

The sharing (borrowing and lending) of needles and syringes is well-established as a means of acquiring HIV infection and is common among IDU:

- A study of IDU in Regina in 2000 found that 30% of respondents reported borrowing used needles or syringes in the past six months.³

12

CIDPC Website:

www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

- A cohort study of IDU in Vancouver showed that 27.6% of the participants reported sharing needles in previous six month period (administered during January 1999 to October 2000). Furthermore, 19.1% of the participants reported that they had shared even though they did not report having difficulty obtaining new, sterile needles.⁴
- Results from the SurvUDI study show that the prevalence of needle borrowing in the past six months among first time needle exchange program (NEP) attendees in Montreal has decreased from 45.1% in 1995 to 36.4% in 2000, and in Quebec City, needle borrowing has declined from 41.2% to 21.6% during the same period. While these results suggest that positive trends in sharing behaviour among IDU may be occurring in these jurisdictions, the proportions of participants who report sharing needles are still relatively high.⁵
- In a study conducted in Saskatoon in 1998, 53% of IDU reported sharing of needles and 24% had shared needles in the six months preceding the study.⁶

The borrowing and lending of other injecting equipment (e.g., spoons, filters, and water), often referred to as “indirect sharing,” have also been found to be associated with HIV infection. Research indicates that indirect sharing also occurs frequently among IDU:

- Results from the Ottawa arm of the SurvUDI study showed that 42.0% of IDU shared equipment other than needles in the past six months, and 20.0% shared only such equipment.⁷
- In the Regina IDU study, 44% of participants reported borrowing used injecting equipment in the past six months. The most common item borrowed was a spoon (cooker), reported by 37% of participants, followed by needles (29%), cotton (27%), and water (24%). Forty two

percent of participants also reported lending any injecting equipment in the past six months.³

- In a 1998 study in Prince Albert, Saskatchewan, 30.0% of current drug injectors (i.e., those who had injected drugs in the six months prior to the study) had borrowed cookers in the past six months, and the proportions that had borrowed filters and water in this same time period were 26.2% and 27.1% respectively.⁸
- A 1998 study in Saskatoon found that 62% of IDU reported sharing of injection equipment, of whom, about half had shared equipment in the six months preceding the study.⁶
- In a study conducted in Calgary’s NEP, 25% of the participants reported that they had shared injection equipment in the six months preceding the study.⁹
- In a cohort study in Vancouver during 1996 to 2000, 38% of men and 37% of women reported borrowing injection equipment and it was found to be one of the risk factors for seroconversion among men.¹⁰
- International studies¹¹⁻¹³ of IDU have identified other aspects of drug injecting, such as “front-loading” or “back-loading”, that may also increase the risk of HIV transmission (These are practices where two or more IDU use only one syringe to prepare a drug solution. The solution is then squirted into one or more additional syringes either via the front of the recipient syringe after removing its needle (front-loading), or via the back after removing the plunger (back-loading). However, the full extent of such risk behaviours among Canadian IDU is still under investigation.

Risky Business: Trading Unprotected Sex for Money and Drugs

Many IDU in Canada are involved in the commercial sex trade and often engage in unprotected sex with clients:

- Among IDU in a cohort study in Montreal, 18.1% of males reported that they had ever been a prostitute.¹⁴
- In a 1998 study in Winnipeg, 71.5% of female IDU and 30.2% of male IDU reported that they had ever been paid for sex. Among females, 25.0% used condoms inconsistently with their sex trade clients. Among men with male clients, 52.0% reported inconsistent condom use.¹⁵
- In a 1998 study in Saskatoon, half of the female IDU population reported having been paid for sex and 19% having exchanged sex for drugs or a place to sleep in the preceding six months.⁶ In the same study, condom use with casual partner was found to be 93% but one quarter of those did not always use a condom. Overall, 41% of the study population used condoms with regular partners.

Not Safe Enough: Sex with Regular and Casual Partners

12

Among IDU with regular and casual opposite-sex partners, condom use is also low:

- In the 1998 study of IDU in Winnipeg, 68% of women and 57% of men who had had regular partners in the past year reported that they never used condoms. Of those who reported having had casual partners in this time period, approximately 30% of both men and women never used condoms.¹⁵
- Among IDU in the 2000 Regina study, condom use with regular and casual partners was low. For example, 94% of male IDU and

92% of female IDU reported inconsistent or no condom use during vaginal sex with regular, opposite-sex partners. Of those respondents who had casual partners, 58% of men and 71% of women reported inconsistent or no use of condoms with this type of partner.³

- In a study in Calgary, 27% of the participants reported always using a condom and 37% reported never using condoms.⁹
- In the VIDUS cohort study in Vancouver during 1996-2000, 18% of men and 20% of women reported use of condom with regular sex partners and non-use of condom with a regular sex partner was the most significant risk factor for seroconversion among women.¹⁰

Same Sex Partners and Male IDU

A substantial minority of male IDU report sexual intercourse with same sex partners:

- Among male IDU in a Vancouver study who reported having had sexual intercourse in the past six months, 7% reported having had only same sex partners, and 6% reported having had partners of both sexes in this time period.¹⁶
- In the SurvUDI study, 13% of male subjects report same sex partners in the past six months with few reporting consistent condom use.¹⁷
- In the Calgary study, 7% of men and 12% of women reported having had sex with the same sex partner in the six months preceding the study.⁹
- In the Omega cohort study among MSM in Montreal, 6% of the MSM reported injecting drugs, among whom 48% had borrowed used needles and 4% had exchanged sex for drugs.¹⁸

Protective Behaviour Changes or Higher Risk Practices Following an HIV Positive Test?

More research is needed to determine whether IDU continue to engage in high risk behaviours or modify their behaviours after receiving a positive HIV-antibody test:

- Among IDU in a Quebec study, 73.1% of HIV-positive drug injectors had stopped lending needles compared to 56.0% of their HIV-negative counterparts in the six months following their HIV serostatus result. However, 8.5% of HIV-positive IDU compared to 16.0% of their non-infected peers began lending needles to HIV-positive partners in this same time period. In the same study, 62.2% of HIV-positive drug injectors had stopped borrowing needles compared to 58.6% of their HIV-negative counterparts in the six months following their HIV serostatus result and 16.7% of HIV-positive IDU compared to 19.5% of their non-infected peers began borrowing needles from HIV-positive partners in this same time period.¹⁹
- In a study of IDU in Vancouver, 35% of subjects who were HIV-positive reported that they borrowed needles prior to learning about their serostatus. In the months following their HIV-positive test, only 21% of these subjects reported that they continued to borrow needles. Similarly, 37% of HIV-positive IDU reported needle lending prior to their positive HIV test; whereas, only 21% of these subjects continued this practice after receiving their positive test results.²⁰
- In a study among women in Montreal, the rate of condom use following a positive HIV test was low among IDU (19%) as compared to non-IDU of Haitian origin (30%) and non-IDU of Caucasian origin (62%).²¹

Injecting Drug Use Is a Problem Among Street Youth and Inmates

Appropriate and accessible HIV prevention programs for drug injecting street-involved youth and inmates are clearly needed:

- Results from an ongoing study of Montreal street youth (13-25 years) show that 23.2% of the sample had injected drugs in the previous six months. A total of 58.2% of injectors had borrowed a used needle at least once, and 67.5% had borrowed other injection materials. Almost 8.0% of injectors reported borrowing a used needle from an HIV-infected person.²²
- Among female inmates in a Quebec prison, 38% reported injecting drugs before they were incarcerated, and about half of these women had shared needles. Of those who reported drug injection before going to prison, 11% admitted to injecting drugs during their incarceration, and most (80%) shared needles.²³
- Among male inmates in this same study, 26% reported that they had injected drugs before being incarcerated, and about half of these had shared needles. Of those who admitted to injecting drugs outside prison, 2% reported injection drug use during their incarceration, and most (92%) shared needles.²³
- In a Student Drug Use Survey in New Brunswick, less than 1% of grade 7, 9, 10, and 12 had injected drugs in one year preceding the study period.²⁴

Comment

Although several ongoing regional studies in Canada collect risk behaviour data on injecting drug users and a large number of one-time, cross-sectional surveys on risk-taking among IDU have been conducted, it is challenging, if not impossible, to compare levels of risk

behaviours between data sets. In addition to disparities across study methodologies, different researchers have collected risk behaviour data using different questions or differently worded questions, different variable or concept definitions, different time frames for reported behaviours, and different response categories. It is therefore currently difficult to use available IDU risk behaviour information to identify trends or to help evaluate the effectiveness of prevention programs and policies at more than the regional or local level.

In addition, although the national HIV estimates for 1999 showed a drop in the number of new infections attributed to injecting drug use in that year, the relative lack of behavioural trend data hinder the reliable interpretation of this finding. At this stage in the HIV epidemic in Canada, the need for ongoing monitoring of risk behaviours among IDU populations from across the country is critical. A HIV- and hepatitis C (HCV)-associated risk behaviour surveillance system is being established by Health Canada at sentinel centres across Canada through collaboration with regional health authorities, community stakeholders, and researchers. The pilot phase of this surveillance system was undertaken in October/November 2002 at Regina, Victoria, and Sudbury and Toronto; linkages are also being made with IDU studies in Quebec. The surveillance survey is planned to be conducted on an annual basis. The tracking of injecting and sexual risk behaviours over time would provide important trend data that could be used to inform prevention program design and would help evaluate program effectiveness. Such behavioural data could also be used to interpret changes in HIV prevalence and incidence among IDU and would serve as an early warning system for HIV spread in this population. Behavioural surveillance of key sub-groups of IDU, namely street-involved youth and inmates, are also needed in formulating an appropriate response to the evolving HIV epidemic among IDU in Canada.

References

1. Geduld J, Archibald CP. *National trends of AIDS and HIV in Canada*. CDR 2000; 26:193-201.
2. *HIV and AIDS in Canada. Surveillance Report to June 30, 2002*. Health Canada. Website: www.hc-sc.gc.ca/pphb-dgsppp/hast-vsmnt/public_e.html.
3. Siushansian J, Hay K, Findlater R, Bangura H, Archibald C, Young E. *The Regina Seroprevalence Study: A profile of Injection Drug Use in a Prairie City*. Report prepared for the Regina Health District, Division of HIV/AIDS Epidemiology and Surveillance, CIDPC, 2000.
4. Wood E, Tyndall, MW, Spittal PM, Li K, Kerr T, Hogg RS, Montaner JSG, O'Shaughnessy MV, Schechter MT. *Unsafe injection practices in a cohort of injection drug users in Vancouver: Could safer injection rooms help?* CMAJ 2001; 164 (4) 405.
5. Alary M, Parent R, Hankins C, Claessens C, SurvUDI Working Group. *Synergy between risk factors and the persistence of high HIV incidence among injection drug users in the SurvUDI study*. Can J Infect Dis 2002 Vol 13 Suppl A, 316, 49A.
6. Laurie M L, Green K L. *Health risks and opportunities for harm reduction among injection drug-using clients of Saskatoon's needle exchange program*. Can J Public Health 2000;91(5):350-2.
7. Leonard L, Hansen J, Hotz S. *The vulnerable 20%: a shift towards injection drug users who engage in indirect sharing*. Can J Inf Dis 1999;10(Suppl A):60B #C368P.
8. Siushansian J, Hay K, Findlater R, Bangura H, Archibald C, Young E. *The Prince Albert seroprevalence study (PASS): prevalence of HIV, hepatitis B, and hepatitis C and high risk behaviours among injection drug users and their sexual partners*. Report prepared for the Prince Albert Health District and Saskatchewan Health, Division of HIV/AIDS Epidemiology and Surveillance, CIDPC, 2001.
9. Guenter C D, Fonseca K, Nielsen D M, Wheeler V J, Pim C P. *HIV prevalence remains low among Calgary's needle exchange program participants*. Can J Public Health 2000;91(2):129-32.
10. Spittal P M, Craib K J P, Wood E et al. *Risk factors for elevated HIV rates among female injection drug users in Vancouver*. CMAJ 2002;166(7):894-9.
11. Koester S. *Following the blood: syringe re-use leads to blood-borne virus transmission among injection drug users*. J Acq Imm Defic Synd and Hum Retrovirol 1998;18:S139.
12. Greenfield L, Bigelow G, Brooner R. *HIV risk behaviour in drug users: increased blood "booting" during cocaine injection*. AIDS Educ Prev 1992;4:95-107.
13. Needle R, Coyle S, Cesari H et al. *HIV risk behaviour associated with the injection process: multi-person use of drug injection equipment and paraphernalia in injection drug user networks*. Subst Use Misuse 1998;33:2303-2423.

14. Bruneau J, Lamothe F, Soto J et al. *Sex-specific determinants of HIV infection among injection drug users in Montreal*. CMAJ 2001;164:767-773.
15. Elliott L, Blanchard J, Dawood M et al. *The Winnipeg injection drug epidemiology (W.I.D.E.) study: a study of the epidemiology of injection drug use and HIV infection in Winnipeg, Manitoba*. Final Report submitted to the Division of HIV Epidemiology, LCDC, 1999.
16. Tyndall M. *Vancouver response: March 2001*. Presentation made at the Centre for Infectious Disease Prevention and Control, Consultation Meeting on MSM/IDU Data Issues, March 2001.
17. Hankins C, Parent R, Alary M et al. *Risk factors associated with HIV infection in the SurvIDU*. Can J Inf Dis 1999;10(Suppl A):44B #C309.
18. Dufour A, Alary M, Otis J et al. *Risk behaviours and HIV infection among men having sexual relations with men: Baseline characteristics of participants in the Omega cohort study, Montreal, Quebec, Canada*. Can J Public Health 2000;91(5):345-9.
19. Brogly S B, Bruneau J, Lamothe F, Vincelette J, Franco E L. *HIV Positive notification and behaviour changes in Montreal injection drug users*. AIDS Educ Prev 2002;14(1):17-28.
20. Coulter S, Tyndall M, Currie S et al. *Impact of a positive HIV test on subsequent behaviours among injection drug users*. Paper presented at the 9th Annual Canadian Conference on HIV/AIDS Research. Montreal, Quebec. April 2000.
21. Hankins C, Gendron S, Tran T, Lamping D, Lapointe N. *Sexuality in Montreal women living with HIV*. AIDS CARE 1997;9(3):261- 271.
22. Roy E, Haley N, Boivin J et al. *Prevalence of HIV Infection and risk behaviours among Montreal street youth*. International Journal of STD & AIDS 2000; 11:241-247.
23. Dufour A, Alary M, Poulin C et al. *Prevalence and risk behaviours for HIV infection among inmates of a provincial prison in Quebec City*. AIDS 1996;10:1009-15.
24. A report on "Provincial Student Drug Use Survey-Highlights 2002". New Brunswick, Department of Health and Wellness.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
 Centre for Infectious Disease Prevention & Control
 Health Canada
 Tunney's Pasture, Postal Locator 0900B1
 Ottawa, ON K1A 0L2
 Tel: (613) 954-5169
 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/

Our mission is to help the people of Canada maintain and improve their health

Health Canada



HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- **Unprotected oral sex has been associated with HIV infection in some studies.**
- **Poor oral health increases the risk of HIV transmission from oral sex.**
- **The actual risk of HIV transmission through oral sex is difficult to assess since research subjects may under-report sexual activities that are of higher risk.**
- **Oral sex, particularly unprotected receptive fellatio with ejaculation, should be considered as a potential risk behaviour for HIV transmission.**

Oral Sex and the Risk of HIV Transmission

Introduction

The risk of HIV transmission through unprotected anal and vaginal intercourse is well known. Estimates of the per-sex-act probability of HIV transmission among homosexual men in the US through receptive penile-anal intercourse with ejaculation range from 0.005-0.03 during the asymptomatic phase of infection¹ to as high as 0.1-0.3 during primary HIV infection.² Analyses of data from North American and European studies of long-term heterosexual couples estimate the per-sex-act probability of HIV transmission through penile-vaginal intercourse to be approximately 0.001.³ However, the independent risk of HIV transmission through orogenital contact has been more difficult to study and is less well understood. One study calculated the per-sex-act probability of HIV transmission in a cohort of men who have sex with men (MSM) and determined that for unprotected receptive anal intercourse, the probability was 0.82% per act, for unprotected insertive anal intercourse 0.06%, and for unprotected receptive oral intercourse with ejaculation 0.04%.⁴ This remains the only study available that provides a probability for oral transmission, and further study is required to corroborate these estimates. This report updates current information on oral sex and the risk of HIV transmission. Current recommendations on the use of condoms for oral intercourse are also reviewed.

Laboratory and Animal Studies: Evidence Links HIV Infection to Oral Intercourse in Humans

- An animal study found that the minimal dose of simian immunodeficiency virus (SIV) (a virus closely related to HIV-1) required to achieve infection in adult rhesus monkeys through oral exposure was 6,000 times lower

CIDPC Website:

www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

than was the minimal dose needed to achieve infection after rectal exposure. The researchers concluded that as with oral exposure to SIV by rhesus monkeys, oral exposure to HIV-1 by humans likely carries the risk of infection.⁵

- In a laboratory study designed to explore the oral transmission of HIV by seminal fluid and colostrum, normal donor samples of human milk, colostrum, seminal fluid, and blood were separately combined with samples of saliva and HIV-infected white blood cells. All samples, in normal physiologic volumes, prevented saliva from inactivating the HIV infected blood cells, leading the researchers to conclude that successful oral transmission of HIV by seminal fluid, milk, and colostrum may occur.⁶

Oral Sex Between Homosexual Males: Not as Safe as once Perceived

Several epidemiological studies have examined the risk of HIV infection through unprotected receptive oral intercourse (receptive fellatio):

- In a 1996-1999 study of homosexual men recently diagnosed with HIV infection, it was found that 7.8% of subjects (eight of 102) were probably infected through receptive oral sex.⁷
- In a 1986-1988 prospective study of HIV infection and AIDS among homosexual men in the Netherlands, four of 102 cases of seroconversion (3.9%) likely occurred as a result of receptive oral intercourse.⁸
- In a 1990-1992 study of newly diagnosed HIV- infected gay men, six of 37 patients who had been infected within a year before testing claimed only receptive oral sex as the possible route of their infection.⁹

Several studies have also explored the possibility of HIV transmission through unprotected insertive orogenital intercourse (insertive fellatio) or insertive oral-anal sex (insertive anilingus):

- In a prospective study of HIV infection among homosexual men in the Netherlands, five of 102 seroconverters (4.9%) may have been infected through insertive orogenital or oral-anal intercourse.⁸
- In an early cohort study of homosexual men, two of five cases of HIV seroconversion were attributed to insertive orogenital sex.¹⁰

Additional reports or studies, while not distinguishing the type of oral sex between homosexual men, further suggest the possibility of HIV transmission through oral-penile/oral-anal contact:

- In the UK, 13 cases of HIV transmission through oro-genital contact had been reported to the public health authorities up to December 1998. In two of these cases, the reporting physician was not convinced that oro-genital contact was the only risk.¹¹
- In a study to describe the clinical and epidemiologic features of primary HIV infection, four of 46 patients reported having had only unprotected orogenital contact during the suspected sexual encounter that led to their seroconversion.¹²
- In a study of 741 homosexual men in the Netherlands, orogenital contact was identified as an independent risk for HIV acquisition, although this result was not statistically significant.¹³
- In a US study, homosexual males who were participating in a hepatitis B study were found to have a higher risk of HIV infection from both orogenital and oro-anal contact.¹⁴

- In the Omega cohort in Quebec, 10 out of 629 (1.6%) MSM participants seroconverted and listed only unprotected receptive oral intercourse as the possible route of their infection.¹⁵

Prevalence of Oral Sex among Homosexual Males

- The Omega cohort study in Quebec examined the prevalence of unprotected oral sex among MSM by the HIV serostatus of their partners. Researchers found rates for unprotected oral sex of 94% with a seronegative regular partner, 91% with a regular partner of unknown serostatus, and 88% with a seropositive regular partner. For casual partners the rates were 92% with unknown or seronegative partners and 73% with seropositive partners.¹⁶

Female-to-Female Transmission of HIV through Oral Intercourse: Truth or Bias?

- To date, there have been several reports of HIV transmission through orogenital contact between lesbians (cunnilingus).¹⁷ A number of researchers have suggested, however, that bisexual activity may be under-reported by gay women, and therefore that not all of the cases of female-to-female transmission of HIV infection are authentic.¹⁸

Possible Transmission of HIV Between Heterosexual Partners as a Result of Oral Intercourse

- There are several reported cases in the literature of women who acquired HIV infection after performing oral sex on their seropositive male partner (receptive fellatio).¹⁹

- Cases of infection in men following oral sex with their female partners have been reported, including one in which a man was apparently infected via fellatio involving a prostitute.^{20,21}

Potential Co-Factors for HIV Transmission during Oral Sex

Saliva that does not contain blood presents no potential for transmission, as research has shown that an enzyme in saliva inhibits HIV. In general, the mouth and throat are well defended against HIV: the oral mucosal lining contains few cells that are the most susceptible to HIV.²² Other research notes that saliva contains several HIV inhibitors, such as peroxidases and thrombospondin-1, and that the hypotonicity of saliva disrupts the transmission of infected leukocytes (white blood cells).²³

Case reports identify factors potentially associated with increased risk of HIV transmission through oral sex: oral trauma, sores, inflammation, concomitant sexually transmitted infections, ejaculation in the mouth, and systemic immune suppression.¹¹ For receptive fellatio, poor oral health and taking ejaculate in the mouth is a hazardous combination that increases the risk of HIV transmission.²⁴

- In a 1996 cross-sectional study of crack cocaine smokers, oral lesions were associated with HIV infection among persons who reported receptive oral sex.²⁵
- A 1993 study of female sex trade workers found that crack users who inconsistently used condoms when performing oral sex on their clients were more likely to be infected with HIV than were those who consistently used condoms when performing fellatio.²⁶
- Of the eight homosexual men in the Options Project who may have acquired their HIV infection through receptive oral intercourse, three reported oral problems, including occasional bleeding gums.⁷

Oral Sex and “Safer Sex Counselling”: Existing Views and Recommendations

- The Canadian AIDS Society (CAS) currently classifies insertive fellatio between men, or between women and men, as having a negligible risk of HIV transmission regardless of condom use. Receptive fellatio between men, or between men and women, is classified as having negligible risk if a condom is used and as low risk if a condom is not used (whether or not semen is taken in the mouth). CAS presently cautions that the risk of transmission from receptive fellatio is increased if lesions or sores are present in the mouth.²⁷
- With respect to insertive cunnilingus between men and women or between two women, CAS regards this practice as having a negligible risk of HIV transmission if a barrier is used, and as low risk if no barrier is used (regardless of menstrual status). Receptive cunnilingus between men and women or between two women is regarded as having a negligible HIV risk.²⁷
- Both insertive and receptive anilingus, with or without a barrier, between partners of the same sex or opposite sex, are viewed by CAS as having a negligible risk of HIV transmission.²⁷
- CAS emphasizes that the risk of transmission of HIV (or other STDs) from any of these types of oral intercourse can be effectively reduced by the proper use of a latex barrier (condom or dental dam), and thus advocates the avoidance of unprotected orogenital or oro-anal contact.²⁷

Conclusions

The risk of HIV transmission through oral sex is difficult to assess because HIV seroconverters may under-report other higher-risk sexual

practices. A literature review identified exposure to HIV through unprotected oral intercourse as an independent risk factor for HIV acquisition in only three (12.5%) of 24 epidemiological studies designed to examine risk of HIV from different sexual exposures.²⁸ It indicates that the importance of oral sex to HIV transmission is a complex result of the relative frequency of oral sex (among other activities), the infectivity of oral secretions and its modification by oral pathology, and the resistance to infection by inhibitory substances in saliva.²⁸ Also, the HIV incidence and prevalence in the community, the role of the antiretroviral therapy and the extent to which personal prophylaxis is adopted will influence the contribution of oral sex to HIV transmission.²⁸

While oral sex is a lower risk activity than unprotected anal or vaginal intercourse, repeated exposures may increase the risk. Safer sex practices should consider oral sex, particularly unprotected receptive fellatio with ejaculation, as a potential risk behaviour for HIV transmission.

References

1. DeGruttola V, Seage GR III, Mayer KH, Horsburgh CR. *Infectiousness of HIV between male homosexual partners.* J Clin Epidemiol 1989; 42(9): 849-856.
2. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. *Role of the primary infection in epidemics of HIV infection in gay cohorts.* J Acquir Immun Defic Syndr 1994; 7(11):1169-1184.
3. Mastro TD, de Vincenzi I. *Probabilities of sexual HIV-1 transmission.* AIDS 1996; 10(Suppl A):S75-S82.
4. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. *Per-contact risk of human immunodeficiency virus transmission between male sexual partners.* Am J Epidemiol 1999; 150(3):306-11.
5. Baba TW, Trichel AM, An L, Liska V, Martin LN, Murphy- Corb M, and Ruprecht RM. *Infection and AIDS in adult macaques after non-traumatic oral exposure to cell-free SIV.* Science 1996; 272(5267):1486-1489.
6. Baron S, Poast J, Richardson J, Nguyen D, Cloyd M. *Oral transmission of human immunodeficiency virus by infected seminal fluid and milk: a novel mechanism.* J Infect Dis 2000; 181(2):498-504.

7. Dillon B, Hecht FM, Swanson M, Goupil-Sormany I, Grant RM, Chesney MA, Kahn JO. Primary HIV Infections Associated with Oral Transmission. 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, January 30th-February 2nd, 2000 (abstract 473).
8. Keet IP, Albrecht van Lent N, Sandfort TG, Coutinho RA, van Griensven GJ. *Orogenital sex and the transmission of HIV among homosexual men*. AIDS 1992; 6(2):223-226.
9. Grutzmeir S, Bratt G, Ramstedt G, et al. *HIV transmission in gay men in Stockholm 1990-1992*. 1993 International Conference on AIDS (abstract PO-CO2-2584).
10. Rozenbaum W, Gharakhanian S, Cardon B, Duval E, Coulaud JP. *HIV transmission by oral sex*. Lancet 1988; 1(8599):1395.
11. Robinson EK, Evans BG. *Oral sex and HIV transmissions*. AIDS 1999;13(6):737-8.
12. Schacker T, Collier AC, Hughes J, Shea T, Corey L. *Clinical and epidemiologic features of primary HIV infection*. Ann Intern Med 1996;125(4):257-264.
13. van Griensven GJP, Tielman RAP, Goudsmit J, van der Noordaa J, de Wolf F, de Vroome EM, Coutinho RA. *Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands*. Am J Epidemiol 1987; 125(6):1048-1057.
14. Darrow WW, Echenberg DF, Jaffe HW, O'Malley PM, Byers RH, Getchell JP, Curran JW. *Risk factors for human immunodeficiency virus (HIV) infections in homosexual men*. Am J Public Health 1987; 77(4):479-83.
15. Alary M, Remis RS, Otis J, Masse B, Turmel B, LeClerc R, Lavoie R, Vincelette J, Parent R, the Omega Study Group. *Risk factors for HIV seroconversion among men having sex with men (MSM) in Montreal*. Can J Infect Dis 2002; 13(Suppl A):46A.
16. Remis RS, Dufour A, Alary M, Otis J, Vincelette J, Masse B, Turmel B, LeClerc R, the Omega Study Group. *Patterns of oral sex among men who have affective and sexual relations with other men (MASM) in Montreal, Quebec*. Can J Infect Dis 1998; 9(Suppl A):31A (Abstract 210).
17. Perry S, Jacobsberg L, Fogel K. *Orogenital transmission of human immunodeficiency virus*. Ann Intern Med 1989;111(11):951-952.
18. Edwards S, Carne C. *Oral sex and the transmission of viral STIs*. Sex Transm Inf 1998; 74(1):6-10.
19. PuroV, Narciso P, Girardi E, Antonelli L, Zaccarelli M, Visco G. *Male to female transmission of human immunodeficiency virus by orogenital sex*. Eur J Clin Microbiol Infect Dis 1991; 10(1):47.
20. Spitzer PG, Weiner NJ. *Transmission of HIV infection from a woman to a man by oral sex*. N Engl J Med 1989; 320(4):251.
21. Quarto M, Germinario C, Troiano T, Fontana A, Barbuti S. *HIV transmission by fellatio*. Eur J Epidemiol 1990; 6(3):339-340.
22. Reucroft S, Swain J. *Saliva thwarts HIV*. New Sci 1998; 157(2117):23.
23. Baron S. *Oral transmission of HIV, a rarity: emerging hypotheses*. J Dent Res 2001 Jul; 80(7):1602-4.
24. Sayler D. *Oral oversights*. Surviv News (Atlanta Ga) 2001 Nov; 10.
25. Faruque S, Edlin BR, McCoy CB, Word CO, Larsen SA, Schmidt DS, Von Bergen JC, Serrano Y. *Crack cocaine smoking and oral sores in three inner-city neighborhoods*. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13(1):87-92.
26. Wallace JI, Weiner AP. *Intravenous drug use, inconsistent use, and fellatio in relationship to crack smoking as risky behaviour for acquiring HIV among streetwalkers, New York City, April 1989-December 1993*. HIV Infected Women's Conference, February 22-24, 1995 (abstract S62).
27. Canadian AIDS Society. *HIV transmission: guidelines for assessing risk: a resource for educators, counsellors, and health care providers*. 1999, Ottawa.
28. Rothenberg RB, Scarlett M, Del Rio C, Reznik D, O' Daniels C. *Oral transmission of HIV*. AIDS 1998; 12(16):2095-2105.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
 Centre for Infectious Disease Prevention & Control
 Health Canada
 Tunney's Pasture, Postal Locator 0900B1
 Ottawa, ON K1A 0L2
 Tel: (613) 954-5169
 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

*Our mission is to help the people of
 Canada maintain and improve their
 health*

Health Canada

HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- The Canadian HIV Strain and Drug Resistance Program continues to monitor and assess HIV strains and the transmission of drug resistance in Canada.
- Although HIV-1 subtype B continues to predominate, subtypes A, C, D, E, and the circulating recombinants A/B, A/C, and A/G have been identified in Canada.
- The overall prevalence of non-B HIV-1 subtypes is 6.9%.
- Preliminary assessments of HIV-1 strains among newly diagnosed, treatment naïve individuals in Canada suggest:
 - Significantly higher proportions of non-B HIV-1 infections among females (compared to males), among persons reporting heterosexual contact as their primary exposure factor, and among persons of Black, Asian, or mixed ethnicities.
 - Geographic variation in the prevalence of HIV-1 subtypes, likely related to travel and migration from countries where divergent HIV strains predominate.

CIDPC Website:

www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

HIV-1 Strain Surveillance in Canada

Introduction

Two types of HIV have been characterized in humans, HIV-1 and HIV-2. Both HIV-1 and HIV-2 can lead to AIDS. HIV-2 is less common than HIV-1 and is mainly found in West Africa. HIV-1 can be divided into three major groups: “M” (major), “O” (outlier) and “N” (new).¹ The vast majority of isolates cluster in the “M” group. Distinct lineages within Group M have also been identified. These include subtype designations A to E (subtype E is also referred to CRF01_AE (the circulating recombinant form, CRF A/E)), F to H, J, and K.² HIV-1 subtypes A and C are the most common, accounting for about one-half of HIV-1 infections world-wide. In Canada, the United States and Western Europe, HIV-1 subtype B predominates. However, due to travel and migration, non-B subtypes are increasingly being reported in these parts of the world.

This *Epi Update* describes why surveillance of HIV strains is important, and provides a summary of the surveillance of HIV strains in Canada and the prevalence of divergent HIV strains in the United States, and Western Europe.

Why conduct HIV strain surveillance?

The Canadian HIV Strain and Drug Resistance Surveillance Program (CHSDRSP) was initiated as an integrated group of projects aimed at enhancing the national surveillance of HIV. Through a collaborative approach between the provinces, territories, and Health Canada,

laboratory samples (serum from newly diagnosed HIV-positive individuals) and corresponding epidemiological data are sent from the Provincial Health Laboratories to Health Canada for HIV strain and drug resistance testing. The results are shared with key stakeholders including the provinces and territories, when completed. One of the central goals of this program is to conduct the systematic surveillance of HIV subtypes in Canada in order to attain the following four main objectives:

1) *Improve HIV diagnostics and screening strategies*

The broad genetic diversity of HIV has implications for the ability of diagnostic tests to reliably detect circulating HIV strains.^{3,4} The sentinel arm of the CHSDRSP, through the reference services of the National HIV Laboratories, addresses this goal by testing samples with unusual test results. Based on the knowledge of circulating HIV strains, modifications can be made in current tests to ensure that all HIV positive persons are detected upon testing. This is also relevant for ensuring the safety of the blood supply since the tests used for screening donated blood should be able to detect circulating HIV variants.

2) *Inform vaccine development*

It is important to know the distribution of the viral subtypes and intrasubtype variation to target vaccine development and testing since the efficacy and effectiveness of vaccines may be subtype-specific.^{3,4}

3) *Assess HIV transmission patterns*

Although genetic analyses have been used to assess the spread of HIV globally^{4,5}, there is little consensus on whether differences in HIV affect sexual and maternal transmission rates.⁶⁻⁹ Some studies note differences in the biological properties of HIV-1 subtypes¹⁰⁻¹², however, this needs to be confirmed. Knowing the distribution of HIV variants in Canada, along with corresponding epidemiological factors, will help to assess the implications of any differences in transmissibility. The public health implications of such findings, including prevention and treatment strategies, are of special interest.

4) *Assess HIV pathogenesis and progression of HIV-related diseases*

Although the rate of HIV-related disease progression is affected by many factors including host factors and evidence suggests that the immunologic responses may be less suppressed by HIV-2 than by HIV-1^{13,14}, this needs to be clarified. And whereas some studies suggest genetic subtypes play a role in disease progression, other studies suggest the reverse. Many of these studies are reviewed by Hu *et al*³ and by Tatt *et al*.⁴ This area needs further investigation.

Distribution of HIV-1 subtypes

Canada:

- Results from the CHSDRSP show that 6.9% of the sampled population (n=1,312) were infected with non-B subtypes (See Table 1 for subtype distribution)¹⁵

Table 1: Distribution of HIV-1 Subtypes

HIV-1 Subtype	Frequency	Percent
A	24	1.8
A/B	1	0.1
A/C	1	0.1
A/G	1	0.1
B	1222	93.1
C	54	4.1
D	4	0.3
E ^a	5	0.4
Total	1312	100

^aThe recombinant A/E has also been referred to as subtype E

- Preliminary results from the CHSDRSP suggest a significant proportion of individuals infected with a non-B HIV-1 subtype are female, African or Asian origin, and/or identify heterosexual sex as their primary risk factor.¹⁵ These correlations are likely due to travel and migration from endemic areas where divergent HIV-1 subtypes predominate and where heterosexual sex is a major risk factor for HIV-1 infection.

- In 1995 HIV-1 subtype A was reported in an African born male who moved to Canada in 1983.¹⁶
- The BC Centre for Excellence in HIV/AIDS has conducted genetic analyses of HIV linked to cohort studies and to the BC HIV drug treatment program. These studies suggest that non-B subtypes in BC represent at least 4% of HIV infections among individuals starting therapy.¹⁷ HIV-1 subtypes A, C, and D have been identified.
- HIV-2 was detected in Canada as early as 1988.¹⁸

Existing studies on high-risk populations suggest that HIV-1 subtype B is the most common subtype found in the country.

- In 1998, serological samples from 31 HIV positive persons of both genders, representing approximately 25% of known HIV positive persons in Newfoundland, were all of HIV-1 subtype B.¹⁹
- In 1999, all HIV-1 sequences analysed among infected injection drug users (n=17) and men who have sex with men (n=5) residing in Montreal²⁰ were of subtype B.
- As of November 2000, all samples of 31 recent seroconverters in the POLARIS cohort in Ontario are of subtype B.²¹

United States:

- As early as 1993, subtype D was reported in the United States.²²
- Results from CDC's ongoing sentinel surveillance of strain and drug resistance has found 1.6% of persons newly diagnosed with HIV were infected with subtype A (n = 321).²³
- In another cohort study of 88 treatment-naïve individuals presenting to a Boston

hospital in 1999, nine (10%) were infected with non-B HIV-1 (subtypes A, C, and E and the recombinant A/G). All these individuals were born outside the United States.²⁴

- In a population-based study of people with HIV or AIDS, identified as at increased risk for Group "O" infection based on country of birth (n = 155), 2 cases of Group "O" infection and 27 cases of non-B, group M infection were identified. Both cases of Group "O" infections were identified in individuals born in Africa.²⁵

Western Europe:

- Rising prevalence of HIV-1 non-B subtypes has been reported in some Western European countries, and most of these infections could be attributed to countries where non-B HIV subtypes predominate. Many of these studies are reviewed by Thomson and Najera.²⁶
- Group "O" HIV, which is most commonly found in West Africa, has been identified in Western Europe including countries such as Norway²⁷, Spain²⁸, and France.²⁹
- Recombinant strains of HIV-1 have also been detected in countries including the UK³⁰, Spain³¹, and Greece.³²

Comment

The introduction of variant HIV strains into Canada will invariably challenge existing diagnostic tests and interpretation algorithms. Depending on the impact that subtypes have on vaccine effectiveness and efficacy, it may direct the course of future vaccine research and testing. And, depending on future findings related to subtype-specific transmissibility, pathogenicity and treatment, it may play a role in changing the nature of the HIV epidemic in Canada. It is therefore important to implement the systematic collection and analysis of data related to strain surveillance across Canada.

References:

1. Simon F, Mauciere P, Roques P, et al. *Identification of a new human immunodeficiency virus type distinct from group M and group O*. *Nature* 1996; 4:1032-7.
2. Robertson DL, Anderson JP, Bradac JA, et al. *HIV-1 nomenclature proposal*. *Science* 2000. 288(5463):55-6.
3. Hu DJ, Buve A, Baggs J et al. *What role does HIV-1 subtype play in transmission and pathogenesis? An epidemiological perspective* *AIDS* 1999; 13:873-81.
4. Tatt ID, Barlow KL, Nicoll A et al. *The public health significance of HIV-1 subtypes*. *AIDS* 2001; 15(Suppl. 5):S59-S71.
5. Kuiken C, Thakallapalli R, Esklid A, et al. *Genetic analysis reveals epidemiologic patterns in the spread of human immunodeficiency virus*. *Am J Epidemiol* 2000; 152(9):814-22.
6. Kanki PJ, Travers KU, Mboup S, et al. *Slower heterosexual spread of HIV-2 than HIV-1*. *Lancet* 1994; 343:943-6.
7. Adjorlolo-Johnson G, De Cock KM, Ekpini et al. *Prospective comparison of mother-to-child transmission of HIV-1 and HIV-1 in Abidjan, Ivory Coast*. *JAMA* 1994; 272:462-6.
8. Mastro TD & de Vincenzi I. *Probabilities of sexual HIV-1 transmission*. *AIDS* 1996; 10 (suppl A):S75-82.
9. Shaffer N, Roongpisuthipong A, Siriwasin W, et al. *Maternal viral load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand*. *J Infect Dis* 1999; 179:590-9.
10. Kunanusont C, Foy HM, Kreiss JK, et al. *HIV-1 subtypes and male-to-female transmission in Thailand*. *Lancet* 1995; 345(8957):107883.
11. Renjifo B, Fawzi W, Mwakagile D, et al. *Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes*. *J Hum Virol* 2001; 4(1):16-25.
12. Hu DJ, Vanichseni S, Mastro TD, et al. *Viral load differences in early infection with two HIV-1 subtypes*. *AIDS* 2001; 15(6): 683-91.
13. Pepin J, Morgan G, Dunn D et al. *HIV-2 induced immunosuppression among asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but less so than HIV-1*. *AIDS* 1991; 5:1165-72.
14. Whittle H, Morris J, Todd J et al. *HIV-2 infected patients survive longer than HIV-1 infected patients*. *AIDS* 1994; 6:803-7.
15. Health Canada. *HIV-1 strain and primary drug resistance in Canada. Surveillance report to June 30, 2002*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada, 2002. URL: (<http://www.hc-sc.gc.ca/pphb-dgspsp/publicat/>).
16. Montpetit M. *HIV-1 subtype A in Canada*. *AIDS-Res-Hum-Retroviruses*. 1995; 11(11):1421-2.
17. Alexander C, Dong W, Chan K, et al. *HIV-1 non-B subtypes in a large North American cohort: prevalence and response to antiretroviral therapy*. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. Jan. 31-Feb 3, 2000; #174.
18. Neumann PW, Lepine D, Woodside M, et al. *HIV-2 infection detected in Canada*. *Can Dis Wkly Rep* 1988 Jul 16;14(28):1256.
19. Montpetit ML, Ratnam S, Campbell C et al. *Molecular epidemiological analysis of Human Immunodeficiency Virus type 1 in Newfoundland, Canada*. *AIDS-Res-Hum-Retroviruses*, 1998; 14(13):1205-9.
20. Bemier L, Lamothe F, Bruneau J, et al. Eighth Annual Canadian Conference on AIDS, Vancouver BC May 1-4 1999. *Can J Inf Dis* 1999; 10 (suppl B): 104A
21. Major C, for the POLARIS Seroconverter Study Group. Proceedings of the Division of HIV Epidemiology and Surveillance, Annual Meeting, BHST, CIDPC, Health Canada. Halifax, Nov. 16-18 2000.
22. Gao F, Yue L, Hill SC, et al. *HIV-1 sequence subtype D in the United States*. *AIDS Res Hum Retroviruses* 1993; 10:625-7.
23. Zaidi I, Weinstock H, Kalish ML, et al. *Surveillance for HIV-1 subtypes in the United States, 1998-present*. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. Jan 31-Feb 3, 2000; # 215.
24. Hanna GJ, Balaguera H, Steger K, et al. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, IL. Feb 5-8, 2001; #460.
25. Sullivan PS, Do AN, Ellenberger D, et al. *Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States*. *J Infect Dis* 2000; 181(2):461-9.
26. Thomson MM & Najera R. *Travel and the introduction of human immunodeficiency virus type 1 non-B subtype genetic forms into Western countries*. *Clin Infect Dis* 2001; 32(12):1732-7.
27. Jonassen T, Stene-Johansen K, Berg ES, et al. *Sequence analysis of HIV-1 group O from Norwegian patients infected in the 1960s*. *Virology* 1997; 231:43-7.
28. Soriano V, Gutierrez M, Garcia-Lerma G et al. *First case of HIV-1 group O infection in Spain*. *Vox Sang* 1996; 71(1):66
29. Couturier E, Damond F, Roques P et al. *HIV-1 diversity in France, 1996-1998*. *AIDS* 2000 Feb 18; 14(3):28996.
30. Barlow KL, Tatt ID, Cane PA, et al. *Recombinant strains of HIV type 1 in the United Kingdom*. *AIDS Res Hum Retroviruses*, 2001; 17(5):467-74.
31. Holguin A, Rodes B, & Soriano V. *Recombinant human immunodeficiency viruses type 1 circulating in Spain*. *AIDS Res Hum Retroviruses* 2000; 16(5):50511.
32. Paraskevis D, Magiorkinis M, Vandamme AM, et al. *Re-analysis of human immunodeficiency virus type 1 isolates from Cyprus and Greece, initially designated 'subtype I' reveals a unique complex A/G/H/K mosaic pattern*. *J Gen Virol* 2001; 82(Pt 3):57-580.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
Centre for Infectious Disease Prevention & Control
Health Canada
Tunney's Pasture, Postal Locator 0900B1
Ottawa, ON K1A 0L2
Tel: (613) 954-5169 Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

*Our mission is to help the people of Canada
maintain and improve their health*

Health Canada

HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- The Canadian HIV Strain and Drug Resistance Program (CHSDRSP) continues to monitor and assess HIV strains and the transmission of HIV drug resistance in Canada.
- Preliminary observations from the CHSDRSP of HIV drug resistance among newly diagnosed, treatment naïve individuals in Canada (i.e., primary drug resistance) are as follows:
 - The overall prevalence of primary drug resistance to at least one anti-retroviral drug is 7.1%.
 - The overall prevalence of multi-drug resistance to two or more classes of anti-retroviral drugs is 0.7%.
 - Primary drug resistance has been observed among both females and males, across different age groups, ethnicities, and exposure categories, in HIV-1 subtype A, B, and C infections, and among recent and older, prevalent HIV infections.
- The prevalence of primary drug resistance is similar to what have been observed in other countries where highly active anti-retroviral treatment (HAART) is widely used.

CIDPC Website:

www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/

Primary HIV Anti-retroviral Drug Resistance in Canada

Introduction

Drug resistance among individuals on treatment (secondary drug resistance) is well documented. Resistance observed in newly diagnosed, treatment-naïve individuals, presumably due to the transmission of a drug-resistant variant of HIV-1 (primary drug resistance) is less well understood. However, there is increasing evidence to suggest the transmission of drug resistant strains of HIV is becoming more widespread in most countries where HAART is used. Drug resistance makes treatment of HIV more complicated, has important implications for HIV related morbidity and mortality, and may result in increased health care costs.

This *Epi Update* provides a summary of how drug resistance arises, how drug resistance is identified, and key studies on the prevalence of primary drug resistance in countries where HAART is used.

Why conduct primary drug resistance surveillance?

Although HAART has led to a reduction in HIV-1 related morbidity and mortality in Canada and some other countries, there is a concern that its widespread use, increased number of treatment failures, and continuing risk behaviour may result in increased transmission of drug-resistant virus. The first case of primary drug resistance was reported in 1993 with the transmission of a zidovudine-resistant HIV-1 strain.¹ Since then, many reports of transmission of drug resistant HIV strains have been published and there is increasing evidence to suggest the proportion of new HIV infections involving drug resistant strains may be increasing in countries where HAART is routinely used. [For an overview of these studies see Wainberg & Friedland (1998)², and Little (2000)³].

What is less well understood is the prevalence of primary drug resistance and the variation of this prevalence over time, geographic area and population risk group. The Canadian HIV Strain and Drug Resistance Surveillance Program (CHSDRSP) aims to address these questions and the resulting information will help inform the development of any guidelines for initial therapeutic regimens and more effective HIV prevention strategies, including the prevention of vertical transmission.

Evolution of drug resistance

Viral resistance develops largely due to changes in the genetic material (called mutations) coding for the HIV reverse transcriptase (RT) and protease enzymes. Both these enzymes are required for viral reproduction and current anti-retroviral drugs interact with these enzymes to impede their activity. The most commonly used anti-retroviral drugs that are approved for treatment of HIV infection fall into three classes: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). For a review of NRTI, NNRTI, and PI resistance see Loveday (2001)⁴, Deeks (2001)⁵, and Miller (2001)⁶, respectively.

Most mutations are lethal or neutral and are not associated with conferring drug resistance. However, under conditions where treatment does not completely inhibit viral replication, virus with drug resistant mutations can develop and can replicate resulting in treatment failure. In general, it is theoretically possible for every single drug-resistant mutation to be generated daily.⁷ For some drugs (ex: NNRTIs), a single mutation is associated with a high level of drug resistance. Such a mutation is referred to as a 'major' mutation. For other drugs, (ex: most protease inhibitors) a combination of mutations is often required to confer resistance. Such mutations are known as 'minor' mutations.

Methods to identify drug resistance

Genotypic tests identify mutations in the viral genetic material through commercially available probes for particular mutations or via sequencing viral genes of interest. By comparing the generated sequences to databases containing resistance-conferring mutation algorithms, the presence or absence of drug resistance can be identified.

Phenotypic tests determine the enzymatic activity of viral genes or assess viral growth in increasing concentrations of drugs. Resistance is usually defined when, compared to the wild type strain, four or more times the amount of drug is required to inhibit viral growth by 50%. This test is similar in concept to antibiotic resistance testing in bacterial culture.

Note: Genotypic and phenotypic testing and interpretation for patient care are evolving fields that are extremely complex, requiring expert inputs.

Summary of Key Studies on the Prevalence of Primary Drug Resistance

It is difficult to make inter-study comparisons and arrive at firm conclusions because of differences in study design including study populations, types of resistance testing used, and mutations studied and reported. However, the following observations can be made in Canada:

- 1) Results from the CHSDRSP indicate that between 1998 and 2001, the overall prevalence of major mutations to at least one anti-retroviral drug was between 4.1% and 10.9% (Table 1, Column 8). A study conducted in Montreal, Quebec, indicates that between May 1996 and Dec 2001, the prevalence of major mutations to at least one anti-retroviral drug was between 11.4% and 23.2% (Table 1, column 8).
- 2) Primary drug resistance two or more classes of anti-retroviral drugs (multi-drug resistance) has been observed in Canada with an overall prevalence of up-to 9.9% (Table 1, column 7).

Table 1: Summary of key studies on HIV-1 primary drug resistance in Canada

Province ^a	Year of Diagnosis	Risk Exposures ^b	Sample Size	RTIs ^c %	PIs ^d %	MDR ^e %	Total %
BC ⁸	1997-1998	Mixed	423	4.6 (n=416)	4.6	-	-
QC ⁹	1997-1999	IDU (26%) Sexual (69%)	81	20	6	9.9	-
QC ¹⁰	May 1996-June 2000	Mixed	112	-	-	4.1	23.2
	July 2000-Dec 2001	Mixed	36	-	-	0	11.4
ON ¹¹	1997-1999	MSM	23	13	-	-	-
BC, AB, SK, MB, NS ¹²	1997	Mixed	20	0	0	0	0
	1998	Mixed	51	9.8 (NRTI)	0	0	9.8
	1999	Mixed	271	5.1(NRTI)	2.2	0.4	7.7
	2000	Mixed	291	2.4 (NRTI) 0.3 (NNRTI)	1.4	0	4.1
	2001	Mixed	174	5.2(NRTI) 1.7 (NNRTI)	2.3	1.7	10.9

^a BC=British Columbia, QC=Quebec, ON=Ontario, AB=Alberta, SK=Saskatchewan, MB=Manitoba, NS=Nova Scotia.

^b Reported proportions may not add to 100% since risk exposure categories may not be mutually exclusive. IDU=Injection drug use, MSM=Men who have sex with men.

^c RTI=Reverse transcriptase inhibitors, NRTI=Nucleoside reverse transcriptase inhibitor, NNRTI=Non-nucleoside reverse transcriptase inhibitor. Information on NRTI and NNRTI provided where available.

^d PI=Protease inhibitor

^e MDR=Multi-drug resistance

Table 2 shows the results from studies on primary drug resistance that were conducted in the United States and in Western Europe. Please note that this table is NOT meant for inter-study comparisons since such interpretations are difficult to make due to differences in study design including study populations, types of resistance testing used, and

mutations analysed and reported. The results suggest that the prevalence of major mutations associated with at least one anti-retroviral drug is similar to that described in Canada. Of note, mother-to-child transmission of zidovudine, nevirapine, or multi-drug resistant HIV-1 has been reported in the U.S. and in France.^{13,14}

Table 2: Summary of key studies on HIV-1 primary drug resistance in the United States and in Western Europe

Country	Year of Diagnosis	Risk Exposures ^a	Sample Size	RTIs ^b %	PIs ^c %	MDR ^d %	Total ^f %
United States ¹⁵	1989-1998	MSM (80%)	141	0.7 (NNRTI)	1.4	1.4	2.1
United States ¹⁶	1995-1999	MSM (94%)	80	12.5 (NRTI) 7.5 (NNRTI)	3	3.8	16.3
United States ¹⁷	1997-1998	-	114	4 (NRTI) 15 (NNRTI, n=95)	10	5	22
United States ¹⁸	1998	Mixed	238	3.4 (NRTI) 0.4 (NNRTI)	0	0	3.8
	1999		240	8.3 (NRTI) 2.1 (NNRTI)	1.7	1.7	10
	2000		245	6.9 (NRTI) 1.2 (NNRTI)	2	1.2	9
United States (Montreal and Vancouver) ¹⁹	1995-1998	MSM	377	8.5 (NRTI, n=213) 1.7 (NNRTI, n=176)	0.9 (n=213)	3.8 (n=213)	8
	1999-2000			15.9 (NRTI, n=82) 7.3 (NNRTI, n=82)	9.1 (n=88)	10.2 (n=88)	22.7
France ²⁰	1995-1998	Mixed	48	16.6	2	-	-
France ²¹	1999-2000	Mixed	251	7.6 (NRTI) 4 (NNRTI)	5.2	4.8	-
Spain ²²	1996-1998	Mixed	68	16.2	6	4.4	-
Spain ²³	1997-1999	Mixed	31	16.1	9.7	0	25.8
	2000-2001	Mixed	21	0	4.8	0	4.8
Switzerland ²⁴	1996	Mixed	193	5.6	3	-	8.6
	1997			6.9	7.7	-	14.6
	1998			6.8	2	-	8.8
	1999			3.1	1.9	-	5
Switzerland ²⁵	1999-2001	Mixed	200	6.5 (NRTI) 0.5 (NRTI)	1	1.5	10
United Kingdom ²⁶	1994-1996	Mixed	21	0	0	-	0
	1997-1999	Mixed	22	13.6	0	0	13.6
	2000	Mixed	26	19.2	3.8	0	23

^a MSM=Men who have sex with men

^b RTI=Reverse transcriptase inhibitors, NRTI=Nucleoside reverse transcriptase inhibitor, NNRTI=Non-nucleoside reverse transcriptase inhibitor. Information on NRTI and NNRTI provided where available.

^c PI=Protease inhibitors

^d MDR=Multi-drug resistance

^f Total may include major and minor mutations associated with primary drug resistance

Comments

The prevalence of primary HIV drug resistance is widespread in most countries where HAART is used. Although the interpretation of results is difficult and evolving, persons infected with drug resistant variants of HIV may be at increased risk of drug failure despite being therapy-naïve. Surveillance of primary drug resistance is needed not only to develop guidelines for initial therapy, but also to better understand and prevent the transmission of resistant variants.

References

1. Erice A, Mayers DL, Strike DG et al. *Primary infection with zidovudine-resistant human immunodeficiency virus type 1*. N Engl J Med 1993; 328:1163-5.
2. Wainberg MA & Friedland G. *Public health implications of antiretroviral therapy and HIV drug resistance*. JAMA 1998; 279(24): 1977-83.
3. Little S. *Transmission and prevalence of HIV resistance among treatment-naïve subjects*. Antiviral Ther 2000; 5:33-40.
4. Loveday C. *Nucleoside reverse transcriptase inhibitor resistance*. JAIDS 2001; 26:S10-S24.
5. Deeks SG. *Nonnucleoside reverse transcriptase inhibitor resistance*. JAIDS 2001; 26:S25-S33.
6. Miller V. *Resistance to protease inhibitors*. JAIDS 2001; 26:S34-S50.
7. Hirsh MS, Conway B, D'Aquila RT et al. *Antiretroviral drug resistance testing in adults with HIV infection*. JAMA 1998; 279(24):1984-91.
8. Alexander CS, O'Shaughnessy MV, Schechter MT et al. *The prevalence of HIV drug resistance in recently infected injection drug users and individuals seeking treatment in British Columbia*. Eighth Annual Canadian Conference on AIDS, Vancouver BC May 1-4 1999; #B224
9. Salomon H, Wainberg MA, Brenner B et al. *Prevalence of HIV-1 viruses resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or intravenous drug use*. AIDS 2000; 14(2):F17-23.
10. Routy JP, Brenner B, Bruce S et al. *Link between the declines of drug-resistance prevalence in newly infected individuals and of the proportion of patients receiving treatment in Montreal*. XI International HIV Drug Resistance Workshop, Seville, Spain. July 2-5 2002; Antiviral Ther. 7(Suppl. 1): #179.
11. Cassol S, Calzavara L, Major C et al. *HIV-1 drug resistance in Ontario seroconverters*. Ninth Annual Canadian Conference on HIV/AIDS Research. Montreal, QC. April 27 - 30, 2000; #135P.
12. Health Canada. *HIV-1 strain and primary drug resistance in Canada. Surveillance report to June 30, 2002*. Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control, Health Canada, 2002. URL: (<http://www.hc-sc.gc.ca/pphb-dgspsp/publicat/>).
13. Johnson V, Petropoulos CJ, Woods CR, et al. *Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant*. J Infect Dis. 2001; 183:1688-93.
14. Masquelier B, Chaix ML, Burgard, M, et al. *Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort*. J. Acquir Immune Defic Syndr 2001; 27:99-104.
15. Little SJ, Daar ES, D'Aquila RT et al. *Reduced antiretroviral drug susceptibility among patients with primary HIV infection*. JAMA 1999; 282:1142-49.
16. Boden D, Hurley A, Zhang L et al. *HIV-1 drug resistance in newly infected individuals*. JAMA 1999; 282:1135-41
17. Wegner S, Brodine S, Mascola J et al. *Prevalence of genotypic and phenotypic resistance to antiretroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel*. AIDS 2000; 14: 1009-10.
18. Bennett D, Zaidi I, Heneine W et al. *Prevalence of mutations associated with antiretroviral drug resistance among recently diagnosed persons with HIV 1998-2000*. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, WA, Feb 24-28 2002; #95.
19. Little S, Holte S, Routy JP et al. *Antiretroviral drug resistance among patients recently infected with HIV*. New Engl. J. Med 2002; 347(6):385-94.
20. Tamalet C, Pasquier C, Yahi N et al. *Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection*. J Med Virol 2000; 61:181-6.
21. Chaix ML, Descamps D, Deveau C et al. *Antiretroviral resistance, molecular epidemiology and response to initial therapy among patients with HIV-1 primary infection in 1999-2000 in France*. XI International HIV Drug Resistance Workshop, Seville, Spain. July 2-5 2002; Antiviral Ther. 7(Suppl. 1): #166.
22. Puig T, Perez-Olmeda M, Rubio A, et al. *Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain*. The ERASE-2 Study Group. AIDS 2000; 14:727-32
23. De Mendoza C, del Romero J, Rodriguez C et al. *Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Spain*. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, WA Feb 24-28 2002: 371M.

24. Yerly S, Vora S, Rizzardi P et al. *Acute HIV infection: impact on the spread of HIV and transmission of drug resistance.* AIDS 2001; 15:2287-92.
25. Yerly S, Jost S, Telenti A et al. *Transmission of drug resistance: impact of primary and chronic HIV infection.* XI International HIV Drug Resistance Workshop, Seville, Spain. July 2-5 2002; Antiviral Ther. 7(Suppl. 1): #183.
26. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. BMJ 2001; 322:1087-88.

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
Centre for Infectious Disease Prevention & Control
Health Canada
Tunney's Pasture, Postal Locator 0900B1
Ottawa, ON K1A 0L2
Tel: (613) 954-5169
Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/

*Our mission is to help the people of
Canada maintain and improve their
health*

Health Canada



HIV/AIDS **EPI UPDATE**

Centre for Infectious Disease Prevention and Control

AT A GLANCE

- Nonoxynol-9 should not be promoted as a means of HIV prevention.
- Recent data indicate that Nonoxynol-9 does not reduce the risk of HIV transmission and in some circumstances may increase the risk.
- There is an urgent need for the development of an effective and safe anti-HIV microbicide.

CIDPC Website:
www.hc-sc.gc.ca/pphb-dgspsp/hast-vsmt/

Nonoxynol-9 and the Risk of HIV Transmission

Introduction

The purpose of this *Epi Update* is to summarize recent data on the effectiveness of nonoxynol-9 as a microbicide, with particular reference to its effect on HIV transmission. While the effectiveness of nonoxynol-9 as a spermicide is well known, its usefulness as a microbicide has been questioned, and in fact recent data indicate that nonoxynol-9 may actually increase the risk of HIV transmission. This *Epi Update* examines the implications of these data in the context of HIV prevention efforts.

Background

Microbicides are chemical substances that kill viruses and bacteria, and thus, have the potential to reduce the transmission of HIV and other sexually transmitted pathogens when applied vaginally or rectally before sexual intercourse. The development of an effective microbicide is an important research objective since it would not only improve the effectiveness of condoms in preventing disease transmission, but more importantly it would offer an alternative for women to protect themselves from infection without having to obtain the cooperation of their male sexual partner (to wear a male condom). Such an alternative would be especially welcome since the vast majority of global HIV transmissions occur via heterosexual activity.

An ‘ideal’ microbicidal product would be effective against multiple STDs, including HIV, safe to use several times daily, fast acting, acceptable to users, affordable, colorless, odorless, easy to store and to use, easy to obtain, and available in a variety of preparations, including with or without a

contraceptive component. None of the compounds currently in development meet these ideal standards and experts say it is unlikely that any one product will meet them all. The immediate priority is to develop a microbicide product that would provide protection against HIV.¹

Nonoxynol-9 (N-9) is one of the best studied microbicides for the prevention of HIV and other sexually transmitted infections. N-9 was initially developed as a spermicide, a chemical that kills sperm and therefore prevents pregnancy. These chemicals are used in contraceptive spermicide products and as complementary components in the lubricant of barrier methods of contraception, such as the male condom. Studies have demonstrated that when spermicides are used alone, they are 75-85% effective in preventing pregnancy.^{2,3} In addition, N-9 has also been identified as a compound that can kill viruses and bacteria, and so has been proposed as a candidate microbicide for HIV prevention. Laboratory studies have shown that N-9 kills or stops the growth of the HIV virus as well as the pathogens of other sexually transmitted infections such as genital herpes, gonorrhoea, syphilis, trichomoniasis and chlamydia.⁴

A number of products containing N-9 are licenced for use as spermicides in both the United States and Canada. These products are available without a prescription and come in a variety of forms, including creams, films, foams, gels, suppositories, and as a lubricant on spermicidal condoms. In Canada, N-9 is found as a component of the following contraceptive products: Advantage 24 contraceptive gel, Delfen foam, vaginal contraceptive film (VCF), KY Plus Jelly spermicidal lubricant, Protectaid contraceptive sponge, and Emko, Encare, Ramses and Durex brands of condoms with spermicide. However, in Canada at present, there are no products with N-9 that are licensed or indicated for use as microbicides.⁵

Evidence Regarding Nonoxynol-9 and HIV Transmission

The frequent use of nonoxynol-9 can induce lesions and ulcerations to genital mucosa, thereby increasing the probability of transmitting infectious agents.⁶ Studies have also indicated that these adverse effects of N-9 are dose related, supporting the notion that a potentially narrow margin of safety may exist for N-9.⁷

While laboratory studies clearly indicated that N-9 could be an effective barrier to HIV, clinical trials in humans have produced mixed results. Several observational studies have indicated that N-9 may reduce the risk of HIV transmission, but the study design did not permit definitive conclusions.⁸⁻¹⁰ A meta-analysis investigation that combined data from several studies concluded that N-9 may have a protective effect against both gonorrhoea and chlamydia¹¹, but a recent randomized controlled trial found that N-9 gel did not protect against urogenital gonococcal or chlamydial infection.¹² As well, a recent report from WHO concluded that spermicides containing nonoxynol-9 do not protect against gonorrhoea and chlamydia.¹³ A recently-published cohort study found no evidence of N-9 protection against HIV,¹⁴ similar to the results of two controlled trials on this subject. One trial found no significant protection but a higher incidence of genital ulcers in the N-9 group compared to the control group,¹⁵ and another trial found increased HIV infections in the N-9 group compared to the control group though this difference was not statistically significant.¹⁶

The most significant recent data are from a study conducted between 1996 and 2000 among sex trade workers in four countries: Benin, Cote D'Ivoire, South Africa and Thailand with COL-1492, a vaginal gel containing Nonoxynol-9. The results showed that this gel had an adverse effect on vaginal integrity when used frequently, thus increasing women's susceptibility to HIV-1 infection. At low frequency use, nonoxynol-9 had no effect, either positive or negative, on HIV-1 infection.¹⁷

The association between N-9 and genital lesions was also seen in a study of monogamous, low risk women who had a much lower frequency of sexual intercourse than the sex workers in the UNAIDS study. In this second study, women applied a vaginal N-9 gel or a placebo gel twice daily, and the N-9 group had significantly more vaginal itching, burning and mucosal lesions.¹⁸ While it is difficult to extrapolate the findings of these two studies to the general population in terms of sexual frequency and dosage and mode of N-9 use (including the occasional use of an N-9 lubricated condom), the theoretical benefits of N-9 use in such situations would have to be weighed against the demonstrated potential for harmful side effects.

Comment

Taken together, the recent evidence is convincing that frequent use of N-9 does not reduce the risk of infection by HIV, and may in fact increase the risk by causing disruptions and lesions in the genital mucosal lining. There are currently few data available to address the question of whether these results also apply to situations in which the dosage and/or frequency of N-9 use is lower. WHO has stated that Nonoxynol-9 clearly does not prevent HIV infection and may even favour infection if used frequently.¹³

It is worth noting that the United States Food and Drug Administration has proposed new warning labels for over-the counter contraceptive drugs that contain this spermicide.¹⁹ The warning will state that these contraceptives do not protect against infection from HIV or other STDs. The proposed label warnings would also tell consumers that the use of these contraceptives can increase vaginal irritation, which may raise the risk of contracting HIV and other STDs.

Health Canada has never recommended N-9 on its own as an effective means of HIV prevention. Current assessment of the data indicates that:

- N-9 should not be promoted as an effective means of HIV prevention. In particular, individuals who cannot use a condom for HIV prevention should not be counseled to use N-9 as an alternative.
- The best STD and HIV barrier is a latex condom without N-9. However, a condom lubricated with N-9 is probably better than no condom at all. The protection provided by the condom would appear to outweigh the potential risk of the N-9, at least of low frequency of use and dosage.
- If N-9 is used as an aid to contraception, its benefit should be carefully considered in light of the increased risk of genital lesions and the resulting potential for an increased risk of HIV transmission. Similar recommendations have been released from the Centers for Disease Control and Prevention in the USA.^{20,21}

Future directions

These disappointing data on the ineffectiveness of N-9 as a microbicide serve to further reinforce the importance and urgency of research on the development of other possible compounds as microbicides. Other classes of compounds that show promise include topical non-nucleoside reverse transcriptase inhibitors (such as efavirenz), inhibitors of viral attachment (such as cellulose sulphate), and natural products (such as buffer gels). In 2002, there has been a new development of an experimental gel which appears to be a safe, effective contraceptive, according to animal studies. The compound known as mandelic acid condensation polymer or SAMMA, blocked HIV and two strains of herpes simplex virus in laboratory testing. Researchers believe the results are encouraging and justify further testing.²²

There is an urgent need to develop a microbicide which can substantially reduce the transmission of sexually transmitted infections, including HIV, and which can be used by women. For

individuals who are unable to access condoms or negotiate condom use, particularly women, the identification of safe and effective alternatives in HIV prevention is a public health priority.

References

1. *Microbicides. Update: Issue Update.* The Henry J. Kaiser Family Foundation. May 2001.
2. Trussell J, Hatcher RA, Cates W Jr et al. *Contraceptive failure in the United States: an update.* *Stud Fam Plann* 1990;21(1):51-4.
3. Steiner MJ, Hertz-Picciotto I, Schulz KF et al. *Measuring true contraceptive efficacy. A randomized approach-condom vs. spermicide vs. no method.* *Contraception* 1998;58(6):375-8.
4. U.S. National Library of Medicine. Spermicides (Vaginal). MEDLINE plus Health Information. Micromedex Inc. Revised July 28, 1993.
5. Mueller T (Personal communication, September 8, 2000). Therapeutic Products Programme, Health Canada.
6. Gagne, Nathalie; Cormier, Helene; Omar, Rabeea F; Desormeaux, Andre; Gourde, Pierret. *Protective Effect of a thermoreversible gel against the toxicity of nonoxynol-9 Sexually Transmitted Diseases.* 1999, Vol. 26. N.3 177-183
7. Rustomjee R, Abdool Karim Q, Abdool Karim SS et al. *Phase I trial of nonoxynol-9 film among sex workers in South Africa.* *AIDS* 1999;13(12):1511-5.
8. Wittkowski KM, Dietz K. *The protective effect of condoms and Nonoxynol-9 against HIV infection.* National Conference Women and HIV, May 4-7, 1997 (Abstract no. P1.68).
9. Wittkowski KM, Susser E, Dietz K. *Nonoxynol-9 in preventing heterosexual transmission of HIV- using multivariate methods in re-analysing previous and planning future studies.* 12th International AIDS Conference, June 28-July 3, 1998, Geneva, Switzerland (Abstract no. 33142).
10. Wittkowski KM, Susser E, Dietz K. *The protective effect of condoms and Nonoxynol-9 against HIV infection.* *Am J Pub Health* 1998;88(4):590-6 and Comment in: *Am J Public Health* 1999;89(1):198-10.
11. Cook RL, Rosenberg MJ. *Do spermicides containing N-9 prevent sexually transmitted infections? A meta-analysis.* *Sex Transm Dis* 1998;25(3):144-150.
12. Roddy R E, Zekeng L, Ryan KA, Tamoufe U, Tweedy KG. *Effect of nonoxynol-9 gel on urogenital gonorrhoea and chlamydial infection: a randomized controlled trial.* *JAMA* 2002; 287: 1117-1122
13. *Nonoxynol-9 Ineffective in Preventing HIV infection.* 28 June 2002. Press Release WHO/55. <http://www.who.int/en/pr-2002-55.html>.
14. Hira SK, Feldblum PJ, Kamanga J et al. *Condom and Nonoxynol-9 use and the incidence of HIV infection in serodiscordant couples in Zambia.* *Int J STD AIDS* 1997;8(4):243-250.
15. Roddy RE, Zekeng L, Ryan KA et al. *A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases.* *New Engl J Med* 1998;339(8):504-510.
16. Kreiss J, Ngugi E, Holmes K et al. *Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes.* *JAMA* 1992;268(4):477-82.
17. Van Damme, Lut; Ramjee, Gita; Alary, Michel et al. *Effectiveness of COL-1492, a Nonoxynol-9 Vaginal Gel, on HIV-1 Transmission in Female Sex Workers: A Randomised Controlled Trial.* *Lancet* (09.28.02) Vol. 360; No. 9338: p. 971-977.
18. Hoffman T, Taha TE, Martinson F et al. *Adverse health event occurring during an N-9 Gel pilot study: Malawi.* 13th International AIDS Conference, July 9-14, 2000, Durban, South Africa (Abstract no. TuPpC1171).
19. *FDA Proposes New Warning for Over-the Counter Contraceptive Drugs containing Nonoxyl 9.* Associated Press. (01.16.03) Prevention-news@cdncpin.org. CDC HIV/STD/TB Prevention News Update 01/17/03
20. Centers for Disease Control and Prevention. *Dear Colleague Letter*, August 4, 2000.
21. Centers for Disease Control and Prevention. *CDC Statement on study results of product containing nonoxynol-9.* *MMWR* August 11, 2000; 49(31):717.
22. *Vaginal Contraceptive/HIV fighter Seems Promising.* Reuters Health (12.05.02)

For more information please contact:

Division of HIV/AIDS Epidemiology & Surveillance
Centre for Infectious Disease Prevention & Control
Health Canada
Tunney's Pasture, Postal Locator 0900B1
Ottawa, ON K1A 0L2
Tel: (613) 954-5169
Fax: (613) 946-8695
www.hc-sc.gc.ca/pphb-dgsp/hast-vsmt/

Our mission is to help the people of Canada maintain and improve their health

Health Canada